Orbimed Advisors Llc - Insider Trading Tracker

Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)

US ˙ NasdaqCM ˙ US00653A1079

Pengenalan

Halaman ini menyediakan analisis menyeluruh tentang sejarah dagangan orang dalam yang diketahui Orbimed Advisors Llc. Orang dalam ialah pegawai, pengarah atau pelabur penting dalam syarikat. Adalah haram bagi orang dalam untuk membuat perdagangan dalam syarikat mereka berdasarkan maklumat khusus bukan awam. Ini tidak bermakna haram bagi mereka untuk membuat sebarang perdagangan dalam syarikat mereka sendiri. Tetapi mereka mesti melaporkan semua perdagangan kepada SEC melalui Borang 4. Walaupun terdapat sekatan ini, penyelidikan akademik menunjukkan bahawa orang dalam - secara amnya - cenderung untuk mengatasi prestasi pasaran dalam syarikat mereka sendiri.

Purata Keuntungan Perdagangan

Purata keuntungan perdagangan ialah purata pulangan semua pembelian pasaran terbuka yang dibuat oleh orang dalam dalam tempoh tiga tahun terakhir. Untuk mengira ini, kami memeriksa setiap pembelian pasaran terbuka yang tidak dirancang oleh orang dalam, tidak termasuk semua dagangan yang ditandakan sebagai sebahagian daripada pelan dagangan 10b5-1. Kami kemudian mengira prestasi purata dagangan tersebut sepanjang 3, 6 dan 12 bulan, dengan purata setiap tempoh tersebut untuk menjana metrik prestasi akhir bagi setiap dagangan. Akhir sekali, kami puratakan semua metrik prestasi untuk mengira metrik prestasi untuk orang dalam. Senarai ini hanya termasuk orang dalam yang telah membuat sekurang-kurangnya tiga dagangan dalam dua tahun lepas.

Jika keuntungan berdagang orang dalam ini ialah "N/A", maka orang dalam sama ada tidak membuat sebarang pembelian pasaran terbuka dalam tempoh tiga tahun terakhir, atau dagangan yang mereka buat adalah terlalu baru untuk mengira metrik prestasi yang boleh dipercayai.

Kekerapan Kemas Kini: Harian

Lihat senarai pedagang dalaman yang paling menguntungkan.

Lihat Orang Dalam Dengan Kedudukan Tertinggi

Syarikat dengan Kedudukan Orang Dalam yang Dilaporkan

Pemfailan SEC menunjukkan Orbimed Advisors Llc telah melaporkan pegangan atau perdagangan dalam syarikat berikut:

Sekuriti	Tajuk	Pegangan Terkini Dilaporkan
US:STTK / Shattuck Labs, Inc.	Director	1,051,021
US:TSBX / Turnstone Biologics Corp.	Director	0
US:IKNA / Ikena Oncology, Inc.	Director	287,885
US:CRVS / Corvus Pharmaceuticals, Inc.	Director, 10% Owner	7,165,006
US:PASG / Passage Bio, Inc.	10% Owner	6,066,343
US:NPCE / NeuroPace, Inc.	10% Owner	3,238,199
US:XTNT / Xtant Medical Holdings, Inc.	10% Owner	0
US:CMPX / Compass Therapeutics, Inc.	Director, 10% Owner	0
US:EWTX / Edgewise Therapeutics, Inc.	Director, 10% Owner	443,792
US:IRON / Disc Medicine, Inc.	Director	186,541
	Director, 10% Owner	747,887
	Director	3,704,959
	Director	2,677,256
	Director, 10% Owner	4,554,873
US:TRAW / Traws Pharma, Inc.	10% Owner	602,000
US:SPRY / ARS Pharmaceuticals, Inc.	Director	0
US:SCPH / scPharmaceuticals Inc.	10% Owner	252,858
US:KROS / Keros Therapeutics, Inc.	Director	119,522
US:TERN / Terns Pharmaceuticals, Inc.	Director, 10% Owner	755,635
US:TELA / TELA Bio, Inc.	10% Owner	2,407,242
US:ELVN / Enliven Therapeutics, Inc.	Director, 10% Owner	7,663,349
US:ALPN / Alpine Immune Sciences, Inc.	Director	0
US:KNTE / Kinnate Biopharma Inc.	Director, 10% Owner	0
US:QTTB / Q32 Bio Inc.	Director, 10% Owner	2,252,987
US: / THESEUS PHARMACEUTICALS INC	Director, 10% Owner	0
US:AVBP / ArriVent BioPharma, Inc.	Director, 10% Owner	1,513,664
US:ACET / Adicet Bio, Inc.	Director, 10% Owner	1,255,985
US:PMVP / PMV Pharmaceuticals, Inc.	10% Owner	0
US:GLTO / Galecto, Inc.	10% Owner	1,510,375
US:PRLD / Prelude Therapeutics Incorporated	Director, 10% Owner	10,119,756
US:VRNA / Verona Pharma plc - Depositary Receipt (Common Stock)	Director	3,777,778
US:TCDA / Tricida Inc	Director, 10% Owner	0
US: / Third Harmonic Bio, Inc.	Director, 10% Owner	5,779,071
US:SWTX / SpringWorks Therapeutics, Inc.	10% Owner	5,599,842
US:SRRA / Sierra Oncology Inc	Director, 10% Owner	0
US:ARQT / Arcutis Biotherapeutics, Inc.	10% Owner	415,142
US:ETNB / 89bio, Inc.	10% Owner	1,829,436
US:JANX / Janux Therapeutics, Inc.	Director	231,098
US:RPTX / Repare Therapeutics Inc.	Director	96,190
US:AFIB / Acutus Medical, Inc.	Director, 10% Owner	1,677,361
US:SYBX / Synlogic, Inc.	Director	3,696,662
US:ORIC / ORIC Pharmaceuticals, Inc.	Director	2,212,571
US:DBTX / Decibel Therapeutics Inc	Director, 10% Owner	0
	Director, 10% Owner	0
US:CTIC / CTI BioPharma Corp	10% Owner	7,520,600
US:WHWK / Whitehawk Therapeutics, Inc.	10% Owner	0
	Director, 10% Owner	296,296
US:GRAY / Graybug Vision Inc	10% Owner	0
US:INSP / Inspire Medical Systems, Inc.	Director	0
US:FUSN / Fusion Pharmaceuticals Inc.	Director	0
US:ALEC / Alector, Inc.	10% Owner	1,906,718
	10% Owner	1,605,713
US:NXTC / NextCure, Inc.	Director, 10% Owner	0
US:TPTX / Turning Point Therapeutics Inc	Director	0
US:AVDR / New Age Alpha Trust - AVDR US LargeCap Leading ETF	10% Owner	0
US:THOR / Synthorx Inc	Director, 10% Owner	0
US:SIBN / SI-BONE, Inc.	Director	0
US:GH / Guardant Health, Inc.	10% Owner	0
US:STDY / SteadyMed Ltd.	10% Owner	0
US:VRAY / ViewRay Inc.	10% Owner	73,819
	10% Owner	0
US:ARMO / ARMO BioSciences, Inc.	Director, 10% Owner	409,547
US:ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)	Director	4,901,310
US:RYTM / Rhythm Pharmaceuticals, Inc.	10% Owner	2,750,079
US:PIRS / Pieris Pharmaceuticals, Inc.	10% Owner	38,870
US:BOLD / Boundless Bio, Inc.	10% Owner	3,539,997
US:GKOS / Glaukos Corporation	Director	0
US:KALA / KALA BIO, Inc.	10% Owner	3,447,840
US:LOXO / Loxo Oncology, Inc.	Director	941,000
US:ASNS / Actelis Networks, Inc.	10% Owner	0
US:ROKA / Roka Bioscience, Inc.	10% Owner	0
US:AGLE / Aeglea BioTherapeutics Inc	10% Owner	1,469,524
US:NBRV / Nabriva Therapeutics Plc	Director, 10% Owner	559,754
	Director, 10% Owner	0
US:RLYP / Relypsa, Inc.	10% Owner	3,356,400
US:SELB / Selecta Biosciences Inc	Director, 10% Owner	0
US:NTLA / Intellia Therapeutics, Inc.	Director	0
US:OTIC / Otonomy Inc	Director	1,850,094
US:DMTX / Dimension Therapeutics, Inc.	Director, 10% Owner	0
US:SIEN / Sientra, Inc.	10% Owner	17,100
US:ICPT / Intercept Pharmaceuticals Inc	Director	1,120,609
US:MRTX / Mirati Therapeutics, Inc.	10% Owner	1,267,000
US:XLRN / Acceleron Pharma Inc		0
	10% Owner	14,067
US:SUPN / Supernus Pharmaceuticals, Inc.	10% Owner	817,000
US:ANTH / Anthera Pharmaceuticals, Inc.	Director	7,462,000
US:AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock)	Director	5,700
	10% Owner	27,859
US:PCRX / Pacira BioSciences, Inc.	10% Owner	2,446,000
US:CCXI / ChemoCentryx Inc	10% Owner	0

Bagaimana Mentafsir Carta

Carta berikut menunjukkan prestasi saham sekuriti selepas setiap dagangan pasaran terbuka dan tidak dirancang yang dibuat oleh Orbimed Advisors Llc. Perdagangan tidak dirancang ialah dagangan yang tidak dibuat sebagai sebahagian daripada pelan dagangan 10b5-1. Prestasi saham dicatatkan sebagai perubahan peratus kumulatif dalam harga saham. Sebagai contoh, jika perdagangan orang dalam dibuat pada 1 Januari 2019, carta akan menunjukkan perubahan peratusan harian sekuriti kepada hari ini. Jika harga saham naik dari $10 kepada $15 pada masa ini, perubahan peratus terkumpul dalam harga saham ialah 50%. Perubahan dalam harga daripada $10 kepada $20 ialah 100% dan perubahan dalam harga $10 hingga $5 ialah -50%.

Secara dasarnya, kami cuba untuk menentukan sejauh mana dagangan orang dalam berkait rapat dengan pulangan berlebihan (positif atau negatif) dalam harga saham untuk melihat sama ada orang dalam menetapkan masa dagangan mereka untuk mendapat keuntungan daripada maklumat orang dalam. Pertimbangkan situasi di mana orang dalam melakukan perkara ini. Dalam keadaan ini, kami menjangkakan sama ada (a) pulangan positif selepas pembelian, atau (b) pulangan negatif selepas jualan. Dalam kes (a), carta PEMBELIAN akan menunjukkan satu siri keluk condong ke atas, menunjukkan pulangan positif selepas setiap transaksi pembelian. Dalam kes (b), carta JUALAN akan menunjukkan satu siri keluk condong ke bawah, menunjukkan pulangan negatif selepas setiap transaksi jualan.

Walau bagaimanapun, ini sahaja tidak cukup untuk membuat kesimpulan. Jika, sebagai contoh, harga saham syarikat berada dalam pendakian bukan disebabkan kitaran selama bertahun-tahun, maka kami menjangkakan semua plot selepas pembelian akan condong ke atas. Begitu juga, kemerosotan bukan disebabkan kitaran selama bertahun-tahun akan mengakibatkan plot pasca perdagangan condong ke bawah. Kedua-dua carta ini tidak akan mencadangkan aktiviti perdagangan orang dalam.

Penunjuk terkuat ialah keadaan di mana harga saham adalah sangat kitaran, dan terdapat kedua-dua isyarat positif dalam carta PEMBELIAN dan plot negatif pada carta JUALAN. Situasi ini akan sangat menunjukkan orang dalam yang menentukan masa perdagangan untuk kelebihan kewangan mereka.

Pembelian Orang Dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2017-03-27	ADAP	ORBIMED ADVISORS LLC	1,190,476	4.2000	1,190,476	4.2000	4,999,999	364	11.5600	8,761,904	175.24
2016-05-24	ADAP	ORBIMED ADVISORS LLC	518,400	10.4800	518,400	10.4800	5,432,832
2016-05-23	ADAP	ORBIMED ADVISORS LLC	1,191,600	10.4000	1,191,600	10.4000	12,392,640
2016-05-20	ADAP	ORBIMED ADVISORS LLC	2,400	10.0400	2,400	10.0400	24,096

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2018-06-06 ADAP ORBIMED ADVISORS LLC 1,600 13.4900 1,600 13.4900 21,584 357 3.2300 -16,416 -76.06

2018-06-04 ADAP ORBIMED ADVISORS LLC 17,100 13.5700 17,100 13.5700 232,047

2018-06-01 ADAP ORBIMED ADVISORS LLC 50,000 13.4900 50,000 13.4900 674,500

2018-05-30 ADAP ORBIMED ADVISORS LLC 121,000 13.5200 121,000 13.5200 1,635,920

2018-05-14 ADAP ORBIMED ADVISORS LLC 10,300 13.5000 10,300 13.5000 139,050

2018-03-29 ADAP ORBIMED ADVISORS LLC 31,983 11.5300 31,983 11.5300 368,764

2018-03-27 ADAP ORBIMED ADVISORS LLC 1,016,084 11.5000 1,016,084 11.5000 11,684,966

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam AFIB / Acutus Medical, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2021-07-19 AFIB ORBIMED ADVISORS LLC 714,285 14.0000 714,285 14.0000 9,999,990 4 16.7000 1,928,570 19.29

2021-07-19 AFIB ORBIMED ADVISORS LLC 357,143 14.0000 357,143 14.0000 5,000,002

2020-08-10 AFIB ORBIMED ADVISORS LLC 373,500 18.0000 373,500 18.0000 6,723,000

2020-08-10 AFIB ORBIMED ADVISORS LLC 41,500 18.0000 41,500 18.0000 747,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam AFIB / Acutus Medical, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam ALEC / Alector, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2019-02-11 ALEC ORBIMED ADVISORS LLC 157,939 19.0000 157,939 19.0000 3,000,841 361 35.2800 2,571,247 85.68

2019-02-11 ALEC ORBIMED ADVISORS LLC 50,561 19.0000 50,561 19.0000 960,659

2019-02-11 ALEC ORBIMED ADVISORS LLC 203,200 19.0000 203,200 19.0000 3,860,800

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam ALEC / Alector, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2020-04-16 ALEC ORBIMED ADVISORS LLC 47,097 23.5300 47,097 23.5300 1,108,192 187 9.4 -665,480 -60.05

2020-04-16 ALEC ORBIMED ADVISORS LLC 15,086 23.5300 15,086 23.5300 354,974

2020-04-14 ALEC ORBIMED ADVISORS LLC 17,595 23.5200 17,595 23.5200 413,834

2020-04-14 ALEC ORBIMED ADVISORS LLC 5,636 23.5200 5,636 23.5200 132,559

2020-04-09 ALEC ORBIMED ADVISORS LLC 218,208 23.7900 218,208 23.7900 5,191,168

2020-04-09 ALEC ORBIMED ADVISORS LLC 69,893 23.7900 69,893 23.7900 1,662,754

2020-04-08 ALEC ORBIMED ADVISORS LLC 62,573 23.6500 62,573 23.6500 1,479,851

2020-04-08 ALEC ORBIMED ADVISORS LLC 20,041 23.6500 20,041 23.6500 473,970

2020-04-07 ALEC ORBIMED ADVISORS LLC 6,946 23.1000 6,946 23.1000 160,453

2020-04-07 ALEC ORBIMED ADVISORS LLC 2,224 23.1000 2,224 23.1000 51,374

2020-03-31 ALEC ORBIMED ADVISORS LLC 189,355 24.5000 189,355 24.5000 4,639,198

2020-03-31 ALEC ORBIMED ADVISORS LLC 60,645 24.5000 60,645 24.5000 1,485,802

2020-03-25 ALEC ORBIMED ADVISORS LLC 42,727 24.6600 42,727 24.6600 1,053,648

2020-03-25 ALEC ORBIMED ADVISORS LLC 13,684 24.6600 13,684 24.6600 337,447

2020-03-24 ALEC ORBIMED ADVISORS LLC 51,235 24.4500 51,235 24.4500 1,252,696

2020-03-24 ALEC ORBIMED ADVISORS LLC 16,409 24.4500 16,409 24.4500 401,200

2020-03-23 ALEC ORBIMED ADVISORS LLC 11,057 26.0500 11,057 26.0500 288,035

2020-03-23 ALEC ORBIMED ADVISORS LLC 3,541 26.0500 3,541 26.0500 92,243

2020-03-02 ALEC ORBIMED ADVISORS LLC 1,390,309 26.0000 1,390,309 26.0000 36,148,034

2020-03-02 ALEC ORBIMED ADVISORS LLC 445,086 26.0000 445,086 26.0000 11,572,236

2020-03-02 ALEC ORBIMED ADVISORS LLC 38,808 26.0000 38,808 26.0000 1,009,008

2020-01-09 ALEC ORBIMED ADVISORS LLC 286,787 19.5000 286,787 19.5000 5,592,346

2020-01-09 ALEC ORBIMED ADVISORS LLC 91,818 19.5000 91,818 19.5000 1,790,451

2020-01-09 ALEC ORBIMED ADVISORS LLC 1,392 19.5000 1,392 19.5000 27,144

2019-12-26 ALEC ORBIMED ADVISORS LLC 7,275 18.6000 7,275 18.6000 135,315

2019-12-26 ALEC ORBIMED ADVISORS LLC 2,325 18.6000 2,325 18.6000 43,245

2019-12-26 ALEC ORBIMED ADVISORS LLC 1,200 18.6000 1,200 18.6000 22,320

2019-12-24 ALEC ORBIMED ADVISORS LLC 48,324 19.5900 48,324 19.5900 946,667

2019-12-24 ALEC ORBIMED ADVISORS LLC 15,476 19.5900 15,476 19.5900 303,175

2019-12-24 ALEC ORBIMED ADVISORS LLC 8,000 19.5900 8,000 19.5900 156,720

2019-12-23 ALEC ORBIMED ADVISORS LLC 63,535 19.8200 63,535 19.8200 1,259,264

2019-12-23 ALEC ORBIMED ADVISORS LLC 20,350 19.8200 20,350 19.8200 403,337

2019-12-23 ALEC ORBIMED ADVISORS LLC 10,400 19.8200 10,400 19.8200 206,128

2019-12-20 ALEC ORBIMED ADVISORS LLC 230,721 19.6600 230,721 19.6600 4,535,975

2019-12-20 ALEC ORBIMED ADVISORS LLC 73,879 19.6600 73,879 19.6600 1,452,461

2019-12-20 ALEC ORBIMED ADVISORS LLC 37,900 19.6600 37,900 19.6600 745,114

2019-12-17 ALEC ORBIMED ADVISORS LLC 642,807 18.5200 642,807 18.5200 11,904,786

2019-12-17 ALEC ORBIMED ADVISORS LLC 205,793 18.5200 205,793 18.5200 3,811,286

2019-12-17 ALEC ORBIMED ADVISORS LLC 105,500 18.5200 105,500 18.5200 1,953,860

2019-08-07 ALEC ORBIMED ADVISORS LLC 492,364 17.9000 492,364 17.9000 8,813,316

2019-08-07 ALEC ORBIMED ADVISORS LLC 157,636 17.9000 157,636 17.9000 2,821,684

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2012-06-19 AMRN ORBIMED ADVISORS LLC 611,200 12.9127 30,560 258.2540 7,892,242 310 6.39 -7,696,964 -97.53

2012-06-19 AMRN ORBIMED ADVISORS LLC 5,900 12.9127 295 258.2540 76,185

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam ANTH / Anthera Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2013-01-30 ANTH ORBIMED ADVISORS LLC 5,700,000 0.6600 712,500 5.2800 3,762,000 170 4.53 -534,375 -14.20

2013-01-25 ANTH ORBIMED ADVISORS LLC 1,762,000 0.6484 220,250 5.1872 1,142,481

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam ANTH / Anthera Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2012-06-29 ANTH ORBIMED ADVISORS LLC 1,283,300 0.7341 160,412 5.8728 942,071 364 0.4631 -867,783 -92.11

2012-03-22 ANTH ORBIMED ADVISORS LLC 1,306,700 2.4031 163,338 19.2248 3,140,131

2012-03-21 ANTH ORBIMED ADVISORS LLC 125,000 2.8665 15,625 22.9320 358,312

2012-03-20 ANTH ORBIMED ADVISORS LLC 116,800 2.8993 14,600 23.1944 338,638

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam ARQT / Arcutis Biotherapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2020-10-02 ARQT ORBIMED ADVISORS LLC 200,000 25.0000 200,000 25.0000 5,000,000 129 36.98 2,396,000 47.92

2020-10-02 ARQT ORBIMED ADVISORS LLC 296,000 25.0000 296,000 25.0000 7,400,000

2020-02-03 ARQT ORBIMED ADVISORS LLC 382,388 17.0000 382,388 17.0000 6,500,596

2020-02-03 ARQT ORBIMED ADVISORS LLC 176,500 17.0000 176,500 17.0000 3,000,500

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam ARQT / Arcutis Biotherapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2022-06-24 ARQT ORBIMED ADVISORS LLC 306,027 21.3100 306,027 21.3100 6,521,435 341 7.5100 -4,223,172 -64.76

2022-06-24 ARQT ORBIMED ADVISORS LLC 35,944 21.3100 35,944 21.3100 765,967

2022-04-08 ARQT ORBIMED ADVISORS LLC 97,200 20.7100 97,200 20.7100 2,013,012

2022-04-08 ARQT ORBIMED ADVISORS LLC 102,800 20.7100 102,800 20.7100 2,128,988

2022-04-07 ARQT ORBIMED ADVISORS LLC 167,800 20.6600 167,800 20.6600 3,466,748

2022-04-07 ARQT ORBIMED ADVISORS LLC 177,196 20.6600 177,196 20.6600 3,660,869

2022-04-06 ARQT ORBIMED ADVISORS LLC 162,000 20.6900 162,000 20.6900 3,351,780

2022-04-06 ARQT ORBIMED ADVISORS LLC 171,204 20.6900 171,204 20.6900 3,542,211

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam AVBP / ArriVent BioPharma, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2024-01-30 AVBP ORBIMED ADVISORS LLC 222,222 18.0000 222,222 18.0000 3,999,996 282 35.6300 3,917,774 97.94

2024-01-30 AVBP ORBIMED ADVISORS LLC 222,222 18.0000 222,222 18.0000 3,999,996

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam AVBP / ArriVent BioPharma, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam BOLD / Boundless Bio, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2016-07-25 BOLD ORBIMED ADVISORS LLC 33,334 15.0000 33,334 15.0000 500,010 730

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam BOLD / Boundless Bio, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2018-03-12 BOLD ORBIMED ADVISORS LLC 1,066 36.0400 1,066 36.0400 38,419 731

2018-03-12 BOLD ORBIMED ADVISORS LLC 16,937 34.9200 16,937 34.9200 591,440

2018-03-09 BOLD ORBIMED ADVISORS LLC 21,300 34.6700 21,300 34.6700 738,471

2018-03-09 BOLD ORBIMED ADVISORS LLC 47,395 35.8600 47,395 35.8600 1,699,585

2018-03-09 BOLD ORBIMED ADVISORS LLC 11,305 36.4400 11,305 36.4400 411,954

2018-03-08 BOLD ORBIMED ADVISORS LLC 58,428 34.0600 58,428 34.0600 1,990,058

2018-03-06 BOLD ORBIMED ADVISORS LLC 11,372 33.0300 11,372 33.0300 375,617

2018-03-05 BOLD ORBIMED ADVISORS LLC 200 36.0600 200 36.0600 7,212

2018-03-02 BOLD ORBIMED ADVISORS LLC 386,080 35.0600 386,080 35.0600 13,535,965

2018-03-02 BOLD ORBIMED ADVISORS LLC 35,558 36.3300 35,558 36.3300 1,291,822

2017-09-29 BOLD ORBIMED ADVISORS LLC 672,000 28.2500 672,000 28.2500 18,984,000

2017-09-07 BOLD ORBIMED ADVISORS LLC 5,000 22.3500 5,000 22.3500 111,750

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam CALC / CalciMedica, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2020-09-25 GRAY ORBIMED ADVISORS LLC 562,500 16.0000 40,179 224.0000 9,000,000 119 490 10,687,220 118.75

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam CALC / CalciMedica, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam CMPX / Compass Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2022-11-08 CMPX ORBIMED ADVISORS LLC 402,000 3.2100 402,000 3.2100 1,290,420 63 5.4800 912,540 70.72

2022-05-13 CMPX ORBIMED ADVISORS LLC 30,722 2.4900 30,722 2.4900 76,498

2022-05-12 CMPX ORBIMED ADVISORS LLC 97,094 2.3500 97,094 2.3500 228,171

2022-05-11 CMPX ORBIMED ADVISORS LLC 64,700 1.7900 64,700 1.7900 115,813

2022-05-10 CMPX ORBIMED ADVISORS LLC 24,447 1.6000 24,447 1.6000 39,115

2022-05-09 CMPX ORBIMED ADVISORS LLC 90,712 1.5600 90,712 1.5600 141,511

2022-05-06 CMPX ORBIMED ADVISORS LLC 10,200 1.6300 10,200 1.6300 16,626

2021-11-04 CMPX ORBIMED ADVISORS LLC 1,785,715 3.5000 1,785,715 3.5000 6,250,002

2021-11-04 CMPX ORBIMED ADVISORS LLC 3,571,428 3.5000 3,571,428 3.5000 12,499,998

2020-06-19 NONE ORBIMED ADVISORS LLC 1,455,132 5.0000 1,455,132 5.0000 7,275,660

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam CMPX / Compass Therapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2025-04-09 CMPX ORBIMED ADVISORS LLC 3,571,428 1.5900 3,571,428 1.5900 5,678,571 1 1.6500 214,286 3.77

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam CRVS / Corvus Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2021-02-17 CRVS ORBIMED ADVISORS LLC 1,285,714 3.5000 1,285,714 3.5000 4,499,999 216 8.53 6,467,141 143.71

2019-08-06 CRVS ORBIMED ADVISORS LLC 142,656 3.5100 142,656 3.5100 500,723

2019-07-01 CRVS ORBIMED ADVISORS LLC 59,243 3.9100 59,243 3.9100 231,640

2019-06-28 CRVS ORBIMED ADVISORS LLC 565,178 3.7200 565,178 3.7200 2,102,462

2019-06-27 CRVS ORBIMED ADVISORS LLC 32,923 3.3400 32,923 3.3400 109,963

2018-03-12 CRVS ORBIMED ADVISORS LLC 588,235 8.5000 588,235 8.5000 4,999,998

2016-06-24 CRVS ORBIMED ADVISORS LLC 900 12.9900 900 12.9900 11,691

2016-06-23 CRVS ORBIMED ADVISORS LLC 100 12.9200 100 12.9200 1,292

2016-06-21 CRVS ORBIMED ADVISORS LLC 26,083 12.8700 26,083 12.8700 335,688

2016-06-17 CRVS ORBIMED ADVISORS LLC 12,300 12.4800 12,300 12.4800 153,504

2016-06-16 CRVS ORBIMED ADVISORS LLC 5,000 12.0400 5,000 12.0400 60,200

2016-06-15 CRVS ORBIMED ADVISORS LLC 5,000 11.9400 5,000 11.9400 59,700

2016-06-14 CRVS ORBIMED ADVISORS LLC 10,000 12.7100 10,000 12.7100 127,100

2016-06-10 CRVS ORBIMED ADVISORS LLC 20,000 12.9800 20,000 12.9800 259,600

2016-06-09 CRVS ORBIMED ADVISORS LLC 30,000 12.9500 30,000 12.9500 388,500

2016-05-20 CRVS ORBIMED ADVISORS LLC 4,716 13.0900 4,716 13.0900 61,732

2016-05-19 CRVS ORBIMED ADVISORS LLC 2,539 12.1100 2,539 12.1100 30,747

2016-05-19 CRVS ORBIMED ADVISORS LLC 61 12.7500 61 12.7500 778

2016-05-18 CRVS ORBIMED ADVISORS LLC 4,200 11.5500 4,200 11.5500 48,510

2016-03-29 CRVS ORBIMED ADVISORS LLC 550,000 15.0000 550,000 15.0000 8,250,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam CRVS / Corvus Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2025-06-27 CRVS ORBIMED ADVISORS LLC 1,176,332 4.1586 1,176,332 4.1586 4,891,894 4 3.8600 -351,252 -7.18

2021-09-20 CRVS ORBIMED ADVISORS LLC 1,109,644 6.0900 1,109,644 6.0900 6,757,732

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam ETNB / 89bio, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2019-11-11 ETNB ORBIMED ADVISORS LLC 418,750 16.0000 418,750 16.0000 6,700,000 112 41.77 10,791,188 161.06

2019-11-11 ETNB ORBIMED ADVISORS LLC 418,750 16.0000 418,750 16.0000 6,700,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam ETNB / 89bio, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2022-01-26 ETNB ORBIMED ADVISORS LLC 10,742 8.3800 10,742 8.3800 90,018 103 2.0900 -67,566 -75.06

2022-01-26 ETNB ORBIMED ADVISORS LLC 10,740 8.3800 10,740 8.3800 90,001

2022-01-25 ETNB ORBIMED ADVISORS LLC 24,546 8.4000 24,546 8.4000 206,186

2022-01-25 ETNB ORBIMED ADVISORS LLC 24,545 8.4000 24,545 8.4000 206,178

2020-09-21 ETNB ORBIMED ADVISORS LLC 137,500 28.0000 137,500 28.0000 3,850,000

2020-09-21 ETNB ORBIMED ADVISORS LLC 137,500 28.0000 137,500 28.0000 3,850,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam EWTX / Edgewise Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2025-04-03 EWTX ORBIMED ADVISORS LLC 372,578 20.1300 372,578 20.1300 7,499,995 29 16.9100 -1,199,701 -16.00

2025-04-03 EWTX ORBIMED ADVISORS LLC 124,193 20.1300 124,193 20.1300 2,500,005

2024-01-23 EWTX ORBIMED ADVISORS LLC 454,545 11.0000 454,545 11.0000 4,999,995

2022-09-16 EWTX ORBIMED ADVISORS LLC 484,496 10.3200 484,496 10.3200 4,999,999

2022-05-18 EWTX ORBIMED ADVISORS LLC 138,000 7.2100 138,000 7.2100 994,980

2021-03-30 EWTX ORBIMED ADVISORS LLC 46,875 16.0000 46,875 16.0000 750,000

2021-03-30 EWTX ORBIMED ADVISORS LLC 312,500 16.0000 312,500 16.0000 5,000,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam EWTX / Edgewise Therapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam GH / Guardant Health, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam GH / Guardant Health, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam GKOS / Glaukos Corporation - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam GKOS / Glaukos Corporation - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2018-03-06 GKOS ORBIMED ADVISORS LLC 93,008 30.0100 93,008 30.0100 2,791,170 38 27.6200 -222,289 -7.96

2018-03-06 GKOS ORBIMED ADVISORS LLC 886 30.0100 886 30.0100 26,589

2018-03-06 GKOS ORBIMED ADVISORS LLC 20,114 30.7700 20,114 30.7700 618,908

2018-03-06 GKOS ORBIMED ADVISORS LLC 192 30.7700 192 30.7700 5,908

2018-03-06 GKOS ORBIMED ADVISORS LLC 46,676 32.0600 46,676 32.0600 1,496,433

2018-03-06 GKOS ORBIMED ADVISORS LLC 445 32.0600 445 32.0600 14,267

2018-03-05 GKOS ORBIMED ADVISORS LLC 128,092 32.0500 128,092 32.0500 4,105,349

2018-03-05 GKOS ORBIMED ADVISORS LLC 1,220 32.0500 1,220 32.0500 39,101

2018-03-05 GKOS ORBIMED ADVISORS LLC 80,516 33.0600 80,516 33.0600 2,661,859

2018-03-05 GKOS ORBIMED ADVISORS LLC 768 33.0600 768 33.0600 25,390

2018-03-02 GKOS ORBIMED ADVISORS LLC 265,766 31.9200 265,766 31.9200 8,483,251

2018-03-02 GKOS ORBIMED ADVISORS LLC 2,533 31.9200 2,533 31.9200 80,853

2018-03-02 GKOS ORBIMED ADVISORS LLC 194,433 32.8000 194,433 32.8000 6,377,402

2018-03-02 GKOS ORBIMED ADVISORS LLC 1,851 32.8000 1,851 32.8000 60,713

2017-09-05 GKOS ORBIMED ADVISORS LLC 173,349 37.9400 173,349 37.9400 6,576,861

2017-09-05 GKOS ORBIMED ADVISORS LLC 1,651 37.9400 1,651 37.9400 62,639

2017-09-05 GKOS ORBIMED ADVISORS LLC 189,792 39.6300 189,792 39.6300 7,521,457

2017-09-05 GKOS ORBIMED ADVISORS LLC 1,808 39.6300 1,808 39.6300 71,651

2017-09-05 GKOS ORBIMED ADVISORS LLC 58,047 40.7700 58,047 40.7700 2,366,576

2017-09-05 GKOS ORBIMED ADVISORS LLC 553 40.7700 553 40.7700 22,546

2017-09-01 GKOS ORBIMED ADVISORS LLC 109,040 37.7200 109,040 37.7200 4,112,989

2017-09-01 GKOS ORBIMED ADVISORS LLC 1,038 37.7200 1,038 37.7200 39,153

2017-08-31 GKOS ORBIMED ADVISORS LLC 44,498 37.8200 44,498 37.8200 1,682,914

2017-08-31 GKOS ORBIMED ADVISORS LLC 424 37.8200 424 37.8200 16,036

2017-08-17 GKOS ORBIMED ADVISORS LLC 224,780 37.8500 224,780 37.8500 8,507,923

2017-08-17 GKOS ORBIMED ADVISORS LLC 2,140 37.8500 2,140 37.8500 80,999

2017-08-16 GKOS ORBIMED ADVISORS LLC 64,961 38.0100 64,961 38.0100 2,469,168

2017-08-16 GKOS ORBIMED ADVISORS LLC 619 38.0100 619 38.0100 23,528

2017-08-15 GKOS ORBIMED ADVISORS LLC 32,193 38.2900 32,193 38.2900 1,232,670

2017-08-15 GKOS ORBIMED ADVISORS LLC 307 38.2900 307 38.2900 11,755

2017-03-14 GKOS ORBIMED ADVISORS LLC 73,401 44.5400 73,401 44.5400 3,269,281

2017-03-14 GKOS ORBIMED ADVISORS LLC 699 44.5400 699 44.5400 31,133

2017-03-13 GKOS ORBIMED ADVISORS LLC 208,712 45.3000 208,712 45.3000 9,454,654

2017-03-13 GKOS ORBIMED ADVISORS LLC 1,998 45.3000 1,998 45.3000 90,509

2017-03-13 GKOS ORBIMED ADVISORS LLC 693 46.1300 693 46.1300 31,968

2017-03-13 GKOS ORBIMED ADVISORS LLC 7 46.1300 7 46.1300 323

2017-03-10 GKOS ORBIMED ADVISORS LLC 96,113 45.9800 96,113 45.9800 4,419,276

2017-03-10 GKOS ORBIMED ADVISORS LLC 915 45.9800 915 45.9800 42,072

2017-03-03 GKOS ORBIMED ADVISORS LLC 55,246 47.0500 55,246 47.0500 2,599,324

2017-03-03 GKOS ORBIMED ADVISORS LLC 526 47.0500 526 47.0500 24,748

2016-08-12 GKOS ORBIMED ADVISORS LLC 13,967 33.7200 13,967 33.7200 470,967

2016-08-12 GKOS ORBIMED ADVISORS LLC 133 33.7200 133 33.7200 4,485

2016-08-11 GKOS ORBIMED ADVISORS LLC 159,382 33.6300 159,382 33.6300 5,360,017

2016-08-11 GKOS ORBIMED ADVISORS LLC 1,518 33.6300 1,518 33.6300 51,050

2016-08-10 GKOS ORBIMED ADVISORS LLC 116,825 33.7700 116,825 33.7700 3,945,180

2016-08-10 GKOS ORBIMED ADVISORS LLC 1,113 33.7700 1,113 33.7700 37,586

2016-08-03 GKOS ORBIMED ADVISORS LLC 420,990 30.5900 420,990 30.5900 12,878,084

2016-08-03 GKOS ORBIMED ADVISORS LLC 4,010 30.5900 4,010 30.5900 122,666

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam GLTO / Galecto, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2020-11-02 GLTO ORBIMED ADVISORS LLC 523,833 15.0000 20,953 375.0000 7,857,495 21 16.84 -7,504,646 -95.51

2020-11-02 GLTO ORBIMED ADVISORS LLC 209,500 15.0000 8,380 375.0000 3,142,500

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam GLTO / Galecto, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2023-08-15 GLTO ORBIMED ADVISORS LLC 38,327 0.7500 1,533 18.7500 28,745 322 0.4615 -28,038 -97.54

2023-08-15 GLTO ORBIMED ADVISORS LLC 248,819 0.7500 9,953 18.7500 186,614

2023-08-15 GLTO ORBIMED ADVISORS LLC 535,534 0.7500 21,421 18.7500 401,650

2023-07-31 GLTO ORBIMED ADVISORS LLC 26,622 3.0000 1,065 75.0000 79,866

2023-07-31 GLTO ORBIMED ADVISORS LLC 29,700 3.0000 1,188 75.0000 89,100

2023-07-31 GLTO ORBIMED ADVISORS LLC 153,078 3.0000 6,123 75.0000 459,234

2023-07-25 GLTO ORBIMED ADVISORS LLC 7,800 2.9200 312 73.0000 22,776

2023-07-25 GLTO ORBIMED ADVISORS LLC 4,700 2.9200 188 73.0000 13,724

2023-07-25 GLTO ORBIMED ADVISORS LLC 26,700 2.9200 1,068 73.0000 77,964

2023-07-13 GLTO ORBIMED ADVISORS LLC 9,800 2.4000 392 60.0000 23,520

2023-07-13 GLTO ORBIMED ADVISORS LLC 52,800 2.4000 2,112 60.0000 126,720

2023-07-13 GLTO ORBIMED ADVISORS LLC 132,100 2.4000 5,284 60.0000 317,040

2023-04-17 GLTO ORBIMED ADVISORS LLC 660 1.9700 26 49.2500 1,300

2023-04-17 GLTO ORBIMED ADVISORS LLC 3,551 1.9700 142 49.2500 6,995

2023-04-17 GLTO ORBIMED ADVISORS LLC 8,878 1.9700 355 49.2500 17,490

2023-04-14 GLTO ORBIMED ADVISORS LLC 2,091 1.8600 84 46.5000 3,889

2023-04-14 GLTO ORBIMED ADVISORS LLC 11,245 1.8600 450 46.5000 20,916

2023-04-14 GLTO ORBIMED ADVISORS LLC 28,110 1.8600 1,124 46.5000 52,285

2023-04-13 GLTO ORBIMED ADVISORS LLC 703 1.8200 28 45.5000 1,279

2023-04-13 GLTO ORBIMED ADVISORS LLC 3,784 1.8200 151 45.5000 6,887

2023-04-13 GLTO ORBIMED ADVISORS LLC 9,459 1.8200 378 45.5000 17,215

2023-04-12 GLTO ORBIMED ADVISORS LLC 119 1.8100 5 45.2500 215

2023-04-12 GLTO ORBIMED ADVISORS LLC 641 1.8100 26 45.2500 1,160

2023-04-12 GLTO ORBIMED ADVISORS LLC 1,603 1.8100 64 45.2500 2,901

2023-04-11 GLTO ORBIMED ADVISORS LLC 703 1.8200 28 45.5000 1,279

2023-04-11 GLTO ORBIMED ADVISORS LLC 3,784 1.8200 151 45.5000 6,887

2023-04-11 GLTO ORBIMED ADVISORS LLC 9,459 1.8200 378 45.5000 17,215

2023-04-10 GLTO ORBIMED ADVISORS LLC 2,584 1.7900 103 44.7500 4,625

2023-04-10 GLTO ORBIMED ADVISORS LLC 13,899 1.7900 556 44.7500 24,879

2023-04-10 GLTO ORBIMED ADVISORS LLC 34,745 1.7900 1,390 44.7500 62,194

2023-04-06 GLTO ORBIMED ADVISORS LLC 487 2.0000 19 50.0000 974

2023-04-06 GLTO ORBIMED ADVISORS LLC 2,620 2.0000 105 50.0000 5,240

2023-04-06 GLTO ORBIMED ADVISORS LLC 6,558 2.0000 262 50.0000 13,116

2023-04-05 GLTO ORBIMED ADVISORS LLC 4,687 2.1800 187 54.5000 10,218

2023-04-05 GLTO ORBIMED ADVISORS LLC 25,220 2.1800 1,009 54.5000 54,980

2023-04-05 GLTO ORBIMED ADVISORS LLC 63,058 2.1800 2,522 54.5000 137,466

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2021-07-16 IMRA ORBIMED ADVISORS LLC 1,666,666 6.0000 416,666 24.0000 9,999,996 18 5.9400 -7,525,000 -75.25

2020-03-12 IMRA ORBIMED ADVISORS LLC 937,500 16.0000 234,375 64.0000 15,000,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2024-05-16 ELVN ORBIMED ADVISORS LLC 33,300 22.1400 33,300 22.1400 737,262 329 14.9100 -240,759 -32.66

2024-05-16 ELVN ORBIMED ADVISORS LLC 1,000,000 22.1400 1,000,000 22.1400 22,140,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam INSP / Inspire Medical Systems, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2018-05-07 INSP ORBIMED ADVISORS LLC 312,500 16.0000 312,500 16.0000 5,000,000 297 62 14,375,000 287.50

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam INSP / Inspire Medical Systems, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2020-08-18 INSP ORBIMED ADVISORS LLC 43,543 108.5400 43,543 108.5400 4,726,157 1 110.97 105,810 2.24

2020-08-17 INSP ORBIMED ADVISORS LLC 94,900 107.4900 94,900 107.4900 10,200,801

2020-08-14 INSP ORBIMED ADVISORS LLC 20,257 109.0300 20,257 109.0300 2,208,621

2020-08-13 INSP ORBIMED ADVISORS LLC 29,251 109.9300 29,251 109.9300 3,215,562

2020-08-12 INSP ORBIMED ADVISORS LLC 42,679 107.4500 42,679 107.4500 4,585,859

2020-08-11 INSP ORBIMED ADVISORS LLC 39,877 105.7800 39,877 105.7800 4,218,189

2020-08-10 INSP ORBIMED ADVISORS LLC 47,700 105.2300 47,700 105.2300 5,019,471

2020-08-07 INSP ORBIMED ADVISORS LLC 28,993 106.1800 28,993 106.1800 3,078,477

2020-03-06 INSP ORBIMED ADVISORS LLC 500,000 83.5200 500,000 83.5200 41,760,000

2020-03-03 INSP ORBIMED ADVISORS LLC 75,000 83.2100 75,000 83.2100 6,240,750

2020-03-03 INSP ORBIMED ADVISORS LLC 25,000 84.5500 25,000 84.5500 2,113,750

2020-03-03 INSP ORBIMED ADVISORS LLC 400,000 84.4200 400,000 84.4200 33,768,000

2019-03-08 INSP ORBIMED ADVISORS LLC 290,231 57.7500 290,231 57.7500 16,760,840

2019-03-07 INSP ORBIMED ADVISORS LLC 68,218 55.0100 68,218 55.0100 3,752,672

2018-12-11 INSP ORBIMED ADVISORS LLC 614,772 37.6000 614,772 37.6000 23,115,427

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam JANX / Janux Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2021-06-15 JANX ORBIMED ADVISORS LLC 588,203 17.0000 588,203 17.0000 9,999,451 51 34.69 10,405,311 104.06

2021-06-15 JANX ORBIMED ADVISORS LLC 117,650 17.0000 117,650 17.0000 2,000,050

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam JANX / Janux Therapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2021-12-29 JANX ORBIMED ADVISORS LLC 36,700 20.3000 36,700 20.3000 745,010 154 9.5200 -395,626 -53.10

2021-12-29 JANX ORBIMED ADVISORS LLC 3,700 20.3000 3,700 20.3000 75,110

2021-12-21 JANX ORBIMED ADVISORS LLC 108,300 19.0000 108,300 19.0000 2,057,700

2021-12-21 JANX ORBIMED ADVISORS LLC 11,100 19.0000 11,100 19.0000 210,900

2021-12-16 JANX ORBIMED ADVISORS LLC 356,800 19.0700 356,800 19.0700 6,804,176

2021-12-16 JANX ORBIMED ADVISORS LLC 36,500 19.0700 36,500 19.0700 696,055

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam KALA / KALA BIO, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2018-02-08 KALA ORBIMED ADVISORS LLC 25,000 12.9300 500 646.5000 323,250 36 905 129,250 39.98

2018-02-02 KALA ORBIMED ADVISORS LLC 37,840 14.7300 757 736.5000 557,383

2018-02-01 KALA ORBIMED ADVISORS LLC 22,840 14.9900 457 749.5000 342,372

2018-01-31 KALA ORBIMED ADVISORS LLC 339,400 15.0000 6,788 750.0000 5,091,000

2018-01-29 KALA ORBIMED ADVISORS LLC 50,000 14.9900 1,000 749.5000 749,500

2018-01-26 KALA ORBIMED ADVISORS LLC 22,760 14.9300 455 746.5000 339,807

2018-01-24 KALA ORBIMED ADVISORS LLC 64,637 14.9100 1,293 745.5000 963,738

2018-01-23 KALA ORBIMED ADVISORS LLC 4,363 14.9900 87 749.5000 65,401

2018-01-22 KALA ORBIMED ADVISORS LLC 75,000 14.9800 1,500 749.0000 1,123,500

2018-01-19 KALA ORBIMED ADVISORS LLC 74,931 14.9500 1,499 747.5000 1,120,218

2018-01-12 KALA ORBIMED ADVISORS LLC 28,446 15.4000 569 770.0000 438,068

2018-01-12 KALA ORBIMED ADVISORS LLC 38,354 14.5000 767 725.0000 556,133

2018-01-11 KALA ORBIMED ADVISORS LLC 41,700 13.6500 834 682.5000 569,205

2018-01-10 KALA ORBIMED ADVISORS LLC 170,338 12.8300 3,407 641.5000 2,185,437

2017-07-25 KALA ORBIMED ADVISORS LLC 319,333 15.0000 6,387 750.0000 4,789,995

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam KALA / KALA BIO, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam KROS / Keros Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2020-04-13 KROS ORBIMED ADVISORS LLC 375,200 16.0000 375,200 16.0000 6,003,200 248 82.74 25,040,848 417.12

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam KROS / Keros Therapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2024-08-13 KROS ORBIMED ADVISORS LLC 220,600 44.0100 220,600 44.0100 9,708,606 231 9.5500 -7,601,876 -78.30

2024-08-13 KROS ORBIMED ADVISORS LLC 29,400 44.0100 29,400 44.0100 1,293,894

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam NBRVF / Nabriva Therapeutics plc - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam NBRVF / Nabriva Therapeutics plc - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam NPCE / NeuroPace, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2021-04-21 NPCE ORBIMED ADVISORS LLC 235,000 17.0000 235,000 17.0000 3,995,000 6 26.5 2,232,500 55.88

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam NPCE / NeuroPace, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2025-05-14 NPCE ORBIMED ADVISORS LLC 134,136 15.8300 134,136 15.8300 2,123,373 97 8.2500 -1,016,750 -47.88

2025-05-14 NPCE ORBIMED ADVISORS LLC 34,000 15.9400 34,000 15.9400 541,960

2024-05-03 NPCE ORBIMED ADVISORS LLC 4,674 14.0300 4,674 14.0300 65,576

2024-05-02 NPCE ORBIMED ADVISORS LLC 8,842 14.0100 8,842 14.0100 123,876

2024-05-01 NPCE ORBIMED ADVISORS LLC 15,690 14.0200 15,690 14.0200 219,974

2024-04-24 NPCE ORBIMED ADVISORS LLC 1,781 14.0600 1,781 14.0600 25,041

2024-04-23 NPCE ORBIMED ADVISORS LLC 21,791 14.2900 21,791 14.2900 311,393

2024-04-22 NPCE ORBIMED ADVISORS LLC 24,609 14.0500 24,609 14.0500 345,756

2024-04-19 NPCE ORBIMED ADVISORS LLC 18,253 14.0200 18,253 14.0200 255,907

2024-04-18 NPCE ORBIMED ADVISORS LLC 2,623 14.0600 2,623 14.0600 36,879

2024-04-17 NPCE ORBIMED ADVISORS LLC 300 14.1500 300 14.1500 4,245

2024-04-16 NPCE ORBIMED ADVISORS LLC 14,069 14.0100 14,069 14.0100 197,107

2024-04-12 NPCE ORBIMED ADVISORS LLC 23,101 14.4200 23,101 14.4200 333,116

2024-04-11 NPCE ORBIMED ADVISORS LLC 461,899 14.4900 461,899 14.4900 6,692,917

2023-10-03 NPCE ORBIMED ADVISORS LLC 700 9.0200 700 9.0200 6,314

2023-10-02 NPCE ORBIMED ADVISORS LLC 7,614 9.0800 7,614 9.0800 69,135

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam NTLA / Intellia Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2016-05-11 NTLA ORBIMED ADVISORS LLC 191,466 18.0000 191,466 18.0000 3,446,388 20 29.57 2,215,262 64.28

2016-05-11 NTLA ORBIMED ADVISORS LLC 58,534 18.0000 58,534 18.0000 1,053,612

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam NTLA / Intellia Therapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam NXTC / NextCure, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2019-05-13 NXTC ORBIMED ADVISORS LLC 350,000 15.0000 29,167 180.0000 5,250,000 176 92.22 -2,560,311 -48.77

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam NXTC / NextCure, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam ORIC / ORIC Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2020-04-24 ORIC ORBIMED ADVISORS LLC 281,250 16.0000 281,250 16.0000 4,500,000 244 39.8 6,693,750 148.75

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam ORIC / ORIC Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam PASG / Passage Bio, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2023-06-28 PASG ORBIMED ADVISORS LLC 575,195 0.8400 28,760 16.8000 483,164 245 1.73 -433,410 -89.70

2023-06-27 PASG ORBIMED ADVISORS LLC 617,382 0.8400 30,869 16.8000 518,601

2022-01-20 PASG ORBIMED ADVISORS LLC 369,100 5.4200 18,455 108.4000 2,000,522

2022-01-20 PASG ORBIMED ADVISORS LLC 50,800 5.0000 2,540 100.0000 254,000

2022-01-19 PASG ORBIMED ADVISORS LLC 43,300 5.1100 2,165 102.2000 221,263

2022-01-18 PASG ORBIMED ADVISORS LLC 114,700 5.4600 5,735 109.2000 626,262

2022-01-14 PASG ORBIMED ADVISORS LLC 10,300 5.6000 515 112.0000 57,680

2022-01-13 PASG ORBIMED ADVISORS LLC 41,800 5.5200 2,090 110.4000 230,736

2022-01-12 PASG ORBIMED ADVISORS LLC 100,000 5.6500 5,000 113.0000 565,000

2022-01-11 PASG ORBIMED ADVISORS LLC 8,200 5.5300 410 110.6000 45,346

2020-02-28 PASG ORBIMED ADVISORS LLC 373,300 18.0000 18,665 360.0000 6,719,400

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam PASG / Passage Bio, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2025-06-26 PASG ORBIMED ADVISORS LLC 213,257 0.3300 10,663 6.6000 70,375 0 0.3300 -66,856 -95.00

2025-06-25 PASG ORBIMED ADVISORS LLC 138,800 0.3300 6,940 6.6000 45,804

2025-06-24 PASG ORBIMED ADVISORS LLC 231,600 0.3500 11,580 7.0000 81,060

2025-04-24 PASG ORBIMED ADVISORS LLC 68,195 0.3200 3,410 6.4000 21,822

2025-04-23 PASG ORBIMED ADVISORS LLC 89,328 0.3400 4,466 6.8000 30,372

2025-04-22 PASG ORBIMED ADVISORS LLC 78,049 0.3400 3,902 6.8000 26,537

2025-04-17 PASG ORBIMED ADVISORS LLC 77,090 0.3300 3,854 6.6000 25,440

2025-04-16 PASG ORBIMED ADVISORS LLC 61,638 0.3300 3,082 6.6000 20,341

2025-04-15 PASG ORBIMED ADVISORS LLC 10,326 0.3800 516 7.6000 3,924

2025-01-14 PASG ORBIMED ADVISORS LLC 79,024 0.6000 3,951 12.0000 47,414

2025-01-13 PASG ORBIMED ADVISORS LLC 17,986 0.6400 899 12.8000 11,511

2025-01-10 PASG ORBIMED ADVISORS LLC 126,209 0.6600 6,310 13.2000 83,298

2025-01-08 PASG ORBIMED ADVISORS LLC 75,007 0.6800 3,750 13.6000 51,005

2025-01-07 PASG ORBIMED ADVISORS LLC 52,536 0.7100 2,627 14.2000 37,301

2025-01-06 PASG ORBIMED ADVISORS LLC 19,481 0.7700 974 15.4000 15,000

2024-12-20 PASG ORBIMED ADVISORS LLC 230,321 0.6000 11,516 12.0000 138,193

2024-12-11 PASG ORBIMED ADVISORS LLC 80 0.8000 4 16.0000 64

2024-12-10 PASG ORBIMED ADVISORS LLC 8,015 0.8000 401 16.0000 6,412

2024-12-09 PASG ORBIMED ADVISORS LLC 54,181 0.8400 2,709 16.8000 45,512

2024-12-06 PASG ORBIMED ADVISORS LLC 20,903 0.8200 1,045 16.4000 17,140

2024-12-04 PASG ORBIMED ADVISORS LLC 76,200 0.7900 3,810 15.8000 60,198

2024-09-19 PASG ORBIMED ADVISORS LLC 39,300 0.7100 1,965 14.2000 27,903

2024-09-18 PASG ORBIMED ADVISORS LLC 25,631 0.7300 1,282 14.6000 18,711

2024-09-17 PASG ORBIMED ADVISORS LLC 111,400 0.7300 5,570 14.6000 81,322

2024-09-16 PASG ORBIMED ADVISORS LLC 63,100 0.7400 3,155 14.8000 46,694

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam PCRX / Pacira BioSciences, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam PCRX / Pacira BioSciences, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2012-03-12 PCRX ORBIMED ADVISORS LLC 62,400 11.0318 62,400 11.0318 688,384 31 9.73 -81,232 -11.80

2012-03-12 PCRX ORBIMED ADVISORS LLC 700 11.0318 700 11.0318 7,722

2012-03-09 PCRX ORBIMED ADVISORS LLC 36,700 11.2456 36,700 11.2456 412,714

2012-03-09 PCRX ORBIMED ADVISORS LLC 300 11.2456 300 11.2456 3,374

2012-02-29 PCRX ORBIMED ADVISORS LLC 3,000 10.8614 3,000 10.8614 32,584

2012-02-28 PCRX ORBIMED ADVISORS LLC 10,000 11.1204 10,000 11.1204 111,204

2012-02-28 PCRX ORBIMED ADVISORS LLC 100 11.1204 100 11.1204 1,112

2012-02-27 PCRX ORBIMED ADVISORS LLC 28,700 11.0472 28,700 11.0472 317,055

2012-02-27 PCRX ORBIMED ADVISORS LLC 300 11.0472 300 11.0472 3,314

2012-02-03 PCRX ORBIMED ADVISORS LLC 49,500 10.7904 49,500 10.7904 534,125

2012-02-03 PCRX ORBIMED ADVISORS LLC 500 10.7904 500 10.7904 5,395

2012-02-02 PCRX ORBIMED ADVISORS LLC 23,100 10.8548 23,100 10.8548 250,746

2012-02-02 PCRX ORBIMED ADVISORS LLC 200 10.8548 200 10.8548 2,171

2012-02-01 PCRX ORBIMED ADVISORS LLC 69,300 11.0058 69,300 11.0058 762,702

2012-02-01 PCRX ORBIMED ADVISORS LLC 700 11.0058 700 11.0058 7,704

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam PMVP / PMV Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2020-09-25 PMVP ORBIMED ADVISORS LLC 475,000 18.0000 475,000 18.0000 8,550,000 97 61.51 20,667,250 241.72

2020-09-25 PMVP ORBIMED ADVISORS LLC 475,000 18.0000 475,000 18.0000 8,550,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam PMVP / PMV Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2023-11-22 PMVP ORBIMED ADVISORS LLC 87,786 2.2300 87,786 2.2300 195,763 261 1.4400 -69,350 -35.43

2022-05-26 PMVP ORBIMED ADVISORS LLC 26,253 15.9300 26,253 15.9300 418,210

2022-03-31 PMVP ORBIMED ADVISORS LLC 34,500 21.1700 34,500 21.1700 730,365

2022-03-30 PMVP ORBIMED ADVISORS LLC 75,000 22.3900 75,000 22.3900 1,679,250

2022-03-29 PMVP ORBIMED ADVISORS LLC 365,000 21.5200 365,000 21.5200 7,854,800

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam PRLD / Prelude Therapeutics Incorporated - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2023-05-22 PRLD ORBIMED ADVISORS LLC 869,565 5.7500 869,565 5.7500 4,999,999 14 5.9400 165,218 3.30

2021-01-11 PRLD ORBIMED ADVISORS LLC 41,700 60.0000 41,700 60.0000 2,502,000

2020-09-25 PRLD ORBIMED ADVISORS LLC 526,300 19.0000 526,300 19.0000 9,999,700

2020-09-25 PRLD ORBIMED ADVISORS LLC 710,500 19.0000 710,500 19.0000 13,499,500

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam PRLD / Prelude Therapeutics Incorporated - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam QTTB / Q32 Bio Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam QTTB / Q32 Bio Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam RNAC / Cartesian Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2016-06-27 SELB ORBIMED ADVISORS LLC 5,189 14.0000 5,189 14.0000 72,646 151 26.3300 63,980 88.07

2016-06-27 SELB ORBIMED ADVISORS LLC 544,811 14.0000 544,811 14.0000 7,627,354

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam RNAC / Cartesian Therapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam RPTX / Repare Therapeutics Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2020-06-23 RPTX ORBIMED ADVISORS LLC 675,000 20.0000 675,000 20.0000 13,500,000 198 44.46 16,510,500 122.30

2020-06-23 RPTX ORBIMED ADVISORS LLC 99,200 20.0000 99,200 20.0000 1,984,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam RPTX / Repare Therapeutics Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam RYTM / Rhythm Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2017-10-10 RYTM ORBIMED ADVISORS LLC 355,000 17.0000 355,000 17.0000 6,035,000 268 35.85 6,691,750 110.88

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam RYTM / Rhythm Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2018-05-22 RYTM ORBIMED ADVISORS LLC 17,980 30.3800 17,980 30.3800 546,232 216 24.11 -112,734 -20.64

2018-05-22 RYTM ORBIMED ADVISORS LLC 1,600 30.9600 1,600 30.9600 49,536

2018-05-21 RYTM ORBIMED ADVISORS LLC 62,500 31.0100 62,500 31.0100 1,938,125

2018-05-18 RYTM ORBIMED ADVISORS LLC 69,136 30.7700 69,136 30.7700 2,127,315

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam SCPH / scPharmaceuticals Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2024-08-13 SCPH ORBIMED ADVISORS LLC 478,342 4.0000 478,342 4.0000 1,913,368 345 5.8400 880,149 46.00

2024-08-13 SCPH ORBIMED ADVISORS LLC 21,658 4.0000 21,658 4.0000 86,632

2022-11-25 SCPH ORBIMED ADVISORS LLC 762,380 5.2500 762,380 5.2500 4,002,495

2020-05-21 SCPH ORBIMED ADVISORS LLC 1,156,083 8.6500 1,156,083 8.6500 10,000,118

2020-05-21 SCPH ORBIMED ADVISORS LLC 231,200 8.6500 231,200 8.6500 1,999,880

2017-11-21 SCPH ORBIMED ADVISORS LLC 833,333 14.0000 833,333 14.0000 11,666,662

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam SCPH / scPharmaceuticals Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam SIBN / SI-BONE, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2018-10-19 SIBN ORBIMED ADVISORS LLC 200,000 15.0000 200,000 15.0000 3,000,000 90 22.35 1,470,000 49.00

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam SIBN / SI-BONE, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam SPRY / ARS Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2023-08-29 SPRY ORBIMED ADVISORS LLC 500,000 6.2000 500,000 6.2000 3,100,000 357 14.8900 4,345,000 140.16

2020-12-08 SBTX ORBIMED ADVISORS LLC 238,100 21.0000 238,100 21.0000 5,000,100

2020-12-08 SBTX ORBIMED ADVISORS LLC 952,377 21.0000 952,377 21.0000 19,999,917

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam SPRY / ARS Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2024-08-26 SPRY ORBIMED ADVISORS LLC 83,695 13.0000 83,695 13.0000 1,088,035 189 10.1800 -236,020 -21.69

2024-08-23 SPRY ORBIMED ADVISORS LLC 69,500 13.0300 69,500 13.0300 905,585

2024-08-22 SPRY ORBIMED ADVISORS LLC 391,482 12.9400 391,482 12.9400 5,065,777

2024-08-21 SPRY ORBIMED ADVISORS LLC 394,400 13.5200 394,400 13.5200 5,332,288

2024-08-21 SPRY ORBIMED ADVISORS LLC 13,300 14.6100 13,300 14.6100 194,313

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam STTK / Shattuck Labs, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2025-08-25 STTK ORBIMED ADVISORS LLC 5,255,106 0.8677 5,255,106 0.8677 4,559,855 11 1.5500 3,585,559 78.63

2025-08-25 STTK ORBIMED ADVISORS LLC 1,051,021 0.8677 1,051,021 0.8677 911,971

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam STTK / Shattuck Labs, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam SUPN / Supernus Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2012-05-04 SUPN ORBIMED ADVISORS LLC 734,128 5.0000 734,128 5.0000 3,670,640 76 14.86 7,238,502 197.20

2012-05-04 SUPN ORBIMED ADVISORS LLC 274,873 5.0000 274,873 5.0000 1,374,365

2012-05-04 SUPN ORBIMED ADVISORS LLC 90,999 5.0000 90,999 5.0000 454,995

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam SUPN / Supernus Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2013-02-13 SUPN ORBIMED ADVISORS LLC 108,900 7.5757 108,900 7.5757 824,994 71 4.51 -333,854 -40.47

2013-02-13 SUPN ORBIMED ADVISORS LLC 41,100 7.5757 41,100 7.5757 311,361

2013-02-12 SUPN ORBIMED ADVISORS LLC 110,700 7.5218 110,700 7.5218 832,663

2013-02-12 SUPN ORBIMED ADVISORS LLC 41,483 7.5218 41,483 7.5218 312,027

2012-12-18 SUPN ORBIMED ADVISORS LLC 100,000 7.0767 100,000 7.0767 707,670

2012-12-17 SUPN ORBIMED ADVISORS LLC 197,815 6.8479 197,815 6.8479 1,354,617

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam SYBX / Synlogic, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam SYBX / Synlogic, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam SYRE / Spyre Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2017-02-21 AGLE ORBIMED ADVISORS LLC 7,000 5.3600 280 134.0000 37,520 27 200.75 18,690 49.81

2017-02-17 AGLE ORBIMED ADVISORS LLC 71,800 5.1900 2,872 129.7500 372,642

2017-02-16 AGLE ORBIMED ADVISORS LLC 30,500 5.0400 1,220 126.0000 153,720

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam SYRE / Spyre Therapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam TELA / TELA Bio, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2019-11-08 TELA ORBIMED ADVISORS LLC 384,615 13.0000 384,615 13.0000 4,999,995 224 22.61 3,696,150 73.92

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam TELA / TELA Bio, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2024-07-02 TELA ORBIMED ADVISORS LLC 36,600 4.5400 36,600 4.5400 166,164 293 0.8900 -133,590 -80.40

2024-07-01 TELA ORBIMED ADVISORS LLC 13,700 4.6800 13,700 4.6800 64,116

2024-06-28 TELA ORBIMED ADVISORS LLC 378,000 4.7400 378,000 4.7400 1,791,720

2023-04-21 TELA ORBIMED ADVISORS LLC 27,700 9.4100 27,700 9.4100 260,657

2023-04-20 TELA ORBIMED ADVISORS LLC 28,300 9.4300 28,300 9.4300 266,869

2023-04-19 TELA ORBIMED ADVISORS LLC 136,000 9.3000 136,000 9.3000 1,264,800

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam TERN / Terns Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2022-12-23 TERN ORBIMED ADVISORS LLC 137,931 7.2500 137,931 7.2500 1,000,000 118 13.2900 833,104 83.31

2022-08-16 TERN ORBIMED ADVISORS LLC 2,470,200 2.4200 2,470,200 2.4200 5,977,884

2022-08-16 TERN ORBIMED ADVISORS LLC 457,400 2.4200 457,400 2.4200 1,106,908

2022-08-16 TERN ORBIMED ADVISORS LLC 762,400 2.4200 762,400 2.4200 1,845,008

2021-02-09 TERN ORBIMED ADVISORS LLC 190,000 17.0000 190,000 17.0000 3,230,000

2021-02-09 TERN ORBIMED ADVISORS LLC 285,000 17.0000 285,000 17.0000 4,845,000

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam TERN / Terns Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2024-07-16 TERN ORBIMED ADVISORS LLC 4,009 10.0000 4,009 10.0000 40,090 265 2.0000 -32,072 -80.00

2024-07-16 TERN ORBIMED ADVISORS LLC 556 10.0000 556 10.0000 5,560

2024-07-16 TERN ORBIMED ADVISORS LLC 623 10.0000 623 10.0000 6,230

2024-07-15 TERN ORBIMED ADVISORS LLC 39,433 10.0000 39,433 10.0000 394,330

2024-07-15 TERN ORBIMED ADVISORS LLC 5,401 10.0000 5,401 10.0000 54,010

2024-07-15 TERN ORBIMED ADVISORS LLC 6,142 10.0000 6,142 10.0000 61,420

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam TRAW / Traws Pharma, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam TRAW / Traws Pharma, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam VRAYQ / ViewRay, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2017-01-18 VRAY ORBIMED ADVISORS LLC 327,459 3.0000 327,459 3.0000 982,377 358 10.1200 2,331,508 237.33

2017-01-18 VRAY ORBIMED ADVISORS LLC 3,118 3.0000 3,118 3.0000 9,354

2016-08-22 VRAY ORBIMED ADVISORS LLC 1,127,338 2.9500 1,127,338 2.9500 3,325,647

2016-08-22 VRAY ORBIMED ADVISORS LLC 10,736 2.9500 10,736 2.9500 31,671

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam VRAYQ / ViewRay, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2018-08-20 VRAY ORBIMED ADVISORS LLC 153,921 9.9800 153,921 9.9800 1,536,132 354 3.1000 -1,058,976 -68.94

2018-08-20 VRAY ORBIMED ADVISORS LLC 1,466 9.9800 1,466 9.9800 14,631

2018-08-20 VRAY ORBIMED ADVISORS LLC 153,921 9.9800 153,921 9.9800 1,536,132

2018-08-20 VRAY ORBIMED ADVISORS LLC 153,921 9.9800 153,921 9.9800 1,536,132

2018-08-16 VRAY ORBIMED ADVISORS LLC 362,765 9.9400 362,765 9.9400 3,605,884

2018-08-16 VRAY ORBIMED ADVISORS LLC 3,455 9.9400 3,455 9.9400 34,343

2018-08-16 VRAY ORBIMED ADVISORS LLC 362,765 9.9400 362,765 9.9400 3,605,884

2018-08-16 VRAY ORBIMED ADVISORS LLC 3,455 9.9400 3,455 9.9400 34,343

2018-08-15 VRAY ORBIMED ADVISORS LLC 77,314 9.9300 77,314 9.9300 767,728

2018-08-15 VRAY ORBIMED ADVISORS LLC 736 9.9300 736 9.9300 7,308

2018-08-14 VRAY ORBIMED ADVISORS LLC 20,777 9.9400 20,777 9.9400 206,523

2018-08-14 VRAY ORBIMED ADVISORS LLC 198 9.9400 198 9.9400 1,968

2018-08-13 VRAY ORBIMED ADVISORS LLC 86,103 9.9800 86,103 9.9800 859,308

2018-08-13 VRAY ORBIMED ADVISORS LLC 820 9.9800 820 9.9800 8,184

2018-08-10 VRAY ORBIMED ADVISORS LLC 678,333 9.9600 678,333 9.9600 6,756,197

2018-08-10 VRAY ORBIMED ADVISORS LLC 6,460 9.9600 6,460 9.9600 64,342

2018-08-09 VRAY ORBIMED ADVISORS LLC 108,729 9.9500 108,729 9.9500 1,081,854

2018-08-09 VRAY ORBIMED ADVISORS LLC 1,036 9.9500 1,036 9.9500 10,308

2018-08-09 VRAY ORBIMED ADVISORS LLC 64,575 9.9100 64,575 9.9100 639,938

2018-08-09 VRAY ORBIMED ADVISORS LLC 615 9.9100 615 9.9100 6,095

2018-08-09 VRAY ORBIMED ADVISORS LLC 26,139 9.8600 26,139 9.8600 257,731

2018-08-09 VRAY ORBIMED ADVISORS LLC 249 9.8600 249 9.8600 2,455

2018-08-08 VRAY ORBIMED ADVISORS LLC 478,107 10.0000 478,107 10.0000 4,781,070

2018-08-08 VRAY ORBIMED ADVISORS LLC 4,553 10.0000 4,553 10.0000 45,530

2018-08-07 VRAY ORBIMED ADVISORS LLC 50,149 10.0100 50,149 10.0100 501,991

2018-08-07 VRAY ORBIMED ADVISORS LLC 478 10.0100 478 10.0100 4,785

2018-08-03 VRAY ORBIMED ADVISORS LLC 118,168 11.7100 118,168 11.7100 1,383,747

2018-08-03 VRAY ORBIMED ADVISORS LLC 1,125 11.7100 1,125 11.7100 13,174

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2023-05-15 VRNA ORBIMED ADVISORS LLC 14,400 21.9600 14,400 21.9600 316,224 163 11.9400 -144,288 -45.63

2023-05-15 VRNA ORBIMED ADVISORS LLC 345,313 20.0000 345,313 20.0000 6,906,260

2023-05-12 VRNA ORBIMED ADVISORS LLC 43,200 21.6400 43,200 21.6400 934,848

2023-05-11 VRNA ORBIMED ADVISORS LLC 80,000 22.2600 80,000 22.2600 1,780,800

2022-12-23 VRNA ORBIMED ADVISORS LLC 961,328 22.2700 961,328 22.2700 21,408,775

2022-12-23 VRNA ORBIMED ADVISORS LLC 1,116,048 23.2300 1,116,048 23.2300 25,925,795

2022-12-23 VRNA ORBIMED ADVISORS LLC 92,992 24.1100 92,992 24.1100 2,242,037

2022-12-22 VRNA ORBIMED ADVISORS LLC 3,284,800 21.7100 3,284,800 21.7100 71,313,008

2022-12-22 VRNA ORBIMED ADVISORS LLC 684,696 22.0700 684,696 22.0700 15,111,241

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam WHWK / Whitehawk Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2018-06-28 ARPO ORBIMED ADVISORS LLC 777,500 3.8500 51,833 57.7500 2,993,375 11

2017-03-15 NONE ORBIMED ADVISORS LLC 762,995 5.0000 50,866 75.0000 3,814,975

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam WHWK / Whitehawk Therapeutics, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2020-12-08 ARPO ORBIMED ADVISORS LLC 21,400 1.9600 1,427 29.4000 41,944 21

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Pembelian Orang Dalam XTNT / Xtant Medical Holdings, Inc. - Analisis Keuntungan Jangka Pendek

Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .

Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Maks Harga pada
Maks Maks
Keuntungan ($) Pulangan Maks (%)

2018-02-14 XTNT ORBIMED ADVISORS LLC 603,687 7.2000 50,307 86.4000 4,346,546 33 9.75 -3,856,053 -88.72

2018-02-14 XTNT ORBIMED ADVISORS LLC 342,132 7.2000 28,511 86.4000 2,463,350

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Jualan Orang Dalam XTNT / Xtant Medical Holdings, Inc. - Analisis Kerugian Jangka Pendek

Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .

Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.

Tarikh Dagangan Simbol Saham Orang dalam Saham
Dilaporkan Harga
Dilaporkan Saham
Dilaraskan Harga
Dilaraskan Asas Kos Hari ke
Min Harga pada
Min Kerugian Maks
Dielakkan ($) Kerugian Maks
Dielakkan (%)

2025-04-10 XTNT ORBIMED ADVISORS LLC 56,004,974 0.4200 56,004,974 0.4200 23,522,089 0 0.3800 -2,240,199 -9.52

2025-04-10 XTNT ORBIMED ADVISORS LLC 17,109,618 0.4200 17,109,618 0.4200 7,186,040

Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.

Sejarah Dagangan Orang Dalam

Jadual ini menunjukkan senarai lengkap dagangan orang dalam yang dibuat oleh Orbimed Advisors Llc seperti yang didedahkan kepada Suruhanjaya Bursa Sekuriti (SEC).

Tarikh Fail Tarikh Tran Borang Simbol Saham Sekuriti Kod 10b5-1 Saham Baki Saham Peratus
Ubah Saham
harga Tran
Nilai Baki
Nilai

2025-09-02 2025-08-25 4 STTK Shattuck Labs, Inc.
Common Stock P - Purchase 1,051,021 1,051,021 0.87 911,971 911,971

2025-09-02 2025-08-25 4 STTK Shattuck Labs, Inc.
Common Stock P - Purchase 5,255,106 5,255,106 0.87 4,559,855 4,559,855

2025-08-12 2025-08-08 4 TSBX Turnstone Biologics Corp.
Common Stock U - Other -3,099,265 0 -100.00

2025-07-30 2025-07-25 4 IKNA ImageneBio, Inc.
Common Stock A - Award 83,611 287,885 40.93 2.49 208,191 716,834

2025-07-01 2025-06-27 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock S - Sale -1,176,332 7,165,006 -14.10 4.16 -4,891,894 29,796,394

2025-07-01 2025-06-27 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock X - Other 1,397,684 8,341,338 20.13 3.50 4,891,894 29,194,683

2025-06-26 2025-06-26 4 PASG Passage BIO, Inc.
Common Stock S - Sale -213,257 6,066,343 -3.40 0.33 -70,375 2,001,893

2025-06-26 2025-06-25 4 PASG Passage BIO, Inc.
Common Stock S - Sale -138,800 6,279,600 -2.16 0.33 -45,804 2,072,268

2025-06-26 2025-06-24 4 PASG Passage BIO, Inc.
Common Stock S - Sale -231,600 6,418,400 -3.48 0.35 -81,060 2,246,440

2025-05-16 2025-05-14 4 NPCE NeuroPace Inc
Common Stock S - Sale -34,000 3,238,199 -1.04 15.94 -541,960 51,616,892

2025-05-16 2025-05-14 4 NPCE NeuroPace Inc
Common Stock S - Sale -134,136 3,272,199 -3.94 15.83 -2,123,373 51,798,910

2025-04-24 2025-04-24 4 PASG Passage BIO, Inc.
Common Stock S - Sale -68,195 6,650,000 -1.02 0.32 -21,822 2,128,000

2025-04-24 2025-04-23 4 PASG Passage BIO, Inc.
Common Stock S - Sale -89,328 6,718,195 -1.31 0.34 -30,372 2,284,186

2025-04-24 2025-04-22 4 PASG Passage BIO, Inc.
Common Stock S - Sale -78,049 6,807,523 -1.13 0.34 -26,537 2,314,558

2025-04-17 2025-04-17 4 PASG Passage BIO, Inc.
Common Stock S - Sale -77,090 6,885,572 -1.11 0.33 -25,440 2,272,239

2025-04-17 2025-04-16 4 PASG Passage BIO, Inc.
Common Stock S - Sale -61,638 6,962,662 -0.88 0.33 -20,341 2,297,678

2025-04-17 2025-04-15 4 PASG Passage BIO, Inc.
Common Stock S - Sale -10,326 7,024,300 -0.15 0.38 -3,924 2,669,234

2025-04-14 2025-04-10 4 XTNT Xtant Medical Holdings, Inc.
Common Stock S - Sale -17,109,618 0 -100.00 0.42 -7,186,040

2025-04-14 2025-04-10 4 XTNT Xtant Medical Holdings, Inc.
Common Stock S - Sale -56,004,974 0 -100.00 0.42 -23,522,089

2025-04-11 2025-04-09 4 CMPX Compass Therapeutics, Inc.
Common Stock S - Sale -3,571,428 0 -100.00 1.59 -5,678,571

2025-04-04 2025-04-03 4 EWTX Edgewise Therapeutics, Inc.
Common Stock P - Purchase 124,193 443,792 38.86 20.13 2,500,005 8,933,533

2025-04-04 2025-04-03 4 EWTX Edgewise Therapeutics, Inc.
Common Stock P - Purchase 372,578 14,809,075 2.58 20.13 7,499,995 298,106,680

2025-03-26 2025-03-24 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -756 186,541 -0.40 54.11 -40,907 10,093,734

2025-03-26 2025-03-24 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -3,026 746,171 -0.40 54.11 -163,737 40,375,313

2025-03-26 2025-03-24 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -1,956 482,308 -0.40 54.11 -105,839 26,097,686

2025-03-21 2025-03-21 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -1,320 187,297 -0.70 54.00 -71,280 10,114,038

2025-03-21 2025-03-21 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -5,279 749,197 -0.70 54.00 -285,066 40,456,638

2025-03-21 2025-03-21 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -3,412 484,264 -0.70 54.00 -184,248 26,150,256

2025-03-21 2025-03-20 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -364 188,617 -0.19 54.01 -19,660 10,187,204

2025-03-21 2025-03-20 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -1,457 754,476 -0.19 54.01 -78,693 40,749,249

2025-03-21 2025-03-20 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -941 487,676 -0.19 54.01 -50,823 26,339,381

2025-03-21 2025-03-19 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -5,228 188,981 -2.69 54.02 -282,417 10,208,754

2025-03-21 2025-03-19 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -20,911 755,933 -2.69 54.02 -1,129,612 40,835,501

2025-03-21 2025-03-19 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -13,517 488,617 -2.69 54.02 -730,188 26,395,090

2025-03-12 2025-03-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -10,733 194,209 -5.24 54.44 -584,305 10,572,738

2025-03-12 2025-03-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -42,930 776,844 -5.24 54.44 -2,337,109 42,291,387

2025-03-12 2025-03-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -27,750 502,134 -5.24 54.44 -1,510,710 27,336,175

2025-03-12 2025-03-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -233 204,942 -0.11 55.05 -12,827 11,282,057

2025-03-12 2025-03-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -933 819,774 -0.11 55.05 -51,362 45,128,559

2025-03-12 2025-03-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -603 529,884 -0.11 55.05 -33,195 29,170,114

2025-03-12 2025-03-11 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -3,567 205,175 -1.71 54.01 -192,654 11,081,502

2025-03-12 2025-03-11 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -14,267 820,707 -1.71 54.01 -770,561 44,326,385

2025-03-12 2025-03-11 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -9,222 530,487 -1.71 54.01 -498,080 28,651,603

2025-03-12 2025-03-10 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -53 208,742 -0.03 55.01 -2,916 11,482,897

2025-03-12 2025-03-10 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -211 834,974 -0.03 55.01 -11,607 45,931,920

2025-03-12 2025-03-10 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -136 539,709 -0.03 55.01 -7,481 29,689,392

2025-03-12 2025-03-10 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -26,596 208,795 -11.30 54.29 -1,443,897 11,335,481

2025-03-12 2025-03-10 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -106,384 835,185 -11.30 54.29 -5,775,587 45,342,194

2025-03-12 2025-03-10 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -68,766 539,845 -11.30 54.29 -3,733,306 29,308,185

2025-02-19 2025-02-18 4 MBX MBX Biosciences, Inc.
Common Stock P - Purchase 94,100 747,887 14.39 10.84 1,020,044 8,107,095

2025-02-19 2025-02-18 4 MBX MBX Biosciences, Inc.
Common Stock P - Purchase 49,070 3,255,000 1.53 10.84 531,919 35,284,200

2025-02-19 2025-02-14 4 MBX MBX Biosciences, Inc.
Common Stock P - Purchase 29,540 3,205,930 0.93 9.85 290,969 31,578,410

2025-02-19 2025-02-14 4 MBX MBX Biosciences, Inc.
Common Stock P - Purchase 17,962 3,176,390 0.57 9.90 177,824 31,446,261

2025-02-10 2025-02-10 4 SION Sionna Therapeutics, Inc.
Common Stock P - Purchase 550,000 3,704,959 17.43 18.00 9,900,000 66,689,262

2025-02-10 2025-02-10 4 SION Sionna Therapeutics, Inc.
Common Stock C - Conversion 3,154,959 3,154,959

2025-01-14 2025-01-14 4 PASG Passage BIO, Inc.
Common Stock S - Sale -79,024 7,034,626 -1.11 0.60 -47,414 4,220,776

2025-01-14 2025-01-13 4 PASG Passage BIO, Inc.
Common Stock S - Sale -17,986 7,113,650 -0.25 0.64 -11,511 4,552,736

2025-01-14 2025-01-10 4 PASG Passage BIO, Inc.
Common Stock S - Sale -126,209 7,131,636 -1.74 0.66 -83,298 4,706,880

2025-01-08 2025-01-08 4 PASG Passage BIO, Inc.
Common Stock S - Sale -75,007 7,257,845 -1.02 0.68 -51,005 4,935,335

2025-01-08 2025-01-07 4 PASG Passage BIO, Inc.
Common Stock S - Sale -52,536 7,332,852 -0.71 0.71 -37,301 5,206,325

2025-01-08 2025-01-06 4 PASG Passage BIO, Inc.
Common Stock S - Sale -19,481 7,385,388 -0.26 0.77 -15,000 5,686,749

2024-12-26 2024-12-20 4 PASG Passage BIO, Inc.
Common Stock S - Sale -230,321 7,404,869 -3.02 0.60 -138,193 4,442,921

2024-12-11 2024-12-11 4 PASG Passage BIO, Inc.
Common Stock S - Sale -80 7,635,190 0.00 0.80 -64 6,108,152

2024-12-11 2024-12-10 4 PASG Passage BIO, Inc.
Common Stock S - Sale -8,015 7,635,270 -0.10 0.80 -6,412 6,108,216

2024-12-11 2024-12-09 4 PASG Passage BIO, Inc.
Common Stock S - Sale -54,181 7,643,285 -0.70 0.84 -45,512 6,420,359

2024-12-06 2024-12-06 4 PASG Passage BIO, Inc.
Common Stock S - Sale -20,903 7,697,466 -0.27 0.82 -17,140 6,311,922

2024-12-06 2024-12-04 4 PASG Passage BIO, Inc.
Common Stock S - Sale -76,200 7,718,369 -0.98 0.79 -60,198 6,097,512

2024-11-05 2024-11-01 4 NONE Lomond Therapeutics Holdings, Inc.
Common Stock A - Award 155,120 2,677,256 6.15 4.00 620,480 10,709,024

2024-11-05 2024-11-01 4 NONE Lomond Therapeutics Holdings, Inc.
Common Stock A - Award 479,736 2,522,136 23.49 4.00 1,918,944 10,088,544

2024-11-05 2024-11-01 4 NONE Lomond Therapeutics Holdings, Inc.
Common Stock A - Award 808,894 2,042,400 65.58 4.00 3,235,576 8,169,600

2024-11-05 2024-11-01 4 NONE Lomond Therapeutics Holdings, Inc.
Common Stock C - Conversion 74,613 1,233,506 6.44 3.60 268,607 4,440,622

2024-11-05 2024-11-01 4 NONE Lomond Therapeutics Holdings, Inc.
Common Stock C - Conversion 230,753 1,158,893 24.86 3.60 830,711 4,172,015

2024-11-05 2024-11-01 4 NONE Lomond Therapeutics Holdings, Inc.
Common Stock C - Conversion 389,078 928,140 72.18 3.60 1,400,681 3,341,304

2024-11-05 2024-11-01 4 NONE Lomond Therapeutics Holdings, Inc.
Common Stock C - Conversion 215,146 539,062 66.42 3.20 688,467 1,724,998

2024-11-05 2024-11-01 4 NONE Lomond Therapeutics Holdings, Inc.
Common Stock C - Conversion 323,916 323,916 3.20 1,036,531 1,036,531

2024-10-17 2024-10-15 4 UPB Upstream Bio, Inc.
Common Stock P - Purchase 660,000 4,554,873 16.95 17.00 11,220,000 77,432,841

2024-10-17 2024-10-15 4 UPB Upstream Bio, Inc.
Common Stock C - Conversion 2,887,833 3,894,873 286.76

2024-10-17 2024-10-15 4 UPB Upstream Bio, Inc.
Common Stock P - Purchase 165,000 1,138,716 16.95 17.00 2,805,000 19,358,172

2024-10-17 2024-10-15 4 UPB Upstream Bio, Inc.
Common Stock C - Conversion 721,956 973,716 286.76

2024-10-10 3 UPB Upstream Bio, Inc.
Common Stock 251,760

2024-10-10 3 UPB Upstream Bio, Inc.
Common Stock 1,007,040

2024-09-23 3 TRAW Traws Pharma, Inc.
Common Stock 602,000

2024-09-23 2024-09-19 4 PASG Passage BIO, Inc.
Common Stock S - Sale -39,300 7,794,569 -0.50 0.71 -27,903 5,534,144

2024-09-18 2024-09-18 4 PASG Passage BIO, Inc.
Common Stock S - Sale -25,631 7,833,869 -0.33 0.73 -18,711 5,718,724

2024-09-18 2024-09-17 4 PASG Passage BIO, Inc.
Common Stock S - Sale -111,400 7,859,500 -1.40 0.73 -81,322 5,737,435

2024-09-18 2024-09-16 4 PASG Passage BIO, Inc.
Common Stock S - Sale -63,100 7,970,900 -0.79 0.74 -46,694 5,898,466

2024-09-17 2024-09-16 4 MBX MBX Biosciences, Inc.
Common Stock P - Purchase 250,000 653,787 61.91 16.00 4,000,000 10,460,592

2024-09-17 2024-09-16 4 MBX MBX Biosciences, Inc.
Common Stock P - Purchase 500,000 3,158,428 18.81 16.00 8,000,000 50,534,848

2024-09-17 2024-09-16 4 MBX MBX Biosciences, Inc.
Common Stock C - Conversion 403,787 403,787

2024-09-17 2024-09-16 4 MBX MBX Biosciences, Inc.
Common Stock C - Conversion 2,658,428 2,658,428

2024-08-28 2024-08-26 4 SPRY ARS Pharmaceuticals, Inc.
Common Stock S - Sale -83,695 0 -100.00 13.00 -1,088,035

2024-08-23 2024-08-23 4 SPRY ARS Pharmaceuticals, Inc.
Common Stock S - Sale -69,500 83,695 -45.37 13.03 -905,585 1,090,546

2024-08-23 2024-08-22 4 SPRY ARS Pharmaceuticals, Inc.
Common Stock S - Sale -391,482 153,195 -71.87 12.94 -5,065,777 1,982,343

2024-08-23 2024-08-21 4 SPRY ARS Pharmaceuticals, Inc.
Common Stock S - Sale -13,300 544,677 -2.38 14.61 -194,313 7,957,731

2024-08-23 2024-08-21 4 SPRY ARS Pharmaceuticals, Inc.
Common Stock S - Sale -394,400 557,977 -41.41 13.52 -5,332,288 7,543,849

2024-08-15 2024-08-13 4 SCPH scPharmaceuticals Inc.
Common Stock P - Purchase 21,658 252,858 9.37 4.00 86,632 1,011,432

2024-08-15 2024-08-13 4 SCPH scPharmaceuticals Inc.
Common Stock P - Purchase 478,342 5,806,670 8.98 4.00 1,913,368 23,226,680

2024-08-15 2024-08-13 4 KROS Keros Therapeutics, Inc.
Common Stock S - Sale -29,400 119,522 -19.74 44.01 -1,293,894 5,260,163

2024-08-15 2024-08-13 4 KROS Keros Therapeutics, Inc.
Common Stock S - Sale -220,600 899,212 -19.70 44.01 -9,708,606 39,574,320

2024-07-17 2024-07-16 4 TERN Terns Pharmaceuticals, Inc.
Common Stock S - Sale -623 755,635 -0.08 10.00 -6,230 7,556,350

2024-07-17 2024-07-16 4 TERN Terns Pharmaceuticals, Inc.
Common Stock S - Sale -556 1,967,924 -0.03 10.00 -5,560 19,679,240

2024-07-17 2024-07-16 4 TERN Terns Pharmaceuticals, Inc.
Common Stock S - Sale -4,009 4,839,412 -0.08 10.00 -40,090 48,394,120

2024-07-17 2024-07-15 4 TERN Terns Pharmaceuticals, Inc.
Common Stock S - Sale -6,142 756,258 -0.81 10.00 -61,420 7,562,580

2024-07-17 2024-07-15 4 TERN Terns Pharmaceuticals, Inc.
Common Stock S - Sale -5,401 1,968,480 -0.27 10.00 -54,010 19,684,800

2024-07-17 2024-07-15 4 TERN Terns Pharmaceuticals, Inc.
Common Stock S - Sale -39,433 4,843,421 -0.81 10.00 -394,330 48,434,210

2024-07-02 2024-07-02 4 TELA TELA Bio, Inc.
Common Stock S - Sale -36,600 2,407,242 -1.50 4.54 -166,164 10,928,879

2024-07-02 2024-07-01 4 TELA TELA Bio, Inc.
Common Stock S - Sale -13,700 2,443,842 -0.56 4.68 -64,116 11,437,181

2024-07-02 2024-06-28 4 TELA TELA Bio, Inc.
Common Stock S - Sale -378,000 2,457,542 -13.33 4.74 -1,791,720 11,648,749

2024-06-20 2024-06-17 4 IRON Disc Medicine, Inc.
Common Stock P - Purchase 10,986 235,391 4.90 36.00 395,496 8,474,076

2024-06-20 2024-06-17 4 IRON Disc Medicine, Inc.
Common Stock P - Purchase 43,944 941,569 4.90 36.00 1,581,984 33,896,484

2024-06-20 2024-06-17 4 IRON Disc Medicine, Inc.
Common Stock P - Purchase 28,404 608,611 4.90 36.00 1,022,544 21,909,996

2024-05-20 2024-05-16 4 ELVN Enliven Therapeutics, Inc.
Common Stock S - Sale -1,000,000 7,663,349 -11.54 22.14 -22,140,000 169,666,547

2024-05-20 2024-05-16 4 ELVN Enliven Therapeutics, Inc.
Common Stock S - Sale -33,300 254,814 -11.56 22.14 -737,262 5,641,582

2024-05-20 2024-05-18 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock U - Other -264,315 0 -100.00

2024-05-20 2024-05-18 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock U - Other -2,416,181 0 -100.00

2024-05-03 2024-05-03 4 NPCE NeuroPace Inc
Common Stock S - Sale -4,674 3,406,335 -0.14 14.03 -65,576 47,790,880

2024-05-03 2024-05-02 4 NPCE NeuroPace Inc
Common Stock S - Sale -8,842 3,411,009 -0.26 14.01 -123,876 47,788,236

2024-05-03 2024-05-01 4 NPCE NeuroPace Inc
Common Stock S - Sale -15,690 3,419,851 -0.46 14.02 -219,974 47,946,311

2024-04-26 2024-04-24 4 NPCE NeuroPace Inc
Common Stock S - Sale -1,781 3,435,541 -0.05 14.06 -25,041 48,303,706

2024-04-23 2024-04-23 4 NPCE NeuroPace Inc
Common Stock S - Sale -21,791 3,437,322 -0.63 14.29 -311,393 49,119,331

2024-04-23 2024-04-22 4 NPCE NeuroPace Inc
Common Stock S - Sale -24,609 3,459,113 -0.71 14.05 -345,756 48,600,538

2024-04-23 2024-04-19 4 NPCE NeuroPace Inc
Common Stock S - Sale -18,253 3,483,722 -0.52 14.02 -255,907 48,841,782

2024-04-18 2024-04-18 4 NPCE NeuroPace Inc
Common Stock S - Sale -2,623 3,501,975 -0.07 14.06 -36,879 49,237,768

2024-04-18 2024-04-17 4 NPCE NeuroPace Inc
Common Stock S - Sale -300 3,504,598 -0.01 14.15 -4,245 49,590,062

2024-04-18 2024-04-16 4 NPCE NeuroPace Inc
Common Stock S - Sale -14,069 3,504,898 -0.40 14.01 -197,107 49,103,621

2024-04-15 2024-04-12 4 NPCE NeuroPace Inc
Common Stock S - Sale -23,101 3,518,967 -0.65 14.42 -333,116 50,743,504

2024-04-15 2024-04-11 4 NPCE NeuroPace Inc
Common Stock S - Sale -461,899 3,542,068 -11.54 14.49 -6,692,917 51,324,565

2024-04-12 3/A TRAW Traws Pharma, Inc.
Common Stock 1,045,261

2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock D - Sale to Issuer -450,000 0 -100.00

2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock D - Sale to Issuer -84,599 0 -100.00

2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock D - Sale to Issuer -1,368,338 0 -100.00

2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock D - Sale to Issuer -4,738,453 0 -100.00

2024-04-05 2024-04-03 4 KNTE Kinnate Biopharma Inc.
Common Stock D - Sale to Issuer -1,368,339 0 -100.00

2024-04-03 3 TRAW Traws Pharma, Inc.
Common Stock 885,532

2024-03-27 3 QTTB Q32 Bio Inc.
Common Stock 2,252,987

2024-02-14 2024-02-14 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock U - Other -650,600 0 -100.00

2024-02-14 2024-02-14 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock U - Other -17,063,000 0 -100.00

2024-01-31 2024-01-30 4 AVBP ArriVent Biopharma, Inc.
Common Stock P - Purchase 222,222 1,513,664 17.21 18.00 3,999,996 27,245,952

2024-01-31 2024-01-30 4 AVBP ArriVent Biopharma, Inc.
Common Stock P - Purchase 222,222 1,513,664 17.21 18.00 3,999,996 27,245,952

2024-01-31 2024-01-30 4 AVBP ArriVent Biopharma, Inc.
Common Stock C - Conversion 469,615 1,291,442 57.14

2024-01-31 2024-01-30 4 AVBP ArriVent Biopharma, Inc.
Common Stock C - Conversion 469,615 1,291,442 57.14

2024-01-31 2024-01-30 4 AVBP ArriVent Biopharma, Inc.
Common Stock C - Conversion 821,827 821,827

2024-01-31 2024-01-30 4 AVBP ArriVent Biopharma, Inc.
Common Stock C - Conversion 821,827 821,827

2024-01-26 2024-01-25 4 ACET Adicet Bio, Inc.
Common Stock P - Purchase 1,041,700 1,255,985 486.13 2.40 2,500,080 3,014,364

2024-01-26 2024-01-25 4 ACET Adicet Bio, Inc.
Common Stock P - Purchase 242,200 990,254 32.38 2.40 581,280 2,376,610

2024-01-26 2024-01-25 4 ACET Adicet Bio, Inc.
Common Stock P - Purchase 1,841,100 7,526,359 32.38 2.40 4,418,640 18,063,262

2024-01-25 2024-01-23 4 EWTX Edgewise Therapeutics, Inc.
Common Stock P - Purchase 454,545 14,436,497 3.25 11.00 4,999,995 158,801,467

2024-01-16 2024-01-11 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock X - Other 145,251 2,416,181 6.40 12.74 1,850,498 30,782,146

2023-12-29 2023-12-28 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock S - Sale -139,166 264,315 -34.49 18.32 -2,549,521 4,842,251

2023-12-29 2023-12-28 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock S - Sale -1,195,683 2,270,930 -34.49 18.32 -21,904,913 41,603,438

2023-12-29 2023-12-28 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock S - Sale -3,128 403,481 -0.77 19.82 -61,997 7,996,993

2023-12-29 2023-12-28 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock S - Sale -26,872 3,466,613 -0.77 19.82 -532,603 68,708,270

2023-12-29 2023-12-27 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock S - Sale -18,922 406,609 -4.45 19.96 -377,683 8,115,916

2023-12-29 2023-12-27 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock S - Sale -162,576 3,493,485 -4.45 19.96 -3,245,017 69,729,961

2023-12-20 2023-12-18 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -1,724 0 -100.00 59.24 -102,130

2023-12-20 2023-12-18 4 IRON Disc Medicine, Inc.
Common Stock M - Exercise 1,724 1,724 38.00 65,512 65,512

2023-12-15 2023-12-14 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -57,100 224,405 -20.28 56.75 -3,240,425 12,734,984

2023-12-15 2023-12-14 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -147,600 580,207 -20.28 56.75 -8,376,300 32,926,747

2023-12-15 2023-12-14 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -228,500 897,625 -20.29 56.75 -12,967,375 50,940,219

2023-12-14 2023-12-14 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -100 727,807 -0.01 57.73 -5,773 42,016,298

2023-12-14 2023-12-14 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -100 727,807 -0.01 57.73 -5,773 42,016,298

2023-12-14 2023-12-13 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -14,100 281,505 -4.77 58.56 -825,696 16,484,933

2023-12-14 2023-12-13 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -36,400 727,907 -4.76 58.56 -2,131,584 42,626,234

2023-12-14 2023-12-13 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -56,200 1,126,225 -4.75 58.56 -3,291,072 65,951,736

2023-12-14 2023-12-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -3,600 295,605 -1.20 60.16 -216,576 17,783,597

2023-12-14 2023-12-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -9,300 764,307 -1.20 60.16 -559,488 45,980,709

2023-12-14 2023-12-12 4 IRON Disc Medicine, Inc.
Common Stock S - Sale -14,400 1,182,425 -1.20 60.16 -866,304 71,134,688

2023-11-24 2023-11-22 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock S - Sale -87,786 0 -100.00 2.23 -195,763

2023-10-04 2023-10-03 4 NPCE NeuroPace Inc
Common Stock S - Sale -700 4,003,967 -0.02 9.02 -6,314 36,115,782

2023-10-04 2023-10-02 4 NPCE NeuroPace Inc
Common Stock S - Sale -7,614 4,004,667 -0.19 9.08 -69,135 36,362,376

2023-09-21 2023-08-04 4/A IKNA Ikena Oncology, Inc.
Non-Voting Common Stock A - Award 153,121 5,582,144 2.82

2023-09-14 2023-08-04 4 IKNA Ikena Oncology, Inc.
Common Stock A - Award 153,121 2,251,218 7.30

2023-08-31 2023-08-29 4 SPRY ARS Pharmaceuticals, Inc.
Common Stock P - Purchase 500,000 8,019,187 6.65 6.20 3,100,000 49,718,959

2023-08-17 2023-08-15 4 GLTO Galecto, Inc.
Common Stock S - Sale -535,534 1,510,375 -26.18 0.75 -401,650 1,132,781

2023-08-17 2023-08-15 4 GLTO Galecto, Inc.
Common Stock S - Sale -248,819 631,048 -28.28 0.75 -186,614 473,286

2023-08-17 2023-08-15 4 GLTO Galecto, Inc.
Common Stock S - Sale -38,327 97,204 -28.28 0.75 -28,745 72,903

2023-08-02 2023-07-31 4 GLTO Galecto, Inc.
Common Stock S - Sale -153,078 2,105,909 -6.78 3.00 -459,234 6,317,727

2023-08-02 2023-07-31 4 GLTO Galecto, Inc.
Common Stock S - Sale -29,700 879,867 -3.27 3.00 -89,100 2,639,601

2023-08-02 2023-07-31 4 GLTO Galecto, Inc.
Common Stock S - Sale -26,622 135,531 -16.42 3.00 -79,866 406,593

2023-07-27 2023-07-25 4 GLTO Galecto, Inc.
Common Stock S - Sale -26,700 2,258,987 -1.17 2.92 -77,964 6,596,242

2023-07-27 2023-07-25 4 GLTO Galecto, Inc.
Common Stock S - Sale -4,700 909,567 -0.51 2.92 -13,724 2,655,936

2023-07-27 2023-07-25 4 GLTO Galecto, Inc.
Common Stock S - Sale -7,800 162,153 -4.59 2.92 -22,776 473,487

2023-07-24 2023-07-20 4 TSBX Turnstone Biologics Corp.
Common Stock P - Purchase 416,666 3,099,265 15.53 12.00 4,999,992 37,191,180

2023-07-24 2023-07-20 4 TSBX Turnstone Biologics Corp.
Common Stock C - Conversion 2,682,599 2,682,599

2023-07-19 2023-07-17 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 151,450 650,600 30.34 3.05 461,922 1,984,330

2023-07-19 2023-07-17 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 328,482 17,063,000 1.96 3.05 1,001,870 52,042,150

2023-07-17 2023-07-13 4 GLTO Galecto, Inc.
Common Stock S - Sale -132,100 2,285,687 -5.46 2.40 -317,040 5,485,649

2023-07-17 2023-07-13 4 GLTO Galecto, Inc.
Common Stock S - Sale -52,800 914,267 -5.46 2.40 -126,720 2,194,241

2023-07-17 2023-07-13 4 GLTO Galecto, Inc.
Common Stock S - Sale -9,800 169,953 -5.45 2.40 -23,520 407,887

2023-06-29 2023-06-28 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 575,195 8,034,000 7.71 0.84 483,164 6,748,560

2023-06-29 2023-06-27 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 617,382 7,458,805 9.02 0.84 518,601 6,265,396

2023-06-29 2023-06-27 4 ACET Adicet Bio, Inc.
Common Stock P - Purchase 58,000 748,054 8.41 2.09 121,220 1,563,433

2023-06-29 2023-06-27 4 ACET Adicet Bio, Inc.
Common Stock P - Purchase 442,000 5,685,259 8.43 2.09 923,780 11,882,191

2023-06-29 2023-06-27 4 ACET Adicet Bio, Inc.
Common Stock P - Purchase 250,000 646,657 63.03 2.09 522,500 1,351,513

2023-06-29 2023-06-27 4 ACET Adicet Bio, Inc.
Common Stock P - Purchase 125,000 1,027,885 13.84 2.09 261,250 2,148,280

2023-05-24 2023-05-22 4 PRLD Prelude Therapeutics Inc
Common Stock P - Purchase 869,565 10,119,756 9.40 5.75 4,999,999 58,188,597

2023-05-19 2023-05-17 4 ELVN Enliven Therapeutics, Inc.
Common Stock M - Exercise 2,125 8,663,349 0.02 4.28 9,095 37,079,134

2023-05-15 2023-05-15 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -345,313 3,777,778 -8.38 20.00 -6,906,260 75,555,560

2023-05-15 2023-05-15 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -14,400 4,123,091 -0.35 21.96 -316,224 90,543,078

2023-05-15 2023-05-12 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -43,200 4,137,491 -1.03 21.64 -934,848 89,535,305

2023-05-15 2023-05-11 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -80,000 4,180,691 -1.88 22.26 -1,780,800 93,062,182

2023-05-08 2023-05-05 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 490,511 1,368,338 55.88 2.82 1,383,241 3,858,713

2023-05-08 2023-05-05 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 490,512 1,368,339 55.88 2.82 1,383,244 3,858,716

2023-05-08 2023-05-04 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 83,459 877,827 10.51 2.75 229,512 2,414,024

2023-05-08 2023-05-04 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 83,459 877,827 10.51 2.75 229,512 2,414,024

2023-05-08 2023-05-04 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 312,991 4,738,453 7.07 2.75 860,725 13,030,746

2023-05-02 2023-05-02 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 58,826 794,368 8.00 2.67 157,065 2,120,963

2023-05-02 2023-05-02 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 58,826 794,368 8.00 2.67 157,065 2,120,963

2023-05-02 2023-05-02 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 220,610 4,425,462 5.25 2.67 589,029 11,815,984

2023-05-02 2023-05-01 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 124,545 735,542 20.38 2.62 326,308 1,927,120

2023-05-02 2023-05-01 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 467,068 4,204,852 12.50 2.62 1,223,718 11,016,712

2023-05-02 2023-05-01 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 124,544 735,542 20.38 2.62 326,305 1,927,120

2023-05-02 2023-04-28 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 60,997 610,997 11.09 2.55 155,542 1,558,042

2023-05-02 2023-04-28 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 228,754 3,737,784 6.52 2.55 583,323 9,531,349

2023-05-02 2023-04-28 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 60,998 610,998 11.09 2.55 155,545 1,558,045

2023-04-21 2023-04-21 4 TELA TELA Bio, Inc.
Common Stock S - Sale -27,700 2,835,542 -0.97 9.41 -260,657 26,682,450

2023-04-21 2023-04-20 4 TELA TELA Bio, Inc.
Common Stock S - Sale -28,300 2,863,242 -0.98 9.43 -266,869 27,000,372

2023-04-21 2023-04-19 4 TELA TELA Bio, Inc.
Common Stock S - Sale -136,000 2,891,542 -4.49 9.30 -1,264,800 26,891,341

2023-04-17 2023-04-17 4 GLTO Galecto, Inc.
Common Stock S - Sale -8,878 2,417,787 -0.37 1.97 -17,490 4,763,040

2023-04-17 2023-04-17 4 GLTO Galecto, Inc.
Common Stock S - Sale -3,551 967,067 -0.37 1.97 -6,995 1,905,122

2023-04-17 2023-04-17 4 GLTO Galecto, Inc.
Common Stock S - Sale -660 179,753 -0.37 1.97 -1,300 354,113

2023-04-17 2023-04-14 4 GLTO Galecto, Inc.
Common Stock S - Sale -28,110 2,426,665 -1.15 1.86 -52,285 4,513,597

2023-04-17 2023-04-14 4 GLTO Galecto, Inc.
Common Stock S - Sale -11,245 970,618 -1.15 1.86 -20,916 1,805,349

2023-04-17 2023-04-14 4 GLTO Galecto, Inc.
Common Stock S - Sale -2,091 180,413 -1.15 1.86 -3,889 335,568

2023-04-17 2023-04-13 4 GLTO Galecto, Inc.
Common Stock S - Sale -9,459 2,454,775 -0.38 1.82 -17,215 4,467,690

2023-04-17 2023-04-13 4 GLTO Galecto, Inc.
Common Stock S - Sale -3,784 981,863 -0.38 1.82 -6,887 1,786,991

2023-04-17 2023-04-13 4 GLTO Galecto, Inc.
Common Stock S - Sale -703 182,504 -0.38 1.82 -1,279 332,157

2023-04-12 2023-04-12 4 GLTO Galecto, Inc.
Common Stock S - Sale -1,603 2,464,234 -0.07 1.81 -2,901 4,460,264

2023-04-12 2023-04-12 4 GLTO Galecto, Inc.
Common Stock S - Sale -641 985,647 -0.06 1.81 -1,160 1,784,021

2023-04-12 2023-04-12 4 GLTO Galecto, Inc.
Common Stock S - Sale -119 183,207 -0.06 1.81 -215 331,605

2023-04-12 2023-04-11 4 GLTO Galecto, Inc.
Common Stock S - Sale -9,459 2,465,837 -0.38 1.82 -17,215 4,487,823

2023-04-12 2023-04-11 4 GLTO Galecto, Inc.
Common Stock S - Sale -3,784 986,288 -0.38 1.82 -6,887 1,795,044

2023-04-12 2023-04-11 4 GLTO Galecto, Inc.
Common Stock S - Sale -703 183,326 -0.38 1.82 -1,279 333,653

2023-04-12 2023-04-10 4 GLTO Galecto, Inc.
Common Stock S - Sale -34,745 2,500,582 -1.37 1.79 -62,194 4,476,042

2023-04-12 2023-04-10 4 GLTO Galecto, Inc.
Common Stock S - Sale -13,899 1,000,187 -1.37 1.79 -24,879 1,790,335

2023-04-12 2023-04-10 4 GLTO Galecto, Inc.
Common Stock S - Sale -2,584 185,910 -1.37 1.79 -4,625 332,779

2023-04-07 2023-04-06 4 GLTO Galecto, Inc.
Common Stock S - Sale -6,558 2,510,041 -0.26 2.00 -13,116 5,020,082

2023-04-07 2023-04-06 4 GLTO Galecto, Inc.
Common Stock S - Sale -2,620 1,003,971 -0.26 2.00 -5,240 2,007,942

2023-04-07 2023-04-06 4 GLTO Galecto, Inc.
Common Stock S - Sale -487 186,613 -0.26 2.00 -974 373,226

2023-04-07 2023-04-05 4 GLTO Galecto, Inc.
Common Stock S - Sale -63,058 2,516,599 -2.44 2.18 -137,466 5,486,186

2023-04-07 2023-04-05 4 GLTO Galecto, Inc.
Common Stock S - Sale -25,220 1,006,591 -2.44 2.18 -54,980 2,194,368

2023-04-07 2023-04-05 4 GLTO Galecto, Inc.
Common Stock S - Sale -4,687 187,100 -2.44 2.18 -10,218 407,878

2023-02-27 2023-02-23 4 ELVN Enliven Therapeutics, Inc.
Common Stock A - Award 288,114 288,114

2023-02-27 2023-02-23 4 ELVN Enliven Therapeutics, Inc.
Common Stock A - Award 7,611,458 8,661,225 725.06

2023-02-23 2023-02-17 4 KNTE Kinnate Biopharma Inc.
Common Stock A - Award 550,000 550,000

2023-02-23 2023-02-17 4 KNTE Kinnate Biopharma Inc.
Common Stock A - Award 550,000 550,000

2023-02-17 2023-02-15 4 IRON Disc Medicine, Inc.
Common Stock P - Purchase 14,329 299,205 5.03 23.00 329,567 6,881,715

2023-02-17 2023-02-15 4 IRON Disc Medicine, Inc.
Common Stock P - Purchase 37,049 773,607 5.03 23.00 852,127 17,792,961

2023-02-17 2023-02-15 4 IRON Disc Medicine, Inc.
Common Stock P - Purchase 57,318 1,196,825 5.03 23.00 1,318,314 27,526,975

2023-01-03 3 IRON Disc Medicine, Inc.
Common Stock 284,876

2023-01-03 3 IRON Disc Medicine, Inc.
Common Stock 1,139,507

2023-01-03 3 IRON Disc Medicine, Inc.
Common Stock 153,936

2023-01-03 2022-12-29 4 IRON Disc Medicine, Inc.
Common Stock J - Other 1,139,507 1,139,507

2023-01-03 2022-12-29 4 IRON Disc Medicine, Inc.
Common Stock J - Other 153,936 736,558 26.42

2023-01-03 2022-12-29 4 IRON Disc Medicine, Inc.
Common Stock J - Other 582,622 582,622

2023-01-03 2022-12-29 4 IRON Disc Medicine, Inc.
Common Stock J - Other 284,876 284,876

2022-12-28 2022-12-23 4 TERN Terns Pharmaceuticals, Inc.
Common Stock P - Purchase 137,931 4,882,854 2.91 7.25 1,000,000 35,400,692

2022-12-27 2022-12-23 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -92,992 34,085,528 -0.27 24.11 -2,242,037 821,802,080

2022-12-27 2022-12-23 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -1,116,048 34,178,520 -3.16 23.23 -25,925,795 793,967,020

2022-12-27 2022-12-23 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -961,328 35,294,568 -2.65 22.27 -21,408,775 786,010,029

2022-12-27 2022-12-22 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -684,696 36,255,896 -1.85 22.07 -15,111,241 800,167,625

2022-12-27 2022-12-22 4 VRNA Verona Pharma plc
Ordinary Shares S - Sale -3,284,800 36,940,592 -8.17 21.71 -71,313,008 801,980,252

2022-11-29 2022-11-25 4 SCPH scPharmaceuticals Inc.
Common Stock P - Purchase 762,380 5,328,328 16.70 5.25 4,002,495 27,973,722

2022-11-25 2022-11-25 4 TCDA Tricida, Inc.
Common Stock S - Sale -3,629,226 0 -100.00 0.22 -798,430

2022-11-25 2022-11-23 4 TCDA Tricida, Inc.
Common Stock S - Sale -5,617,300 3,629,226 -60.75 0.21 -1,179,633 762,137

2022-11-25 2022-11-22 4 TCDA Tricida, Inc.
Common Stock S - Sale -1,034,421 9,246,526 -10.06 0.22 -227,573 2,034,236

2022-11-10 2022-11-08 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 402,000 15,219,994 2.71 3.21 1,290,420 48,856,181

2022-11-09 2022-11-07 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 192,000 16,734,518 1.16 5.21 1,000,320 87,186,839

2022-09-21 2022-09-19 4 THRD Third Harmonic Bio, Inc.
Common Stock P - Purchase 300,000 5,779,071 5.48 17.00 5,100,000 98,244,207

2022-09-21 2022-09-19 4 THRD Third Harmonic Bio, Inc.
Common Stock C - Conversion 5,479,071 5,479,071

2022-09-16 2022-09-16 4 EWTX Edgewise Therapeutics, Inc.
Common Stock P - Purchase 484,496 13,981,952 3.59 10.32 4,999,999 144,293,745

2022-09-14 2022-09-12 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale -30,000 5,599,842 -0.53 31.98 -959,400 179,082,947

2022-09-14 2022-09-12 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale -123,897 5,629,842 -2.15 31.96 -3,959,748 179,929,750

2022-08-18 2022-08-16 4 TERN Terns Pharmaceuticals, Inc.
Common Stock P - Purchase 762,400 762,400 2.42 1,845,008 1,845,008

2022-08-18 2022-08-16 4 TERN Terns Pharmaceuticals, Inc.
Common Stock P - Purchase 457,400 1,973,881 30.16 2.42 1,106,908 4,776,792

2022-08-18 2022-08-16 4 TERN Terns Pharmaceuticals, Inc.
Common Stock P - Purchase 2,470,200 4,744,923 108.59 2.42 5,977,884 11,482,714

2022-08-17 2022-08-15 4 XTNT Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value J - Other 215,415 215,415

2022-08-17 2022-08-15 4 XTNT Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value J - Other 215,415 215,415

2022-08-10 2022-08-09 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale -69,568 5,753,739 -1.19 37.47 -2,606,713 215,592,600

2022-08-10 2022-08-08 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale -205,000 5,823,307 -3.40 38.33 -7,857,650 223,207,357

2022-07-01 2022-07-01 4 SRRA Sierra Oncology, Inc.
Common Stock D - Sale to Issuer -226,704 0 -100.00 55.00 -12,468,720

2022-07-01 2022-07-01 4 SRRA Sierra Oncology, Inc.
Common Stock D - Sale to Issuer -226,704 0 -100.00 55.00 -12,468,720

2022-07-01 2022-07-01 4 SRRA Sierra Oncology, Inc.
Common Stock D - Sale to Issuer -1,511,362 0 -100.00 55.00 -83,124,910

2022-06-28 2022-06-24 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock S - Sale -35,944 415,142 -7.97 21.31 -765,967 8,846,676

2022-06-28 2022-06-24 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock S - Sale -306,027 3,534,537 -7.97 21.31 -6,521,435 75,320,983

2022-06-24 2022-06-24 4 IKNA Ikena Oncology, Inc.
Common Stock P - Purchase -96,035 2,098,097 -4.38 5.37 -515,708 11,266,781

2022-06-24 2022-06-24 4 IKNA Ikena Oncology, Inc.
Common Stock P - Purchase -65,965 2,002,062 -3.19 4.37 -288,267 8,749,011

2022-06-24 2022-06-23 4 IKNA Ikena Oncology, Inc.
Common Stock P - Purchase -23,419 1,936,097 -1.20 3.71 -86,884 7,182,920

2022-06-24 2022-06-22 4 IKNA Ikena Oncology, Inc.
Common Stock P - Purchase -66,806 1,912,678 -3.37 3.55 -237,161 6,790,007

2022-05-31 2022-05-26 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock S - Sale -26,253 87,786 -23.02 15.93 -418,210 1,398,431

2022-05-20 2022-05-18 4 EWTX Edgewise Therapeutics, Inc.
Common Stock P - Purchase 138,000 13,497,456 1.03 7.21 994,980 97,316,658

2022-05-13 2022-05-13 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 30,722 14,817,994 0.21 2.49 76,498 36,896,805

2022-05-13 2022-05-12 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 97,094 14,787,272 0.66 2.35 228,171 34,750,089

2022-05-13 2022-05-11 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 64,700 14,690,178 0.44 1.79 115,813 26,295,419

2022-05-10 2022-05-10 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 24,447 14,625,478 0.17 1.60 39,115 23,400,765

2022-05-10 2022-05-09 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 90,712 14,601,031 0.63 1.56 141,511 22,777,608

2022-05-10 2022-05-06 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 10,200 14,510,319 0.07 1.63 16,626 23,651,820

2022-05-05 2022-01-20 4/A PASG Passage BIO, Inc.
Common Stock P - Purchase 50,800 6,316,423 0.81 5.00 254,000 31,582,115

2022-05-05 2022-05-04 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 303,500 6,841,423 4.64 1.94 588,790 13,272,361

2022-05-05 2022-05-03 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 221,500 6,537,923 3.51 1.93 427,495 12,618,191

2022-04-08 2022-04-08 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock S - Sale -102,800 451,086 -18.56 20.71 -2,128,988 9,341,991

2022-04-08 2022-04-08 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock S - Sale -97,200 3,840,564 -2.47 20.71 -2,013,012 79,538,080

2022-04-08 2022-04-07 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock S - Sale -177,196 553,886 -24.24 20.66 -3,660,869 11,443,285

2022-04-08 2022-04-07 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock S - Sale -167,800 3,937,764 -4.09 20.66 -3,466,748 81,354,204

2022-04-08 2022-04-06 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock S - Sale -171,204 731,082 -18.97 20.69 -3,542,211 15,126,087

2022-04-08 2022-04-06 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock S - Sale -162,000 4,105,564 -3.80 20.69 -3,351,780 84,944,119

2022-03-31 2022-03-31 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock S - Sale -34,500 0 -100.00 21.17 -730,365

2022-03-31 2022-03-30 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock S - Sale -75,000 34,500 -68.49 22.39 -1,679,250 772,455

2022-03-31 2022-03-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock S - Sale -365,000 109,500 -76.92 21.52 -7,854,800 2,356,440

2022-02-15 2022-02-15 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 9,000 3,509,030 0.26 9.96 89,640 34,949,939

2022-02-15 2022-02-14 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 10,000 3,500,030 0.29 9.89 98,900 34,615,297

2022-02-15 2022-02-14 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 20,700 3,490,030 0.60 9.98 206,586 34,830,499

2022-02-15 2022-02-11 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 156,000 3,469,330 4.71 10.22 1,594,320 35,456,553

2022-01-28 2022-01-26 4 SRRA Sierra Oncology, Inc.
Series B Warrants X - Other -56,244 0 -100.00

2022-01-28 2022-01-26 4 SRRA Sierra Oncology, Inc.
Series B Warrants X - Other -56,244 0 -100.00

2022-01-28 2022-01-26 4 SRRA Sierra Oncology, Inc.
Series B Warrants X - Other -374,962 0 -100.00

2022-01-28 2022-01-26 4 SRRA Sierra Oncology, Inc.
Common Stock X - Other 56,244 226,704 33.00 13.20 742,421 2,992,493

2022-01-28 2022-01-26 4 SRRA Sierra Oncology, Inc.
Common Stock X - Other 56,244 226,704 33.00 13.20 742,421 2,992,493

2022-01-28 2022-01-26 4 SRRA Sierra Oncology, Inc.
Common Stock X - Other 374,962 1,511,362 33.00 13.20 4,949,498 19,949,978

2022-01-27 2022-01-26 4 ETNB 89bio, Inc.
Common Stock S - Sale -10,740 1,829,436 -0.58 8.38 -90,001 15,330,674

2022-01-27 2022-01-26 4 ETNB 89bio, Inc.
Common Stock S - Sale -10,742 1,829,433 -0.58 8.38 -90,018 15,330,649

2022-01-27 2022-01-25 4 ETNB 89bio, Inc.
Common Stock S - Sale -24,545 1,840,176 -1.32 8.40 -206,178 15,457,478

2022-01-27 2022-01-25 4 ETNB 89bio, Inc.
Common Stock S - Sale -24,546 1,840,175 -1.32 8.40 -206,186 15,457,470

2022-01-24 2022-01-20 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 369,100 6,634,723 5.89 5.42 2,000,522 35,960,199

2022-01-21 2022-01-21 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 111,896 16,542,652 0.68 9.97 1,115,603 164,930,240

2022-01-21 2022-01-20 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 35,000 16,430,756 0.21 9.95 348,250 163,486,022

2022-01-21 2022-01-19 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 11,521 16,395,756 0.07 9.97 114,864 163,465,687

2022-01-20 2022-01-19 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 43,300 6,265,623 0.70 5.11 221,263 32,017,334

2022-01-20 2022-01-18 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 114,700 6,222,323 1.88 5.46 626,262 33,973,884

2022-01-20 2022-01-14 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 10,300 6,107,623 0.17 5.60 57,680 34,202,689

2022-01-13 2022-01-13 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 17,320 16,384,235 0.11 9.43 163,328 154,503,336

2022-01-13 2022-01-12 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 18,897 16,366,915 0.12 10.06 190,104 164,651,165

2022-01-13 2022-01-11 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 6,900 16,348,018 0.04 10.67 73,623 174,433,352

2022-01-13 2022-01-11 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 1,600 16,341,118 0.01 9.81 15,696 160,306,368

2022-01-13 2022-01-13 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 41,800 6,097,323 0.69 5.52 230,736 33,657,223

2022-01-13 2022-01-12 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 100,000 6,055,523 1.68 5.65 565,000 34,213,705

2022-01-13 2022-01-11 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 8,200 5,955,523 0.14 5.53 45,346 32,934,042

2021-12-30 2021-12-29 4 JANX Janux Therapeutics, Inc.
Common Stock S - Sale -3,700 231,098 -1.58 20.30 -75,110 4,691,289

2021-12-30 2021-12-29 4 JANX Janux Therapeutics, Inc.
Common Stock S - Sale -36,700 2,258,566 -1.60 20.30 -745,010 45,848,890

2021-12-23 2021-12-21 4 JANX Janux Therapeutics, Inc.
Common Stock S - Sale -11,100 234,798 -4.51 19.00 -210,900 4,461,162

2021-12-23 2021-12-21 4 JANX Janux Therapeutics, Inc.
Common Stock S - Sale -108,300 2,295,266 -4.51 19.00 -2,057,700 43,610,054

2021-12-17 2021-12-16 4 JANX Janux Therapeutics, Inc.
Common Stock S - Sale -36,500 245,898 -12.93 19.07 -696,055 4,689,275

2021-12-17 2021-12-16 4 JANX Janux Therapeutics, Inc.
Common Stock S - Sale -356,800 2,403,566 -12.93 19.07 -6,804,176 45,836,004

2021-12-14 2021-12-10 4 ACET Adicet Bio, Inc.
Common Stock A - Award 214,285 242,285 765.30 14.00 2,999,990 3,391,990

2021-11-17 2021-11-15 4 TCDA Tricida, Inc.
Comm on Warrants to Purchase Common Stock A - Award 666,667 666,667

2021-11-17 2021-11-15 4 TCDA Tricida, Inc.
Common Stock A - Award 666,667 10,280,947 6.93 6.00 4,000,002 61,685,682

2021-11-08 2021-11-04 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 3,571,428 3,571,428 3.50 12,499,998 12,499,998

2021-11-08 2021-11-04 4 CMPX Compass Therapeutics, Inc.
Common Stock P - Purchase 1,785,715 14,500,119 14.04 3.50 6,250,002 50,750,416

2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock C - Conversion -436,650 0 -100.00

2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock C - Conversion -873,300 0 -100.00

2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Series A Convertible Preferred Stock C - Conversion -14,903,718 0 -100.00

2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 62,500 499,150 14.31 16.00 1,000,000 7,986,400

2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock P - Purchase 562,500 16,339,518 3.57 16.00 9,000,000 261,432,288

2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock C - Conversion 436,650 436,650

2021-10-14 2021-10-12 4 THRX Theseus Pharmaceuticals, Inc.
Common Stock C - Conversion 15,777,018 15,777,018

2021-09-22 2021-09-20 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value S - Sale -1,109,644 6,943,654 -13.78 6.09 -6,757,732 42,286,853

2021-09-21 2021-09-17 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock P - Purchase 425,531 425,531 9.40 3,999,991 3,999,991

2021-09-21 2021-09-17 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock P - Purchase 585,106 3,656,061 19.05 9.40 5,499,996 34,366,973

2021-09-08 2021-09-07 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -26 96,190 -0.03 33.93 -882 3,263,727

2021-09-08 2021-09-07 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -861 3,177,041 -0.03 33.93 -29,214 107,797,001

2021-09-08 2021-09-03 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -212 96,216 -0.22 34.00 -7,208 3,271,344

2021-09-08 2021-09-03 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -6,985 3,177,902 -0.22 34.00 -237,490 108,048,668

2021-09-02 2021-09-02 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -483 96,428 -0.50 34.24 -16,538 3,301,695

2021-09-02 2021-09-02 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -15,941 3,184,887 -0.50 34.24 -545,820 109,050,531

2021-09-02 2021-09-01 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -382 96,911 -0.39 33.98 -12,980 3,293,036

2021-09-02 2021-09-01 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -12,586 3,200,828 -0.39 33.98 -427,672 108,764,135

2021-09-02 2021-08-31 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -249 97,293 -0.26 33.94 -8,451 3,302,124

2021-09-02 2021-08-31 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -8,223 3,213,414 -0.26 33.94 -279,089 109,063,271

2021-08-30 2021-08-30 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -197 97,542 -0.20 33.92 -6,682 3,308,625

2021-08-30 2021-08-30 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -6,500 3,221,637 -0.20 33.92 -220,480 109,277,927

2021-08-30 2021-08-27 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -209 97,739 -0.21 33.94 -7,093 3,317,262

2021-08-30 2021-08-27 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -6,884 3,228,137 -0.21 33.94 -233,643 109,562,970

2021-08-30 2021-08-26 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -126 97,948 -0.13 34.52 -4,350 3,381,165

2021-08-30 2021-08-26 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -4,157 3,235,021 -0.13 34.52 -143,500 111,672,925

2021-08-25 2021-08-25 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -208 98,074 -0.21 34.34 -7,143 3,367,861

2021-08-25 2021-08-25 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -6,874 3,239,178 -0.21 34.34 -236,053 111,233,373

2021-08-25 2021-08-24 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -119 98,282 -0.12 34.07 -4,054 3,348,468

2021-08-25 2021-08-24 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -3,920 3,246,052 -0.12 34.07 -133,554 110,592,992

2021-08-25 2021-08-23 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -209 98,401 -0.21 34.06 -7,119 3,351,538

2021-08-25 2021-08-23 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -6,885 3,249,972 -0.21 34.06 -234,503 110,694,046

2021-08-19 2021-08-18 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -78 98,610 -0.08 33.99 -2,651 3,351,754

2021-08-19 2021-08-18 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -2,852 3,256,857 -0.09 33.99 -96,939 110,700,569

2021-08-19 2021-08-17 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -512 98,688 -0.52 34.12 -17,469 3,367,235

2021-08-19 2021-08-17 4 RPTX Repare Therapeutics Inc.
Common Stock S - Sale X -16,886 3,259,439 -0.52 34.12 -576,150 111,212,059

2021-08-17 2021-08-15 4 XTNT Xtant Medical Holdings, Inc.
Common Stock J - Other 85,337 120,549 242.35

2021-08-17 2021-08-15 4 XTNT Xtant Medical Holdings, Inc.
Common Stock J - Other 85,337 120,549 242.35

2021-07-23 2021-07-16 4/A IMRA IMARA Inc.
Common Stock P - Purchase 1,666,666 4,199,068 65.81 6.00 9,999,996 25,194,408

2021-07-21 2021-07-19 4 AFIB Acutus Medical, Inc.
Common Stock P - Purchase 357,143 1,677,361 27.05 14.00 5,000,002 23,483,054

2021-07-21 2021-07-19 4 AFIB Acutus Medical, Inc.
Common Stock P - Purchase 714,285 4,872,025 17.18 14.00 9,999,990 68,208,350

2021-07-16 2021-07-16 4 IMRA IMARA Inc.
Common Stock P - Purchase 1,666,666 1,666,666 6.00 9,999,996 9,999,996

2021-07-06 2021-07-01 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -15,959 6,028,307 -0.26 85.01 -1,356,675 512,466,378

2021-06-30 2021-06-28 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -6,502 6,044,266 -0.11 85.17 -553,775 514,790,135

2021-06-25 2021-06-25 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -22,334 6,050,768 -0.37 85.14 -1,901,517 515,162,388

2021-06-25 2021-06-24 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -34,200 6,073,102 -0.56 85.22 -2,914,524 517,549,752

2021-06-25 2021-06-23 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -100 6,107,302 0.00 85.00 -8,500 519,120,670

2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Series B Convertible Preferred Stock C - Conversion -128,609 0 -100.00

2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Series B Convertible Preferred Stock C - Conversion -643,046 0 -100.00

2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Series A Convertible Preferred Stock C - Conversion -1,052,632 0 -100.00

2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock P - Purchase 117,650 282,398 71.41 17.00 2,000,050 4,800,766

2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock C - Conversion 164,748 164,748

2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock P - Purchase 588,203 2,760,366 27.08 17.00 9,999,451 46,926,222

2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock C - Conversion 823,742 2,172,163 61.09

2021-06-16 2021-06-15 4 JANX Janux Therapeutics, Inc.
Common Stock C - Conversion 1,348,421 1,348,421

2021-06-14 2021-06-10 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -30,852 6,107,402 -0.50 85.09 -2,625,197 519,678,836

2021-06-09 2021-06-09 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -5,049 6,138,254 -0.08 85.33 -430,831 523,777,214

2021-06-09 2021-06-08 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -42,633 6,143,303 -0.69 85.37 -3,639,579 524,453,777

2021-06-09 2021-06-07 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale X -371 6,185,936 -0.01 84.90 -31,498 525,185,966

2021-04-26 2021-04-26 4 NPCE NeuroPace Inc
Series B' Preferred Stock C - Conversion -3,605,386 0 -100.00

2021-04-26 2021-04-26 4 NPCE NeuroPace Inc
Series A' Preferred Stock C - Conversion -171,895 0 -100.00

2021-04-26 2021-04-26 4 NPCE NeuroPace Inc
Common Stock C - Conversion 3,777,281 4,012,281 1,607.35

2021-04-23 2021-04-21 4 NPCE NeuroPace Inc
Common Stock P - Purchase 235,000 235,000 17.00 3,995,000 3,995,000

2021-04-22 2021-04-20 4 SYBX SYNLOGIC, INC.
Common Stock, $0.001 par value A - Award 1,666,666 3,696,662 82.10 3.00 4,999,998 11,089,986

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Series B Preferred Stock C - Conversion -42,614 0 -100.00

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Series B Preferred Stock C - Conversion -157,288 0 -100.00

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Series B Preferred Stock C - Conversion -266,336 0 -100.00

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Series B Preferred Stock C - Conversion -983,055 0 -100.00

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Series A-1 Preferred Stock C - Conversion -653,277 0 -100.00

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Series A-1 Preferred Stock C - Conversion -2,411,260 0 -100.00

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Series A Preferred Stock C - Conversion -551,259 0 -100.00

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Series A Preferred Stock C - Conversion -2,034,708 0 -100.00

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Non-Voting Common Stock C - Conversion 157,288 157,288

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Non-Voting Common Stock C - Conversion 5,429,023 5,429,023

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Common Stock P - Purchase 48,400 91,014 113.58 16.00 774,400 1,456,224

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Common Stock P - Purchase 375,000 1,845,872 25.50 16.00 6,000,000 29,533,952

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Common Stock C - Conversion 42,614 42,614

2021-04-13 2021-03-30 4/A IKNA Ikena Oncology, Inc.
Common Stock C - Conversion 1,470,872 1,470,872

2021-04-13 2020-12-21 4/A IKNA Ikena Oncology, Inc.
Series B Preferred Stock A - Award 1,430,103 1,430,103 1.40 1,999,999 1,999,999

2021-04-13 2020-12-21 4/A IKNA Ikena Oncology, Inc.
Series B Preferred Stock A - Award 8,938,148 8,938,148 1.40 12,500,000 12,500,000

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series B Preferred Stock C - Conversion -68,978 0 -100.00

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series B Preferred Stock C - Conversion -130,924 0 -100.00

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series B Preferred Stock C - Conversion -328,907 0 -100.00

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series B Preferred Stock C - Conversion -920,484 0 -100.00

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series A-1 Preferred Stock C - Conversion -806,752 0 -100.00

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series A-1 Preferred Stock C - Conversion -2,257,785 0 -100.00

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series A Preferred Stock C - Conversion -680,766 0 -100.00

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Series A Preferred Stock C - Conversion -1,905,201 0 -100.00

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Non-Voting Common Stock C - Conversion 130,924 130,924

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Non-Voting Common Stock C - Conversion 5,083,470 5,083,470

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Common Stock P - Purchase 48,400 117,378 70.17 16.00 774,400 1,878,048

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Common Stock P - Purchase 375,000 2,191,425 20.64 16.00 6,000,000 35,062,800

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Common Stock C - Conversion 68,978 68,978

2021-04-01 2021-03-30 4 IKNA Ikena Oncology, Inc.
Common Stock C - Conversion 1,816,425 1,816,425

2021-04-01 2020-12-21 4 IKNA Ikena Oncology, Inc.
Series B Preferred Stock A - Award 1,430,103 1,430,103 1.40 1,999,999 1,999,999

2021-04-01 2020-12-21 4 IKNA Ikena Oncology, Inc.
Series B Preferred Stock A - Award 8,938,148 8,938,148 1.40 12,500,000 12,500,000

2021-03-31 2021-03-30 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -27,869 2,212,571 -1.24 23.93 -666,905 52,946,824

2021-03-31 2021-03-29 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -75,555 2,240,440 -3.26 23.31 -1,761,187 52,224,656

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Series C Preferred Stock C - Conversion -272,724 0 -100.00

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Series C Preferred Stock C - Conversion -1,668,350 0 -100.00

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Series B-2 Preferred Stock C - Conversion -1,301,626 0 -100.00

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Series B-1 Preferred Stock C - Conversion -1,572,960 0 -100.00

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Series A Preferred Stock C - Conversion -8,187,100 0 -100.00

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Common Stock P - Purchase 312,500 13,359,456 2.40 16.00 5,000,000 213,751,296

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Common Stock P - Purchase 46,875 319,599 17.19 16.00 750,000 5,113,584

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Common Stock C - Conversion 272,724 272,724

2021-03-31 2021-03-30 4 EWTX Edgewise Therapeutics, Inc.
Common Stock C - Conversion 12,730,036 13,046,956 4,016.80

2021-03-26 2021-03-26 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -27,816 2,315,995 -1.19 23.88 -664,246 55,305,961

2021-03-26 2021-03-25 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -51,523 2,343,811 -2.15 24.70 -1,272,618 57,892,132

2021-03-26 2021-03-24 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -32,959 2,395,334 -1.36 24.80 -817,383 59,404,283

2021-03-25 3 EWTX Edgewise Therapeutics, Inc.
Common Stock 316,920

2021-03-23 2021-03-23 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -3,992 2,428,293 -0.16 24.32 -97,085 59,056,086

2021-03-23 2021-03-22 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -7,673 2,432,285 -0.31 26.47 -203,104 64,382,584

2021-03-23 2021-03-19 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -21,275 2,439,958 -0.86 26.47 -563,149 64,585,688

2021-03-18 2021-03-18 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -6,059 2,461,233 -0.25 28.03 -169,834 68,988,361

2021-03-18 2021-03-17 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -18,790 2,467,292 -0.76 28.43 -534,200 70,145,112

2021-03-18 2021-03-16 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -41,353 2,486,082 -1.64 27.72 -1,146,305 68,914,193

2021-03-15 2021-03-15 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -89,210 2,527,435 -3.41 29.14 -2,599,579 73,649,456

2021-03-15 2021-03-12 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -90,521 2,616,645 -3.34 30.29 -2,741,881 79,258,177

2021-03-15 2021-03-11 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock S - Sale X -58,551 2,707,166 -2.12 33.04 -1,934,525 89,444,765

2021-03-03 2021-03-01 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock S - Sale -1,220,000 6,186,307 -16.47 83.19 -101,491,800 514,638,879

2021-02-19 2021-02-17 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 1,285,714 8,053,298 19.00 3.50 4,499,999 28,186,543

2021-02-19 2021-02-17 4 DBTX Decibel Therapeutics, Inc.
Series D Preferred Stock C - Conversion -1,158,412 0 -100.00

2021-02-19 2021-02-17 4 DBTX Decibel Therapeutics, Inc.
Series D Preferred Stock C - Conversion -1,737,619 0 -100.00

2021-02-19 2021-02-17 4 DBTX Decibel Therapeutics, Inc.
Series D Preferred Stock C - Conversion -14,480,162 0 -100.00

2021-02-19 2021-02-17 4 DBTX Decibel Therapeutics, Inc.
Common Stock P - Purchase 555,566 883,418 169.46 18.00 10,000,188 15,901,524

2021-02-19 2021-02-17 4 DBTX Decibel Therapeutics, Inc.
Common Stock P - Purchase 1,111,100 3,843,206 40.67 18.00 19,999,800 69,177,708

2021-02-19 2021-02-17 4 DBTX Decibel Therapeutics, Inc.
Common Stock C - Conversion 218,568 218,568

2021-02-19 2021-02-17 4 DBTX Decibel Therapeutics, Inc.
Common Stock C - Conversion 327,852 327,852

2021-02-19 2021-02-17 4 DBTX Decibel Therapeutics, Inc.
Common Stock C - Conversion 2,732,106 2,732,106

2021-02-18 2021-02-12 4 ACET Adicet Bio, Inc.
Common Stock A - Award 104,050 396,657 35.56 13.00 1,352,650 5,156,541

2021-02-18 2021-02-12 4 ACET Adicet Bio, Inc.
Common Stock A - Award 420,299 5,243,259 8.71 13.00 5,463,887 68,162,367

2021-02-10 3 GMTX Gemini Therapeutics, Inc. /DE
Common Stock 5,316,224

2021-02-10 3 GMTX Gemini Therapeutics, Inc. /DE
Common Stock 510,000

2021-02-09 2021-02-09 4 TERN Terns Pharmaceuticals, Inc.
Series C Preferred Stock C - Conversion -918,295 0 -100.00

2021-02-09 2021-02-09 4 TERN Terns Pharmaceuticals, Inc.
Series C Preferred Stock C - Conversion -612,196 0 -100.00

2021-02-09 2021-02-09 4 TERN Terns Pharmaceuticals, Inc.
Series B Preferred Stock C - Conversion -1,071,428 0 -100.00

2021-02-09 2021-02-09 4 TERN Terns Pharmaceuticals, Inc.
Series B Preferred Stock C - Conversion -714,285 0 -100.00

2021-02-09 2021-02-09 4 TERN Terns Pharmaceuticals, Inc.
Common Stock P - Purchase 285,000 2,274,723 14.32 17.00 4,845,000 38,670,291

2021-02-09 2021-02-09 4 TERN Terns Pharmaceuticals, Inc.
Common Stock P - Purchase 190,000 1,516,481 14.32 17.00 3,230,000 25,780,177

2021-02-09 2021-02-09 4 TERN Terns Pharmaceuticals, Inc.
Common Stock C - Conversion 1,989,723 1,989,723

2021-02-09 2021-02-09 4 TERN Terns Pharmaceuticals, Inc.
Common Stock C - Conversion 1,326,481 1,326,481

2021-01-26 2021-01-22 4 PRVL Prevail Therapeutics Inc.
Common Stock U - Other -13,822,463 0 -100.00

2021-01-12 2021-01-11 4 PRLD Prelude Therapeutics Inc
Non-Voting Common Stock P - Purchase 41,700 5,596,886 0.75 60.00 2,502,000 335,813,160

2021-01-11 2021-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock S - Sale -2,000,000 7,520,600 -21.01 3.50 -7,000,000 26,322,100

2021-01-05 3 VRNA Verona Pharma plc
Ordinary Shares 40,225,392

2020-12-30 2020-12-28 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock S - Sale -600,000 3,070,955 -16.34 14.25 -8,550,000 43,761,109

2020-12-10 2020-12-08 4 ARPO Aerpio Pharmaceuticals, Inc.
Stock Option (Right to Buy) X - Other -21,400 0 -100.00

2020-12-10 2020-12-08 4 ARPO Aerpio Pharmaceuticals, Inc.
Common Stock S - Sale -21,400 0 -100.00 1.96 -41,944

2020-12-10 2020-12-08 4 ARPO Aerpio Pharmaceuticals, Inc.
Common Stock X - Other 21,400 21,400 0.96 20,544 20,544

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series C Preferred Stock C - Conversion -24,555 0 -100.00

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series B Preferred Stock C - Conversion -9,461 0 -100.00

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series A Preferred Stock C - Conversion -50,501 0 -100.00

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series C Preferred Stock C - Conversion -118,398 0 -100.00

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series B Preferred Stock C - Conversion -2,651,042 0 -100.00

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Series A Preferred Stock C - Conversion -243,494 0 -100.00

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock C - Conversion 24,637 84,599 41.09

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock C - Conversion 9,461 59,962 18.73

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock C - Conversion 50,501 50,501

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock C - Conversion 118,794 3,313,330 3.72

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock C - Conversion 2,651,042 3,194,536 487.78

2020-12-09 2020-12-07 4 KNTE Kinnate Biopharma Inc.
Common Stock C - Conversion 243,494 543,494 81.16

2020-12-08 2020-12-08 4 SBTX Silverback Therapeutics, Inc.
Series C Preferred Stock C - Conversion -3,918,279 0 -100.00

2020-12-08 2020-12-08 4 SBTX Silverback Therapeutics, Inc.
Series B Preferred Stock C - Conversion -9,259,259 0 -100.00

2020-12-08 2020-12-08 4 SBTX Silverback Therapeutics, Inc.
Series A Preferred Stock C - Conversion -12,857,142 0 -100.00

2020-12-08 2020-12-08 4 SBTX Silverback Therapeutics, Inc.
Common Stock P - Purchase 952,377 952,377 21.00 19,999,917 19,999,917

2020-12-08 2020-12-08 4 SBTX Silverback Therapeutics, Inc.
Common Stock C - Conversion 1,055,287 7,519,188 16.33

2020-12-08 2020-12-08 4 SBTX Silverback Therapeutics, Inc.
Common Stock C - Conversion 2,493,741 6,463,901 62.81

2020-12-08 2020-12-08 4 SBTX Silverback Therapeutics, Inc.
Common Stock C - Conversion 3,462,737 3,970,160 682.42

2020-12-08 2020-12-08 4 SBTX Silverback Therapeutics, Inc.
Common Stock P - Purchase 238,100 507,423 88.41 21.00 5,000,100 10,655,883

2020-12-04 2020-12-02 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 450,000 450,000 20.00 9,000,000 9,000,000

2020-12-04 2020-12-02 4 KNTE Kinnate Biopharma Inc.
Common Stock P - Purchase 300,000 300,000 20.00 6,000,000 6,000,000

2020-12-03 3 SBTX Silverback Therapeutics, Inc.
Common Stock 269,323

2020-12-03 3 SBTX Silverback Therapeutics, Inc.
Common Stock 269,323

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) X - Other -868,016 0 -100.00

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) X - Other -1,531,984 0 -100.00

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) X - Other -434,008 0 -100.00

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) X - Other -434,008 0 -100.00

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) X - Other -765,992 0 -100.00

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) X - Other -765,992 0 -100.00

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Common Stock X - Other 868,016 17,036,720 5.37 0.01 8,680 170,367

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Common Stock X - Other 434,008 16,168,704 2.76 0.01 4,340 161,687

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Common Stock X - Other 434,008 16,168,704 2.76 0.01 4,340 161,687

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Common Stock X - Other 1,531,984 55,766,352 2.82 0.01 15,320 557,664

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Common Stock X - Other 765,992 54,234,368 1.43 0.01 7,660 542,344

2020-11-19 2020-11-17 4 XTNT Xtant Medical Holdings, Inc.
Common Stock X - Other 765,992 54,234,368 1.43 0.01 7,660 542,344

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series D Preferred Stock C - Conversion -73,773 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series D Preferred Stock C - Conversion -59,350 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series D Preferred Stock C - Conversion -148,395 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series C-5 Preferred Stock C - Conversion -31,147 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series C-5 Preferred Stock C - Conversion -77,866 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series C-4 Preferred Stock C - Conversion -109,013 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series C-4 Preferred Stock C - Conversion -272,533 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series C-2 Preferred Stock C - Conversion -116,800 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Series C-2 Preferred Stock C - Conversion -291,999 0 -100.00

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Common Shares P - Purchase 209,500 1,031,811 25.48 15.00 3,142,500 15,477,165

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Common Shares P - Purchase 523,833 2,579,657 25.48 15.00 7,857,495 38,694,855

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Common Shares C - Conversion 191,787 191,787

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Common Shares C - Conversion 822,311 822,311

2020-11-04 2020-11-02 4 GLTO Galecto, Inc.
Common Shares C - Conversion 2,055,824 2,055,824

2020-11-04 2020-09-25 4 GLTO Galecto, Inc.
Series D Preferred Stock A - Award -73,773 73,773 -50.00 27.11 -1,999,986 1,999,986

2020-11-04 2020-09-25 4 GLTO Galecto, Inc.
Series D Preferred Stock A - Award -59,350 59,350 -50.00 27.11 -1,608,978 1,608,978

2020-11-04 2020-09-25 4 GLTO Galecto, Inc.
Series D Preferred Stock A - Award -148,395 148,395 -50.00 27.11 -4,022,988 4,022,988

2020-10-06 2020-10-02 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock P - Purchase 296,000 902,286 48.82 25.00 7,400,000 22,557,150

2020-10-06 2020-10-02 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock P - Purchase 200,000 4,267,564 4.92 25.00 5,000,000 106,689,100

2020-10-05 2020-10-01 4 XTNT Xtant Medical Holdings, Inc.
Common Stock A - Award 11,969,619 15,300,688 359.33 1.07 12,807,492 16,371,736

2020-10-05 2020-10-01 4 XTNT Xtant Medical Holdings, Inc.
Common Stock A - Award 46,784,775 52,702,384 790.60 1.07 50,059,709 56,391,551

2020-10-05 2020-10-01 4 LOGC LogicBio Therapeutics, Inc.
Common Stock P - Purchase 296,296 296,296 6.00 1,777,776 1,777,776

2020-10-05 2020-10-01 4 LOGC LogicBio Therapeutics, Inc.
Common Stock P - Purchase 639,212 4,126,972 18.33 6.00 3,835,272 24,761,832

2020-10-05 2020-10-01 4 LOGC LogicBio Therapeutics, Inc.
Common Stock P - Purchase 545,974 3,524,997 18.33 6.00 3,275,844 21,149,982

2020-09-30 2020-08-21 4/A PRLD Prelude Therapeutics Inc
Series C Preferred Stock P - Purchase 1,033,084 1,033,084

2020-09-30 2020-03-27 4/A PRLD Prelude Therapeutics Inc
Series B Preferred Stock P - Purchase 3,681,822 7,363,644 100.00

2020-09-29 2020-09-29 4 GRAY GRAYBUG VISION, INC.
Series C Preferred Stock C - Conversion -846,574 0 -100.00

2020-09-29 2020-09-29 4 GRAY GRAYBUG VISION, INC.
Series B Preferred Stock C - Conversion -2,754,273 0 -100.00

2020-09-29 2020-09-29 4 GRAY GRAYBUG VISION, INC.
Common Stock C - Conversion 3,600,847 4,163,347 640.15

2020-09-29 2020-09-25 4 GRAY GRAYBUG VISION, INC.
Common Stock P - Purchase 562,500 562,500 16.00 9,000,000 9,000,000

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series D Preferred Stock C - Conversion -114,039 0 -100.00

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series D Preferred Stock C - Conversion -380,133 0 -100.00

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series C Preferred Stock C - Conversion -518,191 0 -100.00

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series B Preferred Stock C - Conversion -1,076,891 0 -100.00

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Series A Preferred Stock C - Conversion -4,025,076 0 -100.00

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock C - Conversion 114,039 114,039

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock C - Conversion 380,133 6,475,291 6.24

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock C - Conversion 518,191 6,095,158 9.29

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock C - Conversion 1,076,891 5,576,967 23.93

2020-09-29 2020-09-29 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock C - Conversion 4,025,076 4,500,076 847.38

2020-09-29 2020-09-25 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock P - Purchase 475,000 475,000 18.00 8,550,000 8,550,000

2020-09-29 2020-09-25 4 PMVP PMV Pharmaceuticals, Inc.
Common Stock P - Purchase 475,000 475,000 18.00 8,550,000 8,550,000

2020-09-29 2020-09-29 4 PRLD Prelude Therapeutics Inc
Non-Voting Common Stock C - Conversion 5,555,186 5,555,186

2020-09-29 2020-09-29 4 PRLD Prelude Therapeutics Inc
Series C Preferred Stock C - Conversion -413,234 0 -100.00

2020-09-29 2020-09-29 4 PRLD Prelude Therapeutics Inc
Series C Preferred Stock C - Conversion -619,850 0 -100.00

2020-09-29 2020-09-29 4 PRLD Prelude Therapeutics Inc
Series B Preferred Stock C - Conversion -2,945,458 0 -100.00

2020-09-29 2020-09-29 4 PRLD Prelude Therapeutics Inc
Series B Preferred Stock C - Conversion -4,418,186 0 -100.00

2020-09-29 2020-09-29 4 PRLD Prelude Therapeutics Inc
Series A Prefered Stock C - Conversion -2,196,494 0 -100.00

2020-09-29 2020-09-29 4 PRLD Prelude Therapeutics Inc
Series A Preferred Stock C - Conversion -3,294,743 0 -100.00

2020-09-29 2020-09-29 4 PRLD Prelude Therapeutics Inc
Common Stock C - Conversion 8,332,779 9,250,191 908.29

2020-09-29 2020-09-25 4 PRLD Prelude Therapeutics Inc
Common Stock P - Purchase 710,500 917,412 343.38 19.00 13,499,500 17,430,828

2020-09-29 2020-09-25 4 PRLD Prelude Therapeutics Inc
Common Stock P - Purchase 526,300 526,300 19.00 9,999,700 9,999,700

2020-09-24 3 PRLD Prelude Therapeutics Inc
Common Stock 206,912

2020-09-23 2020-09-21 4 ETNB 89bio, Inc.
Common Stock S - Sale -137,500 1,864,721 -6.87 28.00 -3,850,000 52,212,188

2020-09-23 2020-09-21 4 ETNB 89bio, Inc.
Common Stock S - Sale -137,500 1,864,721 -6.87 28.00 -3,850,000 52,212,188

2020-09-17 2020-09-17 4 ACET Adicet Bio, Inc.
Stock Option (Right to Buy) A - Award 30,000 30,000

2020-09-17 2020-09-17 4 ACET Adicet Bio, Inc.
Stock Option (Right to Buy) A - Award 30,000 30,000

2020-09-17 2020-09-15 4 ACET Adicet Bio, Inc.
Common Stock A - Award 292,607 292,607

2020-09-17 2020-09-15 4 ACET Adicet Bio, Inc.
Common Stock A - Award 902,885 902,855 -3,009,616.67

2020-09-17 2020-09-15 4 ACET Adicet Bio, Inc.
Common Stock A - Award 4,822,960 4,822,960

2020-08-19 2020-08-18 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -43,543 0 -100.00 108.54 -4,726,157

2020-08-19 2020-08-17 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -94,900 43,543 -68.55 107.49 -10,200,801 4,680,437

2020-08-14 2020-08-14 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -20,257 138,443 -12.76 109.03 -2,208,621 15,094,440

2020-08-14 2020-08-13 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -29,251 158,500 -15.58 109.93 -3,215,562 17,423,905

2020-08-14 2020-08-12 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -42,679 187,751 -18.52 107.45 -4,585,859 20,173,845

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Series D Convertible Preferred Stock C - Conversion -378,733 0 -100.00

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Series D Convertible Preferred Stock C - Conversion -1,202,117 0 -100.00

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Series D Convertible Preferred Stock C - Conversion -389,116 0 -100.00

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Series C Convertible Preferred Stock C - Conversion -899,985 0 -100.00

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Series C Convertible Preferred Stock C - Conversion -647,582 0 -100.00

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Series B Convertible Preferred Stock C - Conversion -673,123 0 -100.00

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Series B Convertible Preferred Stock C - Conversion -872,302 0 -100.00

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Common Stock C - Conversion 1,278,718 1,320,218 3,081.25

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Common Stock C - Conversion 3,784,240 4,157,740 1,013.18

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Common Stock P - Purchase 41,500 41,500 18.00 747,000 747,000

2020-08-12 2020-08-10 4 AFIB Acutus Medical, Inc.
Common Stock P - Purchase 373,500 373,500 18.00 6,723,000 6,723,000

2020-08-11 2020-08-11 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -39,877 230,430 -14.75 105.78 -4,218,189 24,374,885

2020-08-11 2020-08-10 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -47,700 270,307 -15.00 105.23 -5,019,471 28,444,406

2020-08-11 2020-08-07 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -28,993 318,007 -8.36 106.18 -3,078,477 33,765,983

2020-07-02 2020-06-30 4 FUSN Fusion Pharmaceuticals Inc.
Class B Preferred Shares C - Conversion -11,878,051 0 -100.00

2020-07-02 2020-06-30 4 FUSN Fusion Pharmaceuticals Inc.
Common Shares P - Purchase 192,100 192,100 17.00 3,265,700 3,265,700

2020-07-02 2020-06-30 4 FUSN Fusion Pharmaceuticals Inc.
Common Shares P - Purchase 705,900 2,930,670 31.73 17.00 12,000,300 49,821,390

2020-07-02 2020-06-30 4 FUSN Fusion Pharmaceuticals Inc.
Common Shares C - Conversion 2,224,770 2,224,770

2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares C - Conversion -2,601,325 0 -100.00

2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Stock P - Purchase 99,200 99,200 20.00 1,984,000 1,984,000

2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Stock P - Purchase 675,000 3,276,325 25.95 20.00 13,500,000 65,526,500

2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Stock C - Conversion 2,601,325 2,601,325

2020-06-23 3 NONE Compass Therapeutics, Inc.
Common Stock 22,518,544

2020-06-23 3 NONE Compass Therapeutics, Inc.
Common Stock 22,518,544

2020-06-23 3 NONE Compass Therapeutics, Inc.
Common Stock 22,518,544

2020-06-23 3 NONE Compass Therapeutics, Inc.
Common Stock 22,518,544

2020-06-23 2020-06-19 4 NONE Compass Therapeutics, Inc.
Common Stock P - Purchase 1,455,132 12,714,404 12.92 5.00 7,275,660 63,572,020

2020-05-26 2020-05-21 4 SCPH scPharmaceuticals Inc.
Common Stock P - Purchase 231,200 231,200 8.65 1,999,880 1,999,880

2020-05-26 2020-05-21 4 SCPH scPharmaceuticals Inc.
Common Stock P - Purchase 1,156,083 4,565,948 33.90 8.65 10,000,118 39,495,450

2020-05-20 2020-05-06 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) A - Award 868,016 868,016

2020-05-20 2020-05-06 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) A - Award 1,531,984 1,531,984

2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Series D Preferred Stock C - Conversion -236,111 0 -100.00

2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Series C Preferred Stock C - Conversion -373,356 0 -100.00

2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Series B Preferred Stock C - Conversion -1,875,000 0 -100.00

2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock C - Conversion 236,111 2,765,717 9.33

2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock C - Conversion 373,356 2,529,606 17.32

2020-04-28 2020-04-28 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock C - Conversion 1,875,000 2,156,250 666.67

2020-04-28 2020-04-24 4 ORIC Oric Pharmaceuticals, Inc.
Common Stock P - Purchase 281,250 281,250 16.00 4,500,000 4,500,000

2020-04-16 2020-04-16 4 ALEC Alector, Inc.
Common Stock S - Sale -15,086 1,906,718 -0.78 23.53 -354,974 44,865,075

2020-04-16 2020-04-16 4 ALEC Alector, Inc.
Common Stock S - Sale -47,097 5,955,674 -0.78 23.53 -1,108,192 140,137,009

2020-04-16 2020-04-14 4 ALEC Alector, Inc.
Common Stock S - Sale -5,636 1,921,804 -0.29 23.52 -132,559 45,200,830

2020-04-16 2020-04-14 4 ALEC Alector, Inc.
Common Stock S - Sale -17,595 6,002,771 -0.29 23.52 -413,834 141,185,174

2020-04-13 2020-04-13 4 KROS Keros Therapeutics, Inc.
Series C Preferred Stock C - Conversion -148,922 0 -100.00

2020-04-13 2020-04-13 4 KROS Keros Therapeutics, Inc.
Series C Preferred Stock C - Conversion -744,612 0 -100.00

2020-04-13 2020-04-13 4 KROS Keros Therapeutics, Inc.
Common Stock P - Purchase 375,200 1,119,812 50.39 16.00 6,003,200 17,916,992

2020-04-13 2020-04-13 4 KROS Keros Therapeutics, Inc.
Common Stock C - Conversion 148,922 148,922

2020-04-13 2020-04-13 4 KROS Keros Therapeutics, Inc.
Common Stock C - Conversion 744,612 744,612

2020-04-09 2020-04-09 4 ALEC Alector, Inc.
Common Stock S - Sale -69,893 1,927,440 -3.50 23.79 -1,662,754 45,853,798

2020-04-09 2020-04-09 4 ALEC Alector, Inc.
Common Stock S - Sale -218,208 6,020,366 -3.50 23.79 -5,191,168 143,224,507

2020-04-09 2020-04-08 4 ALEC Alector, Inc.
Common Stock S - Sale -20,041 1,997,333 -0.99 23.65 -473,970 47,236,925

2020-04-09 2020-04-08 4 ALEC Alector, Inc.
Common Stock S - Sale -62,573 6,238,574 -0.99 23.65 -1,479,851 147,542,275

2020-04-09 2020-04-07 4 ALEC Alector, Inc.
Common Stock S - Sale -2,224 2,017,374 -0.11 23.10 -51,374 46,601,339

2020-04-09 2020-04-07 4 ALEC Alector, Inc.
Common Stock S - Sale -6,946 6,301,147 -0.11 23.10 -160,453 145,556,496

2020-04-02 2020-03-31 4 ALEC Alector, Inc.
Common Stock S - Sale -60,645 2,019,598 -2.92 24.50 -1,485,802 49,480,151

2020-04-02 2020-03-31 4 ALEC Alector, Inc.
Common Stock S - Sale -189,355 6,308,093 -2.91 24.50 -4,639,198 154,548,278

2020-03-25 2020-03-25 4 ALEC Alector, Inc.
Common Stock S - Sale -13,684 2,080,243 -0.65 24.66 -337,447 51,298,792

2020-03-25 2020-03-25 4 ALEC Alector, Inc.
Common Stock S - Sale -42,727 6,497,448 -0.65 24.66 -1,053,648 160,227,068

2020-03-25 2020-03-24 4 ALEC Alector, Inc.
Common Stock S - Sale -16,409 2,093,927 -0.78 24.45 -401,200 51,196,515

2020-03-25 2020-03-24 4 ALEC Alector, Inc.
Common Stock S - Sale -51,235 6,540,175 -0.78 24.45 -1,252,696 159,907,279

2020-03-25 2020-03-23 4 ALEC Alector, Inc.
Common Stock S - Sale -3,541 2,110,336 -0.17 26.05 -92,243 54,974,253

2020-03-25 2020-03-23 4 ALEC Alector, Inc.
Common Stock S - Sale -11,057 6,591,410 -0.17 26.05 -288,035 171,706,230

2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Series B Preferred Stock C - Conversion -10,046,294 0 -100.00

2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Common Stock C - Conversion 1,594,902 2,532,402 170.12

2020-03-16 2020-03-12 4 IMRA IMARA Inc.
Common Stock P - Purchase 937,500 937,500 16.00 15,000,000 15,000,000

2020-03-10 3 CTIC CTI BIOPHARMA CORP
Common Stock 19,040,000

2020-03-10 3 CTIC CTI BIOPHARMA CORP
Common Stock 19,040,000

2020-03-10 3 CTIC CTI BIOPHARMA CORP
Common Stock 19,040,000

2020-03-10 3 CTIC CTI BIOPHARMA CORP
Common Stock 19,040,000

2020-03-10 2020-03-06 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -500,000 347,000 -59.03 83.52 -41,760,000 28,981,440

2020-03-05 2020-03-03 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -400,000 847,000 -32.08 84.42 -33,768,000 71,503,740

2020-03-05 2020-03-03 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -25,000 1,247,000 -1.97 84.55 -2,113,750 105,433,850

2020-03-05 2020-03-03 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -75,000 1,272,000 -5.57 83.21 -6,240,750 105,843,120

2020-03-04 2020-03-02 4 ALEC Alector, Inc.
Common Stock S - Sale -38,808 0 -100.00 26.00 -1,009,008

2020-03-04 2020-03-02 4 ALEC Alector, Inc.
Common Stock S - Sale -445,086 2,113,877 -17.39 26.00 -11,572,236 54,960,802

2020-03-04 2020-03-02 4 ALEC Alector, Inc.
Common Stock S - Sale -1,390,309 6,602,467 -17.39 26.00 -36,148,034 171,664,142

2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series B Preferred Stock C - Conversion -541,002 0 -100.00

2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series A-2 Preferred Stock C - Conversion -1,311,469 0 -100.00

2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Series A-1 Preferred Stock C - Conversion -3,721,552 0 -100.00

2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock C - Conversion 541,002 5,947,323 10.01

2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock C - Conversion 1,311,469 5,406,321 32.03

2020-03-03 2020-03-03 4 PASG Passage BIO, Inc.
Common Stock C - Conversion 3,721,552 4,094,852 996.93

2020-03-03 2020-02-28 4 PASG Passage BIO, Inc.
Common Stock P - Purchase 373,300 373,300 18.00 6,719,400 6,719,400

2020-02-07 2020-02-05 4 XTNT Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value J - Other 70,423 91,256 338.04

2020-02-07 2020-02-05 4 XTNT Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value J - Other 70,423 91,256 338.04

2020-02-04 2020-02-04 4 ARQT Arcutis Biotherapeutics, Inc.
Series C Preferred Stock C - Conversion -429,786 0 -100.00

2020-02-04 2020-02-04 4 ARQT Arcutis Biotherapeutics, Inc.
Series C Preferred Stock C - Conversion -859,573 0 -100.00

2020-02-04 2020-02-04 4 ARQT Arcutis Biotherapeutics, Inc.
Series B Preferred Stock C - Conversion -2,825,603 0 -100.00

2020-02-04 2020-02-04 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock C - Conversion 429,786 606,286 243.50

2020-02-04 2020-02-04 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock C - Conversion 859,573 4,067,564 26.79

2020-02-04 2020-02-04 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock C - Conversion 2,825,603 3,207,991 738.94

2020-02-04 2020-02-03 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock P - Purchase 176,500 176,500 17.00 3,000,500 3,000,500

2020-02-04 2020-02-03 4 ARQT Arcutis Biotherapeutics, Inc.
Common Stock P - Purchase 382,388 382,388 17.00 6,500,596 6,500,596

2020-01-31 2020-01-29 4 SRRA Sierra Oncology, Inc.
Series A Convertible Voting Preferred Stock C - Conversion -19,500 0 -100.00

2020-01-31 2020-01-29 4 SRRA Sierra Oncology, Inc.
Common Stock C - Conversion 1,477,320 1,477,320

2020-01-13 2020-01-09 4 ALEC Alector, Inc.
Common Stock S - Sale -1,392 38,808 -3.46 19.50 -27,144 756,756

2020-01-13 2020-01-09 4 ALEC Alector, Inc.
Common Stock S - Sale -91,818 2,558,963 -3.46 19.50 -1,790,451 49,899,778

2020-01-13 2020-01-09 4 ALEC Alector, Inc.
Common Stock S - Sale -286,787 7,992,776 -3.46 19.50 -5,592,346 155,859,132

2019-12-26 2019-12-26 4 ALEC Alector, Inc.
Common Stock S - Sale -1,200 40,200 -2.90 18.60 -22,320 747,720

2019-12-26 2019-12-26 4 ALEC Alector, Inc.
Common Stock S - Sale -2,325 2,650,781 -0.09 18.60 -43,245 49,304,527

2019-12-26 2019-12-26 4 ALEC Alector, Inc.
Common Stock S - Sale -7,275 8,279,563 -0.09 18.60 -135,315 153,999,872

2019-12-26 2019-12-24 4 ALEC Alector, Inc.
Common Stock S - Sale -8,000 41,400 -16.19 19.59 -156,720 811,026

2019-12-26 2019-12-24 4 ALEC Alector, Inc.
Common Stock S - Sale -15,476 2,653,106 -0.58 19.59 -303,175 51,974,347

2019-12-26 2019-12-24 4 ALEC Alector, Inc.
Common Stock S - Sale -48,324 8,286,838 -0.58 19.59 -946,667 162,339,156

2019-12-26 2019-12-23 4 ALEC Alector, Inc.
Common Stock S - Sale -10,400 49,400 -17.39 19.82 -206,128 979,108

2019-12-26 2019-12-23 4 ALEC Alector, Inc.
Common Stock S - Sale -20,350 2,668,582 -0.76 19.82 -403,337 52,891,295

2019-12-26 2019-12-23 4 ALEC Alector, Inc.
Common Stock S - Sale -63,535 8,335,162 -0.76 19.82 -1,259,264 165,202,911

2019-12-26 2019-12-20 4 ALEC Alector, Inc.
Common Stock S - Sale -37,900 59,800 -38.79 19.66 -745,114 1,175,668

2019-12-26 2019-12-20 4 ALEC Alector, Inc.
Common Stock S - Sale -73,879 2,688,932 -2.67 19.66 -1,452,461 52,864,403

2019-12-26 2019-12-20 4 ALEC Alector, Inc.
Common Stock S - Sale -230,721 8,398,697 -2.67 19.66 -4,535,975 165,118,383

2019-12-19 2019-12-17 4 ALEC Alector, Inc.
Common Stock S - Sale -105,500 97,700 -51.92 18.52 -1,953,860 1,809,404

2019-12-19 2019-12-17 4 ALEC Alector, Inc.
Common Stock S - Sale -205,793 2,762,811 -6.93 18.52 -3,811,286 51,167,260

2019-12-19 2019-12-17 4 ALEC Alector, Inc.
Common Stock S - Sale -642,807 8,629,418 -6.93 18.52 -11,904,786 159,816,821

2019-12-12 2019-12-11 4 TCDA Tricida, Inc.
Common Stock S - Sale -1,500,000 9,614,280 -13.50 40.00 -60,000,000 384,571,200

2019-11-29 2019-11-27 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale X -2,306 1,348,326 -0.17 72.13 -166,332 97,254,754

2019-11-29 2019-11-27 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale X -47,981 1,350,632 -3.43 71.67 -3,438,798 96,799,795

2019-11-29 2019-11-27 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale X -3,100 1,398,613 -0.22 70.60 -218,860 98,742,078

2019-11-29 2019-11-26 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale X -50,478 1,401,713 -3.48 70.16 -3,541,536 98,344,184

2019-11-29 2019-11-26 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale X -20,135 1,452,191 -1.37 69.55 -1,400,389 100,999,884

2019-11-13 2019-11-13 4 ETNB 89bio, Inc.
Series A Preferred Stock C - Conversion -7,944,444 0 -100.00

2019-11-13 2019-11-13 4 ETNB 89bio, Inc.
Series A Preferred Stock C - Conversion -7,944,444 0 -100.00

2019-11-13 2019-11-13 4 ETNB 89bio, Inc.
Common Stock C - Conversion 1,277,858 2,002,221 176.41

2019-11-13 2019-11-13 4 ETNB 89bio, Inc.
Common Stock C - Conversion 1,277,858 2,002,221 176.41

2019-11-13 2019-11-11 4 ETNB 89bio, Inc.
Common Stock P - Purchase 418,750 724,363 137.02 16.00 6,700,000 11,589,808

2019-11-13 2019-11-11 4 ETNB 89bio, Inc.
Common Stock P - Purchase 418,750 724,363 137.02 16.00 6,700,000 11,589,808

2019-11-13 2019-11-13 4 TELA TELA Bio, Inc.
Warrant (right to buy) C - Conversion 758,623 758,623

2019-11-13 2019-11-13 4 TELA TELA Bio, Inc.
Warrant (right to buy) C - Conversion -758,623 0 -100.00

2019-11-13 2019-11-13 4 TELA TELA Bio, Inc.
Series B Preferred Stock C - Conversion -24,142,419 0 -100.00

2019-11-13 2019-11-13 4 TELA TELA Bio, Inc.
Series A Preferred Stock C - Conversion -11,878,249 0 -100.00

2019-11-13 2019-11-13 4 TELA TELA Bio, Inc.
Common Stock C - Conversion 977,820 3,027,542 47.71

2019-11-13 2019-11-13 4 TELA TELA Bio, Inc.
Common Stock C - Conversion 481,095 2,049,722 30.67

2019-11-13 2019-11-08 4 TELA TELA Bio, Inc.
Common Stock P - Purchase 384,615 1,568,627 32.48 13.00 4,999,995 20,392,151

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-11-08 3 ETNB 89bio, Inc.
Common Stock, par value $0.001 per share 916,839

2019-10-31 2019-10-30 4 XTNT Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value J - Other 20,833 20,833

2019-10-31 2019-10-30 4 XTNT Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value J - Other 20,833 20,833

2019-09-19 2019-09-17 4 SWTX SpringWorks Therapeutics, Inc.
Series B Convertible Preferred Stock C - Conversion -1,053,204 0 -100.00

2019-09-19 2019-09-17 4 SWTX SpringWorks Therapeutics, Inc.
Series A Convertible Preferred Stock C - Conversion -6,078,103 0 -100.00

2019-09-19 2019-09-17 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock P - Purchase 275,000 7,406,307 3.86 18.00 4,950,000 133,313,526

2019-09-19 2019-09-17 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock C - Conversion 1,053,204 7,131,307 17.33

2019-09-19 2019-09-17 4 SWTX SpringWorks Therapeutics, Inc.
Common Stock C - Conversion 6,078,103 6,078,103

2019-08-09 2019-08-07 4 ALEC Alector, Inc.
Common Stock S - Sale -157,636 2,968,604 -5.04 17.90 -2,821,684 53,138,012

2019-08-09 2019-08-07 4 ALEC Alector, Inc.
Common Stock S - Sale -492,364 9,272,225 -5.04 17.90 -8,813,316 165,972,828

2019-08-08 2019-08-06 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 142,656 6,767,584 2.15 3.51 500,723 23,754,220

2019-07-01 2019-07-01 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 59,243 6,624,928 0.90 3.91 231,640 25,903,468

2019-07-01 2019-06-28 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 565,178 6,565,685 9.42 3.72 2,102,462 24,424,348

2019-07-01 2019-06-27 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 32,923 6,000,507 0.55 3.34 109,963 20,041,693

2019-06-26 2019-06-24 4 PRVL Prevail Therapeutics Inc.
Series B Preferred Stock C - Conversion -1,011,499 0 -100.00

2019-06-26 2019-06-24 4 PRVL Prevail Therapeutics Inc.
Series A Preferred Stock C - Conversion -3,099,612 0 -100.00

2019-06-26 2019-06-24 4 PRVL Prevail Therapeutics Inc.
Series Seed Preferred Stock C - Conversion -6,399,000 0 -100.00

2019-06-26 2019-06-24 4 PRVL Prevail Therapeutics Inc.
Common Stock P - Purchase 882,352 13,822,463 6.82 17.00 14,999,984 234,981,871

2019-06-26 2019-06-24 4 PRVL Prevail Therapeutics Inc.
Common Stock C - Conversion 10,510,111 12,940,111 432.51

2019-06-19 3 PRVL Prevail Therapeutics Inc.
Common Stock 4,860,000

2019-06-19 3 PRVL Prevail Therapeutics Inc.
Common Stock 4,860,000

2019-06-19 3 PRVL Prevail Therapeutics Inc.
Common Stock 4,860,000

2019-06-19 3 PRVL Prevail Therapeutics Inc.
Common Stock 4,860,000

2019-05-22 2019-05-21 4 PRNB Principia Biopharma Inc.
Common Stock S - Sale -1,000,000 1,605,713 -38.38 30.25 -30,250,000 48,572,818

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Series B-1 Preferred Stock C - Conversion -3,554,466 0 -100.00

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Series A-3 Preferred Stock C - Conversion -5,861,455 0 -100.00

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Series A-2 Preferred Stock C - Conversion -5,970,000 0 -100.00

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Series A-1 Preferred Stock C - Conversion -3,582,000 0 -100.00

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Common Stock P - Purchase 350,000 2,711,013 14.82 15.00 5,250,000 40,665,195

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Common Stock C - Conversion 442,438 2,361,013 23.06

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Common Stock C - Conversion 729,599 1,918,575 61.36

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Common Stock C - Conversion 743,110 1,188,976 166.67

2019-05-13 2019-05-13 4 NXTC NextCure, Inc.
Common Stock C - Conversion 445,866 445,866

2019-04-24 2019-04-22 4 TPTX Turning Point Therapeutics, Inc.
Series D Preferred Stock C - Conversion -2,105,259 0 -100.00

2019-04-24 2019-04-22 4 TPTX Turning Point Therapeutics, Inc.
Series C Preferred Stock C - Conversion -4,314,809 0 -100.00

2019-04-24 2019-04-22 4 TPTX Turning Point Therapeutics, Inc.
Common Stock P - Purchase 360,000 2,027,550 21.59 18.00 6,480,000 36,495,900

2019-04-24 2019-04-22 4 TPTX Turning Point Therapeutics, Inc.
Common Stock C - Conversion 546,820 1,667,550 48.79

2019-04-24 2019-04-22 4 TPTX Turning Point Therapeutics, Inc.
Common Stock C - Conversion 1,120,730 1,120,730

2019-04-05 2019-04-03 4 TCDA Tricida, Inc.
Common Stock P - Purchase 225,000 11,114,280 2.07 36.00 8,100,000 400,114,080

2019-04-03 2019-04-01 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) A - Award 434,008 434,008

2019-04-03 2019-04-01 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) A - Award 765,992 765,992

2019-03-11 2019-03-08 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -290,231 1,471,725 -16.47 57.75 -16,760,840 84,992,119

2019-03-11 2019-03-07 4 INSP Inspire Medical Systems, Inc.
Common Stock, $0.001 par value S - Sale -68,218 1,761,956 -3.73 55.01 -3,752,672 96,925,200

2019-02-19 2019-02-19 4 AVDR AVEDRO INC
Series CC Convertible Preferred Stock C - Conversion -383,746 0 -100.00

2019-02-19 2019-02-19 4 AVDR AVEDRO INC
Series BB Convertible Preferred Stock C - Conversion -333,178 0 -100.00

2019-02-19 2019-02-19 4 AVDR AVEDRO INC
Series AA Convertible Preferred Stock C - Conversion -3,370,786 0 -100.00

2019-02-19 2019-02-19 4 AVDR AVEDRO INC
Common Stock C - Conversion 383,746 4,240,128 9.95

2019-02-19 2019-02-19 4 AVDR AVEDRO INC
Common Stock C - Conversion 333,178 3,856,382 9.46

2019-02-19 2019-02-19 4 AVDR AVEDRO INC
Common Stock C - Conversion 3,370,786 3,523,204 2,211.54

2019-02-13 3 AVDR AVEDRO INC
Common Stock 304,836

2019-02-13 3 AVDR AVEDRO INC
Common Stock 304,836

2019-02-13 3 AVDR AVEDRO INC
Common Stock 304,836

2019-02-13 3 AVDR AVEDRO INC
Common Stock 304,836

2019-02-13 3 AVDR AVEDRO INC
Common Stock 304,836

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series E Preferred Stock C - Conversion -85,295 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series E Preferred Stock C - Conversion -266,437 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series D Preferred Stock C - Conversion -234,601 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series D Preferred Stock C - Conversion -1,012,282 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series C Preferred Stock C - Conversion -528,510 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series C Preferred Stock C - Conversion -2,280,479 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series B Preferred Stock C - Conversion -470,374 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series B Preferred Stock C - Conversion -2,029,626 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series A-2 Preferred Stock C - Conversion -992,437 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series A-2 Preferred Stock C - Conversion -4,282,288 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series A-1 Preferred Stock C - Conversion -94,075 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Series A-1 Preferred Stock C - Conversion -405,925 0 -100.00

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock P - Purchase 203,200 203,200 19.00 3,860,800 3,860,800

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock P - Purchase 50,561 2,455,853 2.10 19.00 960,659 46,661,207

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 85,295 2,405,292 3.68

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 234,601 2,319,997 11.25

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 528,510 2,085,396 33.95

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 470,374 1,556,886 43.29

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 992,437 1,086,512 1,054.94

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 94,075 94,075

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock P - Purchase 157,939 10,434,976 1.54 19.00 3,000,841 198,264,544

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 266,437 10,277,037 2.66

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 1,012,282 10,010,600 11.25

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 2,280,479 8,998,318 33.95

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 2,029,626 6,717,839 43.29

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 4,282,288 4,688,213 1,054.95

2019-02-11 2019-02-11 4 ALEC Alector, Inc.
Common Stock C - Conversion 405,925 405,925

2019-01-23 2019-01-18 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Warrants to Purchase Common Stock P - Purchase 145,251 145,251

2019-01-23 2019-01-18 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock P - Purchase 372,439 3,670,955 11.29 5.37 1,999,997 19,713,028

2018-12-13 2018-12-11 4 INSP Inspire Medical Systems, Inc.
Common Stock S - Sale -614,772 0 -100.00 37.60 -23,115,427

2018-12-13 2018-12-11 4 THOR Synthorx, Inc.
Series C Preferred Stock C - Conversion -6,333,206 0 -100.00

2018-12-13 2018-12-11 4 THOR Synthorx, Inc.
Common Stock C - Conversion 3,952,719 5,316,355 289.87

2018-12-13 2018-12-11 4 THOR Synthorx, Inc.
Common Stock P - Purchase 1,363,636 1,363,636 11.00 14,999,996 14,999,996

2018-10-25 2018-10-23 4 LOGC LogicBio Therapeutics, Inc.
Series B Convertible Preferred Stock C - Conversion -4,352,775 0 -100.00

2018-10-25 2018-10-23 4 LOGC LogicBio Therapeutics, Inc.
Series B Convertible Preferred Stock C - Conversion -3,046,943 2,279,023 -57.21

2018-10-25 2018-10-23 4 LOGC LogicBio Therapeutics, Inc.
Series A Convertible Preferred Stock C - Conversion -2,678,571 0 -100.00

2018-10-25 2018-10-23 4 LOGC LogicBio Therapeutics, Inc.
Common Stock P - Purchase 700,000 6,466,783 12.14 10.00 7,000,000 64,667,830

2018-10-25 2018-10-23 4 LOGC LogicBio Therapeutics, Inc.
Common Stock P - Purchase 490,000 5,766,783 9.29 10.00 4,900,000 57,667,830

2018-10-25 2018-10-23 4 LOGC LogicBio Therapeutics, Inc.
Common Stock C - Conversion 2,279,023 5,276,783 76.02

2018-10-25 2018-10-23 4 LOGC LogicBio Therapeutics, Inc.
Common Stock C - Conversion 2,997,760 2,997,760

2018-10-19 2018-10-19 4 SIBN SI-BONE, Inc.
Series 7 Preferred Stock C - Conversion -179,404 0 -100.00

2018-10-19 2018-10-19 4 SIBN SI-BONE, Inc.
Series 6 Preferred Stock C - Conversion -572,326 0 -100.00

2018-10-19 2018-10-19 4 SIBN SI-BONE, Inc.
Common Stock P - Purchase 200,000 985,368 25.47 15.00 3,000,000 14,780,520

2018-10-19 2018-10-19 4 SIBN SI-BONE, Inc.
Common Stock C - Conversion 179,404 785,368 29.61

2018-10-19 2018-10-19 4 SIBN SI-BONE, Inc.
Common Stock C - Conversion 605,964 605,964

2018-10-11 2018-10-09 4 GH Guardant Health, Inc.
SERIES E PREFERRED STOCK C - Conversion -8,972 0 -100.00

2018-10-11 2018-10-09 4 GH Guardant Health, Inc.
SERIES D PREFERRED STOCK C - Conversion -1,525,492 0 -100.00

2018-10-11 2018-10-09 4 GH Guardant Health, Inc.
Common Stock C - Conversion 8,972 8,972

2018-10-11 2018-10-09 4 GH Guardant Health, Inc.
Common Stock C - Conversion 1,525,492 1,525,492

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Series C Convertible Preferred Stock C - Conversion -167,537 0 -100.00

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Series B-3 Convertible Preferred Stock C - Conversion -544,047 0 -100.00

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Series B-2 Convertible Preferred Stock C - Conversion -260,617 0 -100.00

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Series B-1 Convertible Preferred Stock C - Conversion -312,741 0 -100.00

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Series A Convertible Preferred Stock C - Conversion -1,070,771 0 -100.00

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Common Stock P - Purchase 250,000 2,605,713 10.61 17.00 4,250,000 44,297,121

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Common Stock C - Conversion 167,537 2,355,713 7.66

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Common Stock C - Conversion 544,047 2,188,176 33.09

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Common Stock C - Conversion 260,617 1,644,129 18.84

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Common Stock C - Conversion 312,741 1,383,512 29.21

2018-09-20 2018-09-18 4 PRNB Principia Biopharma Inc.
Common Stock C - Conversion 1,070,771 1,070,771

2018-09-19 2018-09-17 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) A - Award 434,008 434,008

2018-09-19 2018-09-17 4 XTNT Xtant Medical Holdings, Inc.
Warrant (right to buy) A - Award 765,992 765,992

2018-09-07 2018-08-30 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares S - Sale 0

2018-09-07 2018-08-30 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares S - Sale -348,500 0 -100.00

2018-09-07 2018-08-30 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares S - Sale -348,500 0 -100.00

2018-09-07 2018-08-30 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares S - Sale -1,536,098 0 -100.00

2018-09-07 2018-08-30 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares P - Purchase 55,000 348,500 18.74 3.85 211,750 1,341,725

2018-09-07 2018-08-30 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares P - Purchase 55,000 348,500 18.74 3.85 211,750 1,341,725

2018-09-07 2018-08-30 4 STDY SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share S - Sale -2,123,098 0 -100.00 4.46 -9,469,017

2018-09-07 2018-08-30 4 STDY SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share S - Sale -2,123,098 0 -100.00 4.46 -9,469,017

2018-08-21 2018-08-15 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -736 73,819 -0.99 9.93 -7,308 733,023

2018-08-21 2018-08-15 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -77,314 7,751,662 -0.99 9.93 -767,728 76,974,004

2018-08-21 2018-08-14 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -198 74,555 -0.26 9.94 -1,968 741,077

2018-08-21 2018-08-14 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -20,777 7,828,976 -0.26 9.94 -206,523 77,820,021

2018-08-21 2018-08-13 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -820 74,753 -1.09 9.98 -8,184 746,035

2018-08-21 2018-08-13 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -86,103 7,849,753 -1.08 9.98 -859,308 78,340,535

2018-08-21 2018-08-20 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -153,921 68,898 -69.08 9.98 -1,536,132 687,602

2018-08-21 2018-08-20 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -153,921 7,234,976 -2.08 9.98 -1,536,132 72,205,060

2018-08-21 2018-08-16 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -3,455 70,364 -4.68 9.94 -34,343 699,418

2018-08-21 2018-08-16 4/A VRAY ViewRay, Inc.
Common Stock S - Sale -362,765 7,388,897 -4.68 9.94 -3,605,884 73,445,636

2018-08-20 2018-08-20 4 VRAY ViewRay, Inc.
Common Stock S - Sale -1,466 69,617 -2.06 9.98 -14,631 694,778

2018-08-20 2018-08-20 4 VRAY ViewRay, Inc.
Common Stock S - Sale -153,921 7,310,457 -2.06 9.98 -1,536,132 72,958,361

2018-08-20 2018-08-16 4 VRAY ViewRay, Inc.
Common Stock S - Sale -3,455 71,083 -4.64 9.94 -34,343 706,565

2018-08-20 2018-08-16 4 VRAY ViewRay, Inc.
Common Stock S - Sale -362,765 7,464,378 -4.63 9.94 -3,605,884 74,195,917

2018-08-15 2018-08-15 4 VRAY ViewRay, Inc.
Common Stock S - Sale -736 74,538 -0.98 9.93 -7,308 740,162

2018-08-15 2018-08-15 4 VRAY ViewRay, Inc.
Common Stock S - Sale -77,314 7,827,143 -0.98 9.93 -767,728 77,723,530

2018-08-15 2018-08-14 4 VRAY ViewRay, Inc.
Common Stock S - Sale -198 75,274 -0.26 9.94 -1,968 748,224

2018-08-15 2018-08-14 4 VRAY ViewRay, Inc.
Common Stock S - Sale -20,777 7,904,457 -0.26 9.94 -206,523 78,570,303

2018-08-15 2018-08-13 4 VRAY ViewRay, Inc.
Common Stock S - Sale -820 75,472 -1.07 9.98 -8,184 753,211

2018-08-15 2018-08-13 4 VRAY ViewRay, Inc.
Common Stock S - Sale -86,103 7,925,234 -1.07 9.98 -859,308 79,093,835

2018-08-10 2018-08-10 4 VRAY ViewRay, Inc.
Common Stock S - Sale -6,460 75,573 -7.87 9.96 -64,342 752,707

2018-08-10 2018-08-10 4 VRAY ViewRay, Inc.
Common Stock S - Sale -678,333 7,935,856 -7.87 9.96 -6,756,197 79,041,126

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Stock Option (right to buy) M - Exercise -431 0 -100.00

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Stock Option (right to buy) M - Exercise -45,203 0 -100.00

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Stock Option (right to buy) M - Exercise -184 0 -100.00

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Stock Option (right to buy) M - Exercise -19,372 0 -100.00

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock S - Sale -249 82,033 -0.30 9.86 -2,455 808,845

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock S - Sale -26,139 8,614,189 -0.30 9.86 -257,731 84,935,904

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock S - Sale -615 82,282 -0.74 9.91 -6,095 815,415

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock S - Sale -64,575 8,640,328 -0.74 9.91 -639,938 85,625,650

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock M - Exercise 431 82,897 0.52 5.00 2,155 414,485

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock M - Exercise 45,203 8,704,903 0.52 5.00 226,015 43,524,515

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock M - Exercise 184 82,466 0.22 5.00 920 412,330

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock M - Exercise 19,372 8,659,700 0.22 5.00 96,860 43,298,500

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock S - Sale -1,036 82,282 -1.24 9.95 -10,308 818,706

2018-08-10 2018-08-09 4 VRAY ViewRay, Inc.
Common Stock S - Sale -108,729 8,640,328 -1.24 9.95 -1,081,854 85,971,264

2018-08-10 2018-08-08 4 VRAY ViewRay, Inc.
Common Stock S - Sale -4,553 83,318 -5.18 10.00 -45,530 833,180

2018-08-10 2018-08-08 4 VRAY ViewRay, Inc.
Common Stock S - Sale -478,107 8,749,057 -5.18 10.00 -4,781,070 87,490,570

2018-08-10 2018-08-07 4 VRAY ViewRay, Inc.
Restricted Stock Unit M - Exercise -249 0 -100.00

2018-08-10 2018-08-07 4 VRAY ViewRay, Inc.
Restricted Stock Unit M - Exercise -26,139 0 -100.00

2018-08-10 2018-08-07 4 VRAY ViewRay, Inc.
Common Stock M - Exercise 249 87,871 0.28

2018-08-10 2018-08-07 4 VRAY ViewRay, Inc.
Common Stock M - Exercise 26,139 9,227,164 0.28

2018-08-07 2018-08-07 4 VRAY ViewRay, Inc.
Common Stock S - Sale -478 87,622 -0.54 10.01 -4,785 877,096

2018-08-07 2018-08-07 4 VRAY ViewRay, Inc.
Common Stock S - Sale -50,149 9,201,025 -0.54 10.01 -501,991 92,102,260

2018-08-07 2018-08-03 4 VRAY ViewRay, Inc.
Common Stock S - Sale -1,125 88,100 -1.26 11.71 -13,174 1,031,651

2018-08-07 2018-08-03 4 VRAY ViewRay, Inc.
Common Stock S - Sale -118,168 9,251,174 -1.26 11.71 -1,383,747 108,331,248

2018-07-24 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock C - Conversion -3,500,000 0 -100.00

2018-07-24 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock C - Conversion -3,500,000 0 -100.00

2018-07-24 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock P - Purchase 100,000 417,921 31.45 15.00 1,500,000 6,268,815

2018-07-24 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock P - Purchase 100,000 417,921 31.45 15.00 1,500,000 6,268,815

2018-07-24 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock C - Conversion 317,921 317,921

2018-07-24 2018-07-23 4 CNST CONSTELLATION PHARMACEUTICALS INC
Common Stock C - Conversion 317,921 317,921

2018-07-02 2018-06-28 4 ARPO Aerpio Pharmaceuticals, Inc.
Common Stock P - Purchase 777,500 5,193,946 17.60 3.85 2,993,375 19,996,692

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Series D Convertible Preferred Stock C - Conversion -4,255,319 0 -100.00

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Series C Convertible Preferred Stock C - Conversion -14,292,958 0 -100.00

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Series B Convertible Preferred Stock C - Conversion -17,117,085 0 -100.00

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Series A Convertible Preferred Stock C - Conversion -6,207,674 0 -100.00

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock P - Purchase 368,421 10,889,280 3.50 19.00 6,999,999 206,896,320

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock C - Conversion 1,069,175 10,520,859 11.31

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock C - Conversion 3,591,194 9,451,684 61.28

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock C - Conversion 4,300,774 5,860,490 275.74

2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock C - Conversion 1,559,716 1,559,716

2018-06-22 2018-06-22 4 ARMO ARMO BioSciences, Inc.
Common Stock U - Other -409,547 409,547 -50.00 50.00 -20,477,350 20,477,350

2018-06-22 2018-06-22 4 ARMO ARMO BioSciences, Inc.
Common Stock U - Other -3,709,356 3,709,356 -50.00 50.00 -185,467,800 185,467,800

2018-06-06 2018-06-06 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares S - Sale -1,600 4,901,310 -0.03 13.49 -21,584 66,118,672

2018-06-06 2018-06-04 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares S - Sale -17,100 4,902,910 -0.35 13.57 -232,047 66,532,489

2018-06-01 2018-06-01 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares S - Sale -50,000 4,920,010 -1.01 13.49 -674,500 66,370,935

2018-06-01 2018-05-30 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares S - Sale -121,000 4,970,010 -2.38 13.52 -1,635,920 67,194,535

2018-05-24 2018-05-22 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock S - Sale -1,600 2,750,079 -0.06 30.96 -49,536 85,142,446

2018-05-24 2018-05-22 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock S - Sale -17,980 2,751,679 -0.65 30.38 -546,232 83,596,008

2018-05-21 2018-05-21 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock S - Sale -62,500 2,769,659 -2.21 31.01 -1,938,125 85,887,126

2018-05-21 2018-05-18 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock S - Sale -69,136 2,832,159 -2.38 30.77 -2,127,315 87,145,532

2018-05-16 2018-05-14 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares S - Sale -10,300 5,091,010 -0.20 13.50 -139,050 68,728,635

2018-05-09 2018-05-07 4 INSP Inspire Medical Systems, Inc.
Series F Convertible Preferred Stock C - Conversion -3,649,635 0 -100.00

2018-05-09 2018-05-07 4 INSP Inspire Medical Systems, Inc.
Series E Convertible Preferred Stock C - Conversion -9,160,305 0 -100.00

2018-05-09 2018-05-07 4 INSP Inspire Medical Systems, Inc.
Common Stock P - Purchase 312,500 2,444,221 14.66 16.00 5,000,000 39,107,536

2018-05-09 2018-05-07 4 INSP Inspire Medical Systems, Inc.
Common Stock C - Conversion 548,817 2,131,721 34.67

2018-05-09 2018-05-07 4 INSP Inspire Medical Systems, Inc.
Common Stock C - Conversion 1,582,904 1,582,904

2018-05-02 2018-04-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock S - Sale -10,400 38,870 -21.11 6.35 -66,040 246,824

2018-05-02 2018-04-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock S - Sale -989,600 4,511,130 -17.99 6.35 -6,283,960 28,645,676

2018-03-29 2018-03-29 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares S - Sale -31,983 5,101,310 -0.62 11.53 -368,764 58,818,104

2018-03-29 2018-03-27 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares S - Sale -1,016,084 5,133,293 -16.52 11.50 -11,684,966 59,032,870

2018-03-14 2018-03-12 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 588,235 5,967,584 10.94 8.50 4,999,998 50,724,464

2018-03-12 2018-03-12 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -16,937 3,539,997 -0.48 34.92 -591,440 123,616,695

2018-03-12 2018-03-12 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -1,066 3,556,934 -0.03 36.04 -38,419 128,191,901

2018-03-12 2018-03-09 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -11,305 3,558,000 -0.32 36.44 -411,954 129,653,520

2018-03-12 2018-03-09 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -47,395 3,569,305 -1.31 35.86 -1,699,585 127,995,277

2018-03-12 2018-03-09 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -21,300 3,616,700 -0.59 34.67 -738,471 125,390,989

2018-03-12 2018-03-08 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -58,428 3,638,000 -1.58 34.06 -1,990,058 123,910,280

2018-03-06 2018-03-06 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -11,372 3,696,428 -0.31 33.03 -375,617 122,093,017

2018-03-06 2018-03-05 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -200 3,707,800 -0.01 36.06 -7,212 133,703,268

2018-03-06 2018-03-02 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -35,558 3,708,000 -0.95 36.33 -1,291,822 134,711,640

2018-03-06 2018-03-02 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -386,080 3,743,558 -9.35 35.06 -13,535,965 131,249,143

2018-03-06 2018-03-06 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -445 0 -100.00 32.06 -14,267

2018-03-06 2018-03-06 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -46,676 0 -100.00 32.06 -1,496,433

2018-03-06 2018-03-06 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -192 445 -30.14 30.77 -5,908 13,693

2018-03-06 2018-03-06 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -20,114 46,676 -30.12 30.77 -618,908 1,436,221

2018-03-06 2018-03-06 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -886 637 -58.17 30.01 -26,589 19,116

2018-03-06 2018-03-06 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -93,008 66,790 -58.20 30.01 -2,791,170 2,004,368

2018-03-06 2018-03-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -768 1,523 -33.52 33.06 -25,390 50,350

2018-03-06 2018-03-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -80,516 159,798 -33.50 33.06 -2,661,859 5,282,922

2018-03-06 2018-03-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -1,220 2,291 -34.75 32.05 -39,101 73,427

2018-03-06 2018-03-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -128,092 240,314 -34.77 32.05 -4,105,349 7,702,064

2018-03-06 2018-03-02 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -1,851 3,511 -34.52 32.80 -60,713 115,161

2018-03-06 2018-03-02 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -194,433 368,406 -34.55 32.80 -6,377,402 12,083,717

2018-03-06 2018-03-02 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -2,533 5,362 -32.08 31.92 -80,853 171,155

2018-03-06 2018-03-02 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -265,766 562,839 -32.07 31.92 -8,483,251 17,965,821

2018-02-23 2018-02-14 4 XTNT Xtant Medical Holdings, Inc.
Convertible Note D - Sale to Issuer 809,614 0 -100.00 34.80 28,174,567

2018-02-23 2018-02-14 4 XTNT Xtant Medical Holdings, Inc.
Convertible Note D - Sale to Issuer 1,428,553 0 -100.00 34.80 49,713,644

2018-02-23 2018-02-14 4 XTNT Xtant Medical Holdings, Inc.
Convertible Note D - Sale to Issuer 18,810,000 0 -100.00 46.56 875,793,600

2018-02-23 2018-02-14 4 XTNT Xtant Medical Holdings, Inc.
Convertible Note D - Sale to Issuer 33,190,000 0 -100.00 46.56 1,545,326,400

2018-02-23 2018-02-14 4 XTNT Xtant Medical Holdings, Inc.
Common Stock P - Purchase 342,132 3,316,128 11.50 7.20 2,463,350 23,876,122

2018-02-23 2018-02-14 4 XTNT Xtant Medical Holdings, Inc.
Common Stock P - Purchase 603,687 5,890,884 11.42 7.20 4,346,546 42,414,365

2018-02-23 2018-02-14 4 XTNT Xtant Medical Holdings, Inc.
Common Stock A - Award 2,905,396 2,973,996 4,235.27 7.20 20,918,851 21,412,771

2018-02-23 2018-02-14 4 XTNT Xtant Medical Holdings, Inc.
Common Stock A - Award 5,126,534 5,287,197 3,190.86 7.20 36,911,045 38,067,818

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -17 0 -100.00

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -1,765 0 -100.00

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -58 0 -100.00

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -6,057 0 -100.00

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock S - Sale -75 49,270 -0.15 8.98 -674 442,445

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock S - Sale -7,822 5,500,730 -0.14 8.98 -70,242 49,396,555

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 17 49,345 0.03 5.08 86 250,673

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 1,765 5,508,552 0.03 5.08 8,966 27,983,444

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 58 49,328 0.12 4.68 271 230,855

2018-02-15 2018-02-13 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 6,057 5,506,787 0.11 4.68 28,347 25,771,763

2018-02-12 2018-02-08 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 25,000 3,447,840 0.73 12.93 323,250 44,580,571

2018-02-06 2018-02-02 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 37,840 3,422,840 1.12 14.73 557,383 50,418,433

2018-02-02 2018-02-01 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 22,840 3,385,000 0.68 14.99 342,372 50,741,150

2018-02-02 2018-01-31 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 339,400 3,362,160 11.23 15.00 5,091,000 50,432,400

2018-01-30 2018-01-29 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 50,000 3,022,760 1.68 14.99 749,500 45,311,172

2018-01-30 2018-01-26 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 22,760 2,972,760 0.77 14.93 339,807 44,383,307

2018-01-30 2018-01-26 4 SYBX SYNLOGIC, INC.
Common Stock A - Award 715,000 2,029,996 54.37 9.75 6,971,250 19,792,461

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Series C-1 Convertible Preferred Stock C - Conversion -31,315 0 -100.00

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Series C Convertible Preferred Stock C - Conversion -45,961 0 -100.00

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Series B-1 Convertible Preferred Stock C - Conversion -332,271 0 -100.00

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Series C-1 Convertible Preferred Stock C - Conversion -283,627 0 -100.00

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Series C Convertible Preferred Stock C - Conversion -415,869 0 -100.00

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Series B Convertible Preferred Stock C - Conversion -1,226,156 0 -100.00

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Series A Convertible Preferred Stock C - Conversion -1,783,704 0 -100.00

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Common Stock C - Conversion 409,547 409,547

2018-01-30 2018-01-30 4 ARMO ARMO BioSciences, Inc.
Common Stock C - Conversion 3,709,356 3,709,356

2018-01-30 2018-01-30 4 TORC resTORbio, Inc.
Series B Preferred Stock C - Conversion -1,871,569 0 -100.00

2018-01-30 2018-01-30 4 TORC resTORbio, Inc.
Series A Preferred Stock C - Conversion -2,425,482 0 -100.00

2018-01-30 2018-01-30 4 TORC resTORbio, Inc.
Common Stock P - Purchase 533,333 4,830,387 12.41 15.00 7,999,995 72,455,805

2018-01-30 2018-01-30 4 TORC resTORbio, Inc.
Common Stock C - Conversion 1,871,569 4,297,054 77.16

2018-01-30 2018-01-30 4 TORC resTORbio, Inc.
Common Stock C - Conversion 2,425,485 2,425,485

2018-01-24 2018-01-24 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 64,637 2,950,000 2.24 14.91 963,738 43,984,500

2018-01-24 2018-01-23 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 4,363 2,885,363 0.15 14.99 65,401 43,251,591

2018-01-24 2018-01-22 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 75,000 2,881,000 2.67 14.98 1,123,500 43,157,380

2018-01-24 2018-01-19 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 74,931 2,806,000 2.74 14.95 1,120,218 41,949,700

2018-01-24 2018-01-12 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 38,354 2,731,069 1.42 14.50 556,133 39,600,500

2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 4,679,161

2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 3,574,391

2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 4,679,161

2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 3,574,391

2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 4,679,161

2018-01-19 3 XTNT Xtant Medical Holdings, Inc.
Common Stock 3,574,391

2018-01-12 2018-01-12 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 28,446 2,692,715 1.07 15.40 438,068 41,467,811

2018-01-12 2018-01-11 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 41,700 2,664,269 1.59 13.65 569,205 36,367,272

2018-01-12 2018-01-10 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 170,338 2,622,569 6.95 12.83 2,185,437 33,647,560

2018-01-12 3 KALA Kala Pharmaceuticals, Inc.
Common Stock 4,904,462

2018-01-12 3 KALA Kala Pharmaceuticals, Inc.
Common Stock 4,904,462

2018-01-12 3 KALA Kala Pharmaceuticals, Inc.
Common Stock 4,904,462

2018-01-12 3 KALA Kala Pharmaceuticals, Inc.
Common Stock 4,904,462

2018-01-04 2018-01-03 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock S - Sale -16,128 49,270 -24.66 7.35 -118,541 362,134

2018-01-04 2018-01-03 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock S - Sale -1,693,492 5,500,730 -23.54 7.35 -12,447,166 40,430,366

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -47 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -4,971 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -99 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -10,447 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -97 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -97 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -10,216 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -142 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -14,858 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -97 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -10,182 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -92 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -9,642 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -77 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -8,097 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -189 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -19,811 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -10,180 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -83 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -8,717 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -63 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -6,654 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -50 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -5,227 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -259 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) M - Exercise -27,241 0 -100.00

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock S - Sale -1,392 65,398 -2.08 5.70 -7,934 372,769

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock S - Sale -146,243 7,194,222 -1.99 5.70 -833,585 41,007,065

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 47 66,790 0.07 5.64 265 376,696

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 4,971 7,340,465 0.07 5.64 28,036 41,400,223

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 99 66,743 0.15 2.32 230 154,844

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 10,447 7,335,494 0.14 2.32 24,237 17,018,346

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 97 66,644 0.15 2.01 195 133,954

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 10,216 7,325,047 0.14 2.01 20,534 14,723,344

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 142 66,547 0.21 2.01 285 133,759

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 14,858 7,314,831 0.20 2.01 29,865 14,702,810

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 97 66,405 0.15 1.64 159 108,904

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 10,182 7,299,973 0.14 1.64 16,698 11,971,956

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 92 66,308 0.14 1.73 159 114,713

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 9,642 7,289,791 0.13 1.73 16,681 12,611,338

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 77 66,216 0.12 2.05 158 135,743

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 8,097 7,280,149 0.11 2.05 16,599 14,924,305

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 189 66,139 0.29 1.59 301 105,161

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 19,811 7,272,052 0.27 1.59 31,499 11,562,563

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 97 65,950 0.15 1.62 157 106,839

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 10,180 7,252,241 0.14 1.62 16,492 11,748,630

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 83 65,853 0.13 1.94 161 127,755

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 8,717 7,242,061 0.12 1.94 16,911 14,049,598

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 63 65,770 0.10 2.62 165 172,317

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 6,654 7,233,344 0.09 2.62 17,433 18,951,361

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 50 65,707 0.08 3.00 150 197,121

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 5,227 7,226,690 0.07 3.00 15,681 21,680,070

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 259 65,657 0.40 2.00 518 131,314

2017-12-20 2017-12-18 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock M - Exercise 27,241 7,221,463 0.38 2.00 54,482 14,442,926

2017-12-12 2017-12-08 4 LOXO Loxo Oncology, Inc.
Common Stock S - Sale -250,000 941,000 -20.99 82.50 -20,625,000 77,632,500

2017-11-27 2017-11-22 4 LOXO Loxo Oncology, Inc.
Common Stock S - Sale -267,000 1,191,000 -18.31 75.00 -20,025,000 89,325,000

2017-11-21 2017-11-21 4 SCPH scPharmaceuticals Inc.
Series B Preferred Stock C - Conversion -18,500,000 0 -100.00

2017-11-21 2017-11-21 4 SCPH scPharmaceuticals Inc.
Common Stock P - Purchase 833,333 3,409,865 32.34 14.00 11,666,662 47,738,110

2017-11-21 2017-11-21 4 SCPH scPharmaceuticals Inc.
Common Stock C - Conversion 2,576,532 2,576,532

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock C - Conversion -2,232,014 0 -100.00

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series C Convertible Preferred Stock C - Conversion -229,412 0 -100.00

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series B Convertible Preferred Stock C - Conversion -736,648 0 -100.00

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-2 Convertible Preferred Stock C - Conversion -704,846 0 -100.00

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-1 Convertible Preferred Stock C - Conversion -66,667 0 -100.00

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock C - Conversion 500,000 1,868,966 36.52 10.00 5,000,000 18,689,660

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock C - Conversion 653,974 1,368,966 91.47

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock C - Conversion 114,320 714,992 19.03

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock C - Conversion 328,909 600,672 121.03

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock C - Conversion 252,230 271,763 1,291.30

2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock C - Conversion 19,533 19,533

2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock S - Sale -8,377 1,458,000 -0.57 76.23 -638,579 111,143,340

2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock S - Sale -71,598 1,466,377 -4.66 75.37 -5,396,341 110,520,834

2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock S - Sale -100,045 1,537,975 -6.11 74.49 -7,452,352 114,563,758

2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock S - Sale -43,300 1,638,020 -2.58 73.48 -3,181,684 120,361,710

2017-11-20 2017-11-16 4 LOXO Loxo Oncology, Inc.
Common Stock S - Sale -46,680 1,681,320 -2.70 72.46 -3,382,433 121,828,447

2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock C - Conversion -2,546,295 0 -100.00

2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock P - Purchase 355,000 2,901,295 13.94 17.00 6,035,000 49,322,015

2017-10-10 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock C - Conversion 2,546,295 2,546,295

2017-10-05 2017-10-03 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -1,899 0 -100.00 0.68 -1,291

2017-10-05 2017-10-03 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -199,718 0 -100.00 0.68 -135,808

2017-10-02 2017-09-29 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -888 1,899 -31.86 0.74 -657 1,405

2017-10-02 2017-09-29 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -93,246 199,718 -31.83 0.74 -69,002 147,791

2017-10-02 2017-09-28 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -3,592 2,787 -56.31 0.72 -2,586 2,007

2017-10-02 2017-09-28 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -376,950 292,964 -56.27 0.72 -271,404 210,934

2017-09-29 2017-09-29 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -672,000 4,129,638 -14.00 28.25 -18,984,000 116,662,274

2017-09-28 2017-09-27 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -498 6,379 -7.24 0.92 -458 5,869

2017-09-28 2017-09-27 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -52,301 669,914 -7.24 0.92 -48,117 616,321

2017-09-28 2017-09-26 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -706 6,877 -9.31 1.03 -727 7,083

2017-09-28 2017-09-26 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -74,096 722,215 -9.30 1.03 -76,319 743,881

2017-09-11 2017-09-07 4 BOLD Audentes Therapeutics, Inc.
Stock Option (right to buy) X - Other -5,000 0 -100.00

2017-09-11 2017-09-07 4 BOLD Audentes Therapeutics, Inc.
Common Stock S - Sale -5,000 4,801,638 -0.10 22.35 -111,750 107,316,609

2017-09-11 2017-09-07 4 BOLD Audentes Therapeutics, Inc.
Common Stock X - Other 5,000 4,806,638 0.10 15.03 75,150 72,243,769

2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -553 7,895 -6.55 40.77 -22,546 321,879

2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -58,047 828,605 -6.55 40.77 -2,366,576 33,782,226

2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -1,808 8,448 -17.63 39.63 -71,651 334,794

2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -189,792 886,652 -17.63 39.63 -7,521,457 35,138,019

2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -1,651 10,256 -13.87 37.94 -62,639 389,113

2017-09-05 2017-09-05 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -173,349 1,076,444 -13.87 37.94 -6,576,861 40,840,285

2017-09-05 2017-09-01 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -1,038 11,907 -8.02 37.72 -39,153 449,132

2017-09-05 2017-09-01 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -109,040 1,249,793 -8.02 37.72 -4,112,989 47,142,192

2017-09-05 2017-08-31 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -424 12,945 -3.17 37.82 -16,036 489,580

2017-09-05 2017-08-31 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -44,498 1,358,833 -3.17 37.82 -1,682,914 51,391,064

2017-08-30 3 SYBX SYNLOGIC, INC.
Common Stock 2,629,992

2017-08-30 3 SYBX SYNLOGIC, INC.
Common Stock 2,629,992

2017-08-30 3 SYBX SYNLOGIC, INC.
Common Stock 2,629,992

2017-08-30 3 SYBX SYNLOGIC, INC.
Common Stock 2,629,992

2017-08-25 2017-08-24 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -125 7,583 -1.62 1.50 -188 11,374

2017-08-25 2017-08-24 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -13,075 796,311 -1.62 1.50 -19,612 1,194,466

2017-08-25 2017-08-23 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -10 7,708 -0.13 1.50 -15 11,562

2017-08-25 2017-08-23 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -1,090 809,386 -0.13 1.50 -1,635 1,214,079

2017-08-22 2017-08-22 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -52 7,718 -0.67 1.52 -79 11,731

2017-08-22 2017-08-22 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -5,448 810,476 -0.67 1.52 -8,281 1,231,924

2017-08-22 2017-08-21 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -28 7,770 -0.36 1.49 -42 11,577

2017-08-22 2017-08-21 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -2,952 815,924 -0.36 1.49 -4,398 1,215,727

2017-08-22 2017-08-18 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -630 7,798 -7.48 1.52 -958 11,853

2017-08-22 2017-08-18 4 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share S - Sale -66,166 818,876 -7.48 1.52 -100,572 1,244,692

2017-08-17 2017-08-17 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -2,140 13,369 -13.80 37.85 -80,999 506,017

2017-08-17 2017-08-17 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -224,780 1,403,331 -13.81 37.85 -8,507,923 53,116,078

2017-08-17 2017-08-16 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -619 15,509 -3.84 38.01 -23,528 589,497

2017-08-17 2017-08-16 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -64,961 1,628,111 -3.84 38.01 -2,469,168 61,884,499

2017-08-17 2017-08-15 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -307 16,128 -1.87 38.29 -11,755 617,541

2017-08-17 2017-08-15 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -32,193 1,693,072 -1.87 38.29 -1,232,670 64,827,727

2017-07-27 2017-07-25 4 KALA Kala Pharmaceuticals, Inc.
Series C Preferred Stock C - Conversion -10,707,985 0 -100.00

2017-07-27 2017-07-25 4 KALA Kala Pharmaceuticals, Inc.
Common Stock P - Purchase 319,333 2,375,279 15.53 15.00 4,789,995 35,629,185

2017-07-27 2017-07-25 4 KALA Kala Pharmaceuticals, Inc.
Common Stock C - Conversion 2,055,946 2,055,946

2017-07-26 2017-07-24 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock A - Award 3,298,516 3,298,516

2017-06-15 2017-06-13 4 CTIC CTI BIOPHARMA CORP
Series N-3 Preferred Stock C - Conversion -7,500 0 -100.00

2017-06-15 2017-06-13 4 CTIC CTI BIOPHARMA CORP
Common Stock C - Conversion 5,000,000 5,000,000

2017-04-27 2017-04-25 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares P - Purchase 293,500 293,500 0.12 36,688 36,688

2017-04-27 2017-04-25 4 STDY SteadyMed Ltd.
Warrants to Purchase Ordinary Shares P - Purchase 293,500 293,500 0.12 36,688 36,688

2017-04-27 2017-04-25 4 STDY SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share P - Purchase 587,000 2,123,098 38.21 5.90 3,463,300 12,526,278

2017-04-27 2017-04-25 4 STDY SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share P - Purchase 587,000 2,123,098 38.21 5.90 3,463,300 12,526,278

2017-03-28 2017-03-27 4 ADAP Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares P - Purchase 1,190,476 6,149,377 24.01 4.20 4,999,999 25,827,383

2017-03-17 2017-03-15 4 NONE Aerpio Pharmaceuticals, Inc.
Common Stock P - Purchase 762,995 4,416,446 20.88 5.00 3,814,975 22,082,230

2017-03-17 3 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 7,306,902

2017-03-17 3 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 7,306,902

2017-03-17 3 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 7,306,902

2017-03-17 3 NONE Aerpio Pharmaceuticals, Inc.
Common Stock 7,306,902

2017-03-14 2017-03-14 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -699 16,435 -4.08 44.54 -31,133 732,015

2017-03-14 2017-03-14 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -73,401 1,725,265 -4.08 44.54 -3,269,281 76,843,303

2017-03-14 2017-03-13 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -7 17,134 -0.04 46.13 -323 790,391

2017-03-14 2017-03-13 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -693 1,798,666 -0.04 46.13 -31,968 82,972,463

2017-03-14 2017-03-13 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -1,998 17,141 -10.44 45.30 -90,509 776,487

2017-03-14 2017-03-13 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -208,712 1,799,359 -10.39 45.30 -9,454,654 81,510,963

2017-03-14 2017-03-10 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -915 19,129 -4.56 45.98 -42,072 879,551

2017-03-14 2017-03-10 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -96,113 2,008,071 -4.57 45.98 -4,419,276 92,331,105

2017-03-07 2017-03-03 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -526 20,044 -2.56 47.05 -24,748 943,070

2017-03-07 2017-03-03 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -55,246 2,104,184 -2.56 47.05 -2,599,324 99,001,857

2017-02-21 2017-02-21 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock P - Purchase 7,000 1,469,524 0.48 5.36 37,520 7,876,649

2017-02-21 2017-02-17 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock P - Purchase 71,800 1,462,524 5.16 5.19 372,642 7,590,500

2017-02-21 2017-02-16 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock P - Purchase 30,500 1,390,724 2.24 5.04 153,720 7,009,249

2017-01-20 2017-01-18 4 VRAY ViewRay, Inc.
Warrants to purchase common stock P - Purchase 623 3,843 19.35 0.12 78 480

2017-01-20 2017-01-18 4 VRAY ViewRay, Inc.
Warrants to purchase common stock P - Purchase 65,491 403,692 19.36 0.12 8,186 50,462

2017-01-20 2017-01-18 4 VRAY ViewRay, Inc.
Common Stock, par value $0.01 per share P - Purchase 3,118 89,225 3.62 3.00 9,354 267,675

2017-01-20 2017-01-18 4 VRAY ViewRay, Inc.
Common Stock, par value $0.01 per share P - Purchase 327,459 9,369,342 3.62 3.00 982,377 28,108,026

2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 559,754

2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 616,126

2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 559,754

2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 616,126

2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 559,754

2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 616,126

2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 559,754

2016-12-30 3 NBRV Nabriva Therapeutics AG
Common Shares 616,126

2016-12-01 2016-11-29 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock J - Other -2,149,902 0 -100.00

2016-12-01 2016-11-29 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock J - Other -34,291 0 -100.00

2016-12-01 2016-11-29 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock J - Other -3,604,266 0 -100.00

2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Warrants P - Purchase 53,909 53,909

2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Warrants P - Purchase 5,660,377 5,660,377

2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Series A Convertible Preferred Stock P - Purchase 38 38

2016-09-23 2016-09-21 4 ROKA Roka BioScience, Inc.
Series A Convertible Preferred Stock P - Purchase 3,962 3,962

2016-08-24 2016-08-22 4 VRAY ViewRay, Inc.
Warrants to purchase common stock P - Purchase 3,220 3,220 0.12 402 402

2016-08-24 2016-08-22 4 VRAY ViewRay, Inc.
Warrants to purchase common stock P - Purchase 338,201 338,201 0.12 42,275 42,275

2016-08-24 2016-08-22 4 VRAY ViewRay, Inc.
Common Stock, par value $0.01 per share P - Purchase 10,736 86,107 14.24 2.95 31,671 254,016

2016-08-24 2016-08-22 4 VRAY ViewRay, Inc.
Common Stock, par value $0.01 per share P - Purchase 1,127,338 9,041,883 14.24 2.95 3,325,647 26,673,555

2016-08-12 2016-08-10 4 LOXO Loxo Oncology, Inc.
Common Stock S - Sale -447,857 1,728,000 -20.58 26.96 -12,074,225 46,586,880

2016-08-12 2016-08-12 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -133 20,570 -0.64 33.72 -4,485 693,620

2016-08-12 2016-08-12 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -13,967 2,159,430 -0.64 33.72 -470,967 72,815,980

2016-08-12 2016-08-11 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -1,518 20,703 -6.83 33.63 -51,050 696,242

2016-08-12 2016-08-11 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -159,382 2,173,397 -6.83 33.63 -5,360,017 73,091,341

2016-08-12 2016-08-10 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -1,113 22,221 -4.77 33.77 -37,586 750,403

2016-08-12 2016-08-10 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -116,825 2,332,779 -4.77 33.77 -3,945,180 78,777,947

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-12 3 STDY SteadyMed Ltd.
Ordinary Shares 4,608,294

2016-08-05 2016-08-03 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -4,010 23,334 -14.67 30.59 -122,666 713,787

2016-08-05 2016-08-03 4 GKOS GLAUKOS Corp
Common Stock, par value $0.01 per share S - Sale -420,990 2,449,604 -14.67 30.59 -12,878,084 74,933,386

2016-07-26 2016-07-25 4 RLYP Relypsa Inc
Common Stock S - Sale -343,600 3,356,400 -9.29 31.98 -10,988,328 107,337,672

2016-07-26 2016-07-22 4 RLYP Relypsa Inc
Common Stock S - Sale -3,700,000 3,700,000 -50.00 32.00 -118,400,000 118,400,000

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Series C Preferred Stock C - Conversion -332,766 0 -100.00

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Series B Preferred Stock C - Conversion -1,071,992 0 -100.00

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Series A Preferred Stock C - Conversion -2,511,441 0 -100.00

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Series Seed Preferred Stock C - Conversion -627,867 0 -100.00

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Common Stock P - Purchase 33,334 4,801,638 0.70 15.00 500,010 72,024,570

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Common Stock C - Conversion 332,766 4,768,304 7.50

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Common Stock C - Conversion 1,071,992 4,435,538 31.87

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Common Stock C - Conversion 2,511,441 3,363,546 294.73

2016-07-25 2016-07-25 4 BOLD Audentes Therapeutics, Inc.
Common Stock C - Conversion 627,867 852,105 280.00

2016-07-19 3 BOLD Audentes Therapeutics, Inc.
Common Stock 448,476

2016-07-19 3 BOLD Audentes Therapeutics, Inc.
Common Stock 448,476

2016-07-19 3 BOLD Audentes Therapeutics, Inc.
Common Stock 448,476

2016-07-19 3 BOLD Audentes Therapeutics, Inc.
Common Stock 448,476

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock C - Conversion -456,870 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock C - Conversion -4,351 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock C - Conversion -77,697 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock C - Conversion -739 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock C - Conversion -380,986 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock C - Conversion -3,628 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock P - Purchase 544,811 1,825,415 42.54 14.00 7,627,354 25,555,810

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock P - Purchase 5,189 17,382 42.56 14.00 72,646 243,348

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock C - Conversion 1,166,884 1,280,604 1,026.10

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock C - Conversion 11,111 12,193 1,026.89

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock C - Conversion -456,870 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock C - Conversion -4,351 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock C - Conversion -77,697 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock C - Conversion -739 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock C - Conversion -380,986 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock C - Conversion -3,628 0 -100.00

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock P - Purchase 544,811 1,825,415 42.54 14.00 7,627,354 25,555,810

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock P - Purchase 5,189 17,382 42.56 14.00 72,646 243,348

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock C - Conversion 1,166,884 1,280,604 1,026.10

2016-06-29 2016-06-27 4 SELB SELECTA BIOSCIENCES INC
Common Stock C - Conversion 11,111 12,193 1,026.89

2016-06-27 2016-06-24 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 900 5,379,349 0.02 12.99 11,691 69,877,744

2016-06-27 2016-06-23 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 100 5,378,449 0.00 12.92 1,292 69,489,561

2016-06-21 2016-06-21 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 26,083 5,378,349 0.49 12.87 335,688 69,219,352

2016-06-21 2016-06-17 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 12,300 5,352,266 0.23 12.48 153,504 66,796,280

2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 115,884

2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 228,522

2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 115,884

2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 228,522

2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 115,884

2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 228,522

2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 115,884

2016-06-21 3 SELB SELECTA BIOSCIENCES INC
Common Stock 228,522

2016-06-20 2016-06-16 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock P - Purchase 331,225 2,149,902 18.21 0.56 185,486 1,203,945

2016-06-20 2016-06-16 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock P - Purchase 5,294 34,291 18.26 0.56 2,965 19,203

2016-06-20 2016-06-16 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock P - Purchase 556,339 3,604,266 18.25 0.56 311,550 2,018,389

2016-06-16 2016-06-16 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 5,000 5,339,966 0.09 12.04 60,200 64,293,191

2016-06-16 2016-06-15 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 5,000 5,334,966 0.09 11.94 59,700 63,699,494

2016-06-16 2016-06-14 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 10,000 5,329,966 0.19 12.71 127,100 67,743,868

2016-06-13 2016-06-10 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 20,000 5,319,966 0.38 12.98 259,600 69,053,159

2016-06-13 2016-06-09 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 30,000 5,299,966 0.57 12.95 388,500 68,634,560

2016-05-25 2016-05-24 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share P - Purchase 518,400 29,753,404 1.77 10.48 5,432,832 311,815,674

2016-05-25 2016-05-23 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share P - Purchase 1,191,600 29,235,004 4.25 10.40 12,392,640 304,044,042

2016-05-25 2016-05-20 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share P - Purchase 2,400 28,043,404 0.01 10.04 24,096 281,555,776

2016-05-24 2016-05-20 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 4,716 5,269,966 0.09 13.09 61,732 68,983,855

2016-05-20 2016-05-19 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 61 5,265,250 0.00 12.75 778 67,131,938

2016-05-20 2016-05-19 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 2,539 5,265,189 0.05 12.11 30,747 63,761,439

2016-05-20 2016-05-18 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 4,200 5,262,650 0.08 11.55 48,510 60,783,608

2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Series B Preferred Stock C - Conversion -873,475 0 -100.00

2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Series B Preferred Stock C - Conversion -2,857,143 0 -100.00

2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Common Stock P - Purchase 58,534 2,662,180 2.25 18.00 1,053,612 47,919,240

2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Common Stock P - Purchase 191,466 2,603,646 7.94 18.00 3,446,388 46,865,628

2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Common Stock C - Conversion 564,780 2,412,180 30.57

2016-05-13 2016-05-11 4 NTLA Intellia Therapeutics, Inc.
Common Stock C - Conversion 1,847,400 1,847,400

2016-04-19 3 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 2,720,448

2016-04-19 3 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 2,720,448

2016-04-19 3 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 2,720,448

2016-04-19 3 AGLE Aeglea BioTherapeutics, Inc.
Common Stock 2,720,448

2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 15,904,461

2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 8,065,287

2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 15,904,461

2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 8,065,287

2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 15,904,461

2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 8,065,287

2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 15,904,461

2016-03-30 3 VRAY ViewRay, Inc.
Common Stock 8,065,287

2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock C - Conversion -713,776 0 -100.00

2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Series A Convertible Preferred Stock C - Conversion -3,994,674 0 -100.00

2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value P - Purchase 550,000 5,258,450 11.68 15.00 8,250,000 78,876,750

2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value C - Conversion 713,776 4,708,450 17.87

2016-03-29 2016-03-29 4 CRVS Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value C - Conversion 3,994,674 3,994,674

2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 53,449,304

2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 30,673,708

2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 53,449,304

2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 30,673,708

2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 53,449,304

2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 30,673,708

2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 53,449,304

2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share 30,673,708

2015-12-23 2015-12-23 4 RLYP Relypsa Inc
Common Stock S - Sale -52,058 7,400,000 -0.70 27.54 -1,433,677 203,796,000

2015-12-23 2015-12-23 4 RLYP Relypsa Inc
Common Stock S - Sale -47,942 7,452,058 -0.64 26.78 -1,283,887 199,566,113

2015-12-23 2015-12-22 4 RLYP Relypsa Inc
Common Stock S - Sale -38,630 7,500,000 -0.51 27.02 -1,043,783 202,650,000

2015-12-23 2015-12-22 4 RLYP Relypsa Inc
Common Stock S - Sale -111,370 7,538,630 -1.46 26.39 -2,939,054 198,944,446

2015-12-23 2015-12-21 4 RLYP Relypsa Inc
Common Stock S - Sale -14,171 7,650,000 -0.18 28.39 -402,315 217,183,500

2015-12-23 2015-12-21 4 RLYP Relypsa Inc
Common Stock S - Sale -235,829 7,664,171 -2.99 27.50 -6,485,298 210,764,702

2015-11-30 2015-11-30 4 OTIC Otonomy, Inc.
Common Stock S - Sale -590 1,850,094 -0.03 29.22 -17,240 54,059,747

2015-11-30 2015-11-30 4 OTIC Otonomy, Inc.
Common Stock S - Sale -2,716 1,850,684 -0.15 28.64 -77,786 53,003,590

2015-11-30 2015-11-27 4 OTIC Otonomy, Inc.
Common Stock S - Sale -29,000 1,853,400 -1.54 28.97 -840,130 53,692,998

2015-11-30 2015-11-25 4 OTIC Otonomy, Inc.
Common Stock S - Sale -34,800 1,882,400 -1.82 28.91 -1,006,068 54,420,184

2015-11-24 2015-11-24 4 OTIC Otonomy, Inc.
Common Stock S - Sale -36,100 1,917,200 -1.85 28.75 -1,037,875 55,119,500

2015-11-24 2015-11-23 4 OTIC Otonomy, Inc.
Common Stock S - Sale -80,800 1,953,300 -3.97 28.45 -2,298,760 55,571,385

2015-11-24 2015-11-20 4 OTIC Otonomy, Inc.
Common Stock S - Sale -83,900 2,034,100 -3.96 28.59 -2,398,701 58,154,919

2015-11-19 2015-11-19 4 OTIC Otonomy, Inc.
Common Stock S - Sale -127,300 2,118,000 -5.67 28.60 -3,640,780 60,574,800

2015-11-19 2015-11-17 4 OTIC Otonomy, Inc.
Common Stock S - Sale -200 2,245,300 -0.01 29.09 -5,818 65,315,777

2015-11-19 2015-11-17 4 OTIC Otonomy, Inc.
Common Stock S - Sale -10,898 2,245,500 -0.48 28.80 -313,862 64,670,400

2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Series B Preferred Stock C - Conversion -5,692,874 0 -100.00

2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Series A Preferred Stock C - Conversion -9,500,000 0 -100.00

2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Common Stock P - Purchase 200,000 5,397,698 3.85 13.00 2,600,000 70,170,074

2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Common Stock C - Conversion 1,947,613 5,197,698 59.92

2015-10-29 2015-10-27 4 DMTX Dimension Therapeutics, Inc.
Common Stock C - Conversion 3,250,085 3,250,085

2015-10-22 2015-10-22 4 RLYP Relypsa Inc
Common Stock P - Purchase 310,700 7,900,000 4.09 12.92 4,014,244 102,068,000

2015-10-22 2015-10-22 4 RLYP Relypsa Inc
Common Stock P - Purchase 189,300 7,589,300 2.56 11.97 2,265,921 90,843,921

2015-10-13 2015-10-12 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -2,785 17,100 -14.01 5.98 -16,654 102,258

2015-10-13 2015-10-12 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -285,106 1,767,902 -13.89 5.98 -1,704,934 10,572,054

2015-10-09 2015-10-09 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -2,041 19,885 -9.31 7.03 -14,348 139,792

2015-10-09 2015-10-09 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -210,668 2,053,008 -9.31 7.03 -1,480,996 14,432,646

2015-10-09 2015-10-08 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -3,837 21,926 -14.89 7.24 -27,780 158,744

2015-10-09 2015-10-08 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -396,163 2,263,676 -14.89 7.24 -2,868,220 16,389,014

2015-10-09 2015-10-07 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -454 25,763 -1.73 7.36 -3,341 189,616

2015-10-09 2015-10-07 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -53,446 2,659,839 -1.97 7.36 -393,363 19,576,415

2015-10-06 2015-10-06 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -59 26,217 -0.22 7.80 -460 204,493

2015-10-06 2015-10-06 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -6,941 2,713,285 -0.26 7.80 -54,140 21,163,623

2015-10-06 2015-10-05 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -1,163 26,276 -4.24 8.19 -9,525 215,200

2015-10-06 2015-10-05 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -136,937 2,720,226 -4.79 8.19 -1,121,514 22,278,651

2015-10-06 2015-10-02 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -403 27,439 -1.45 10.34 -4,167 283,719

2015-10-06 2015-10-02 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -47,497 2,857,163 -1.64 10.34 -491,119 29,543,065

2015-10-01 2015-10-01 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -400 27,842 -1.42 10.34 -4,136 287,886

2015-10-01 2015-10-01 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -47,100 2,904,660 -1.60 10.34 -487,014 30,034,184

2015-10-01 2015-09-30 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -369 28,242 -1.29 10.17 -3,753 287,221

2015-10-01 2015-09-30 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -43,471 2,951,760 -1.45 10.17 -442,100 30,019,399

2015-10-01 2015-09-29 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -89 28,611 -0.31 10.08 -897 288,399

2015-10-01 2015-09-29 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -10,469 2,995,231 -0.35 10.08 -105,528 30,191,928

2015-09-28 2015-09-28 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -89 28,700 -0.31 10.30 -917 295,610

2015-09-28 2015-09-28 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -10,513 3,005,700 -0.35 10.30 -108,284 30,958,710

2015-09-28 2015-09-25 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -311 28,789 -1.07 11.07 -3,443 318,694

2015-09-28 2015-09-25 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -66,489 3,016,213 -2.16 11.07 -736,033 33,389,478

2015-09-28 2015-09-25 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -800 29,100 -2.68 10.07 -8,056 293,037

2015-09-28 2015-09-25 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -64,400 3,082,702 -2.05 10.07 -648,508 31,042,809

2015-09-28 2015-09-24 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -8,152 3,147,102 -0.26 11.00 -89,672 34,618,122

2015-09-28 2015-09-24 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -148 29,900 -0.49 11.00 -1,628 328,900

2015-09-28 2015-09-24 4 SIEN Sientra, Inc.
Common Stock, par value $0.01 per share S - Sale -6 3,155,254 0.00 9.78 -59 30,858,384

2015-07-21 2015-07-17 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share A - Award 285 1,120,609 0.03

2015-07-21 2015-07-21 4 DNAI ProNAi Therapeutics Inc
Series D Preferred Stock C - Conversion -1,725,790 0 -100.00

2015-07-21 2015-07-21 4 DNAI ProNAi Therapeutics Inc
Common Stock P - Purchase 175,000 1,989,949 9.64 17.00 2,975,000 33,829,133

2015-07-21 2015-07-21 4 DNAI ProNAi Therapeutics Inc
Common Stock J - Other 89,159 1,814,949 5.17 5.22 464,964 9,464,959

2015-07-21 2015-07-21 4 DNAI ProNAi Therapeutics Inc
Common Stock C - Conversion 1,725,790 1,725,790

2015-07-08 2015-07-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock P - Purchase 4,717 65,398 7.77 2.75 12,972 179,844

2015-07-08 2015-07-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock P - Purchase 495,283 7,194,222 7.39 2.75 1,362,028 19,784,110

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock Warrant (right to buy) M - Exercise -261 0 -100.00

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock Warrant (right to buy) M - Exercise -27,346 0 -100.00

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series F Convertible Preferred Stock C - Conversion -2,672 0 -100.00

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series F Convertible Preferred Stock C - Conversion -280,531 0 -100.00

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series E Convertible Preferred Stock C - Conversion -1,599 0 -100.00

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series E Convertible Preferred Stock C - Conversion -167,898 0 -100.00

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock C - Conversion -22,923 0 -100.00

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Series D Convertible Preferred Stock C - Conversion -2,406,441 0 -100.00

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock F - Taxes -111 27,344 -0.40 18.00 -1,998 492,192

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock M - Exercise 261 27,455 0.96

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock F - Taxes -11,623 2,870,593 -0.40 18.00 -209,214 51,670,674

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock M - Exercise 27,346 2,882,216 0.96

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock C - Conversion 27,194 27,194

2015-06-30 2015-06-30 4 GKOS GLAUKOS Corp
Common Stock C - Conversion 2,854,870 2,854,870

2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 13,458,559

2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 6,820,301

2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 13,458,559

2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 6,820,301

2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 13,458,559

2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 6,820,301

2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 13,458,559

2015-06-29 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock 6,820,301

2015-05-20 2015-05-18 4 RLYP Relypsa Inc
Common Stock S - Sale -1,457,551 7,400,000 -16.46 34.13 -49,746,216 252,562,000

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -90 1,120,324 -0.01 294.82 -26,534 330,293,922

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -2,500 1,120,414 -0.22 293.85 -734,625 329,233,654

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -6,000 1,122,914 -0.53 292.13 -1,752,780 328,036,867

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,700 1,128,914 -0.33 291.12 -1,077,144 328,649,444

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -13,974 1,132,614 -1.22 290.02 -4,052,739 328,480,712

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -15,131 1,146,588 -1.30 289.07 -4,373,918 331,444,193

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -26,028 1,161,719 -2.19 288.11 -7,498,927 334,702,861

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -18,041 1,187,747 -1.50 287.16 -5,180,654 341,073,429

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -7,611 1,205,788 -0.63 286.24 -2,178,573 345,144,757

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -23,903 1,213,399 -1.93 285.18 -6,816,658 346,037,127

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -16,845 1,237,302 -1.34 284.20 -4,787,349 351,641,228

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -9,357 1,254,147 -0.74 282.87 -2,646,815 354,760,562

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -8,397 1,263,504 -0.66 282.13 -2,369,046 356,472,384

2015-03-30 2015-03-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -5,623 1,271,901 -0.44 281.11 -1,580,682 357,544,090

2015-03-25 2015-03-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -2,800 1,277,524 -0.22 270.23 -756,644 345,225,311

2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,844 1,280,324 -0.30 275.56 -1,059,253 352,806,081

2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -12,066 1,284,168 -0.93 275.00 -3,318,150 353,146,200

2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -2,700 1,296,234 -0.21 273.19 -737,613 354,118,166

2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,050 1,298,934 -0.23 272.13 -829,996 353,478,909

2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -6,063 1,301,984 -0.46 271.15 -1,643,982 353,032,962

2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -9,574 1,308,047 -0.73 270.13 -2,586,225 353,342,736

2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,539 1,317,621 -0.12 269.10 -414,145 354,571,811

2015-03-25 2015-03-24 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -6,764 1,319,160 -0.51 268.13 -1,813,631 353,706,371

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,000 1,325,924 -0.08 288.60 -288,600 382,661,666

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,400 1,326,924 -0.11 286.04 -400,456 379,553,341

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -52 1,328,324 0.00 283.44 -14,739 376,500,155

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,548 1,328,376 -0.12 283.29 -438,533 376,315,637

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,500 1,329,924 -0.26 282.00 -987,000 375,038,568

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -6,306 1,333,424 -0.47 281.01 -1,772,049 374,705,478

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -9,465 1,339,730 -0.70 280.00 -2,650,200 375,124,400

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,668 1,349,195 -0.27 279.00 -1,023,372 376,425,405

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -14,152 1,352,863 -1.04 278.00 -3,934,256 376,095,914

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -8,195 1,367,015 -0.60 276.96 -2,269,687 378,608,474

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -37,666 1,375,210 -2.67 275.95 -10,393,933 379,489,200

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,579 1,412,876 -0.25 274.86 -983,724 388,343,097

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -11,869 1,416,455 -0.83 273.89 -3,250,800 387,952,860

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -8,638 1,428,324 -0.60 272.79 -2,356,360 389,632,504

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -7,764 1,436,962 -0.54 271.70 -2,109,479 390,422,575

2015-03-25 2015-03-23 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -40,598 1,444,726 -2.73 270.70 -10,989,879 391,087,328

2015-02-05 2015-02-03 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share P - Purchase 100,000 1,267,000 8.57 20.00 2,000,000 25,340,000

2014-10-28 3 SIEN Sientra, Inc.
Common Stock 6,340,568

2014-10-28 3 SIEN Sientra, Inc.
Common Stock 3,215,356

2014-10-28 3 SIEN Sientra, Inc.
Common Stock 6,340,568

2014-10-28 3 SIEN Sientra, Inc.
Common Stock 3,215,356

2014-10-28 3 SIEN Sientra, Inc.
Common Stock 6,340,568

2014-10-28 3 SIEN Sientra, Inc.
Common Stock 3,215,356

2014-10-28 3 SIEN Sientra, Inc.
Common Stock 6,340,568

2014-10-28 3 SIEN Sientra, Inc.
Common Stock 3,215,356

2014-09-18 2014-09-17 4 RLYP Relypsa Inc
Common Stock S - Sale -49,000 8,857,551 -0.55 25.07 -1,228,430 222,058,804

2014-09-18 2014-09-16 4 RLYP Relypsa Inc
Common Stock S - Sale -2,600 8,906,551 -0.03 26.06 -67,756 232,104,719

2014-09-18 2014-09-16 4 RLYP Relypsa Inc
Common Stock S - Sale -42,400 8,909,151 -0.47 25.45 -1,079,080 226,737,893

2014-08-27 2014-08-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -400 1,485,324 -0.03 302.34 -120,936 449,072,858

2014-08-27 2014-08-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -5,400 1,485,724 -0.36 301.36 -1,627,344 447,737,785

2014-08-27 2014-08-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -45,058 1,491,124 -2.93 300.11 -13,522,356 447,501,224

2014-08-27 2014-08-26 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -10,400 1,536,182 -0.67 299.13 -3,110,952 459,518,122

2014-08-27 2014-08-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,990 1,546,582 -0.13 297.26 -591,547 459,736,965

2014-08-27 2014-08-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -10,010 1,548,572 -0.64 296.59 -2,968,866 459,290,969

2014-08-27 2014-08-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -25,442 1,558,582 -1.61 295.52 -7,518,620 460,592,153

2014-08-27 2014-08-25 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -12,558 1,584,024 -0.79 294.67 -3,700,466 466,764,352

2014-08-19 2014-08-18 4 OTIC Otonomy, Inc.
Series D Preferred Stock C - Conversion -378,039 0 -100.00

2014-08-19 2014-08-18 4 OTIC Otonomy, Inc.
Series C Preferred Stock C - Conversion -1,706,484 0 -100.00

2014-08-19 2014-08-18 4 OTIC Otonomy, Inc.
Common Stock P - Purchase 171,875 2,256,398 8.25 16.00 2,750,000 36,102,368

2014-08-19 2014-08-18 4 OTIC Otonomy, Inc.
Common Stock C - Conversion 2,084,523 2,084,523

2014-08-19 2014-08-15 4 RLYP Relypsa Inc
Common Stock S - Sale -990,000 8,951,551 -9.96 26.35 -26,086,500 235,873,369

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -350 1,596,582 -0.02 308.13 -107,844 491,948,425

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -14,640 1,596,932 -0.91 307.06 -4,495,314 490,349,149

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -525 1,611,572 -0.03 306.23 -160,772 493,516,528

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,732 1,612,097 -0.11 305.14 -528,501 491,913,666

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,193 1,613,829 -0.07 303.77 -362,394 490,227,994

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,100 1,615,022 -0.07 302.55 -332,806 488,626,521

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -1,710 1,616,122 -0.11 301.42 -515,426 487,129,877

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,985 1,617,832 -0.25 300.21 -1,196,329 485,686,109

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -100 1,621,817 -0.01 298.61 -29,861 484,290,774

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -9,985 1,621,917 -0.61 297.76 -2,973,134 482,942,006

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -6,192 1,631,902 -0.38 296.86 -1,838,139 484,441,532

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -7,062 1,638,094 -0.43 296.21 -2,091,814 485,214,909

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,254 1,645,156 -0.20 294.96 -959,800 485,255,214

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -4,468 1,648,410 -0.27 293.85 -1,312,908 484,380,333

2014-08-18 2014-08-14 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -3,704 1,652,878 -0.22 292.70 -1,084,165 483,799,043

2014-08-11 2014-08-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units M - Exercise -324 0 -100.00

2014-08-11 2014-08-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share M - Exercise 324 1,656,582 0.02

2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Series B Convertible Preferred Stock C - Conversion -337,973 0 -100.00

2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Series A Convertible Preferred Stock C - Conversion -1,562,499 0 -100.00

2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock P - Purchase 275,385 2,175,857 14.49 13.00 3,580,005 28,286,141

2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock C - Conversion 337,973 1,900,472 21.63

2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock C - Conversion 1,562,499 1,562,499

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series E Convertible Preferred Stock C - Conversion -56,490 0 -100.00

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series E Convertible Preferred Stock C - Conversion -5,931,402 0 -100.00

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series D Convertible Preferred Stock C - Conversion -80,715 0 -100.00

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series D Convertible Preferred Stock C - Conversion -8,475,069 0 -100.00

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series C Convertible Preferred Stock C - Conversion -38,021 0 -100.00

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series C Convertible Preferred Stock C - Conversion -3,992,203 0 -100.00

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series B Convertible Preferred Stock C - Conversion -116,981 0 -100.00

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Series B Convertible Preferred Stock C - Conversion -12,238,019 0 -100.00

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share P - Purchase 3,616 30,378 13.51 12.00 43,392 364,536

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share P - Purchase 379,717 3,190,051 13.51 12.00 4,556,604 38,280,612

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share C - Conversion 5,116 26,762 23.63

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share C - Conversion 537,264 2,810,334 23.64

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share C - Conversion 7,563 21,646 53.70

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share C - Conversion 794,178 2,273,070 53.70

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share C - Conversion 3,443 14,083 32.36

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share C - Conversion 361,612 1,478,892 32.37

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share C - Conversion 10,596 10,640 24,081.82

2014-07-24 2014-07-22 4 ROKA Roka BioScience, Inc.
Common Stock, $0.001 par value per share C - Conversion 1,112,592 1,117,280 23,732.76

2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 9,420

2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 4,776

2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 9,420

2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 4,776

2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 9,420

2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 4,776

2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 9,420

2014-07-16 3 ROKA Roka BioScience, Inc.
Common Stock, par value $0.001 per share 4,776

2014-07-01 2014-07-01 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share S - Sale -5,000 1,167,000 -0.43 20.04 -100,200 23,386,680

2014-07-01 2014-06-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share S - Sale -4,717 1,172,000 -0.40 21.11 -99,576 24,740,920

2014-07-01 2014-06-30 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share S - Sale -9,283 1,176,717 -0.78 20.33 -188,723 23,922,657

2014-07-01 2014-06-27 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share S - Sale -9,212 1,186,000 -0.77 23.09 -212,705 27,384,740

2014-07-01 2014-06-27 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share S - Sale -79,120 1,195,212 -6.21 21.79 -1,724,025 26,043,669

2014-05-09 2014-05-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share M - Exercise 325 1,656,258 0.02

2014-05-09 2014-05-07 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share M - Exercise 1,330 1,655,933 0.08

2014-05-09 2013-05-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units M - Exercise -325 324 -50.08

2014-05-09 2013-05-07 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units M - Exercise -1,330 0 -100.00

2014-04-11 2014-04-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -81,305 1,654,603 -4.68 320.00 -26,017,600 529,472,960

2014-02-11 2014-02-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units M - Exercise -324 649 -33.30

2014-02-11 2014-02-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share M - Exercise 324 1,735,908 0.02

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Common Stock M - Exercise -327,133 0 -100.00

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Common Stock J - Other 327,133 327,133

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Preferred Stock J - Other -327,133 0 -100.00

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Common Stock M - Exercise -1,417,578 0 -100.00

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Common Stock J - Other 1,417,578 1,417,578

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Warrant to Purchase Preferred Stock J - Other -1,417,578 0 -100.00

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Series C-2 Preferred Stock C - Conversion -693,991 0 -100.00

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Series C-1 Preferred Stock C - Conversion -3,007,297 0 -100.00

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Series B-2 Preferred Stock C - Conversion -1,905,702 0 -100.00

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Series B-1 Preferred Stock C - Conversion -1,295,845 0 -100.00

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock P - Purchase 712,192 9,941,551 7.72 11.00 7,834,112 109,357,061

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock F - Taxes -5,116 9,229,359 -0.06 11.00 -56,276 101,522,949

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock M - Exercise 327,133 9,234,475 3.67 0.17 55,613 1,569,861

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock F - Taxes -22,166 8,907,342 -0.25 11.00 -243,826 97,980,762

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock M - Exercise 1,417,578 8,929,508 18.87 0.17 240,988 1,518,016

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock C - Conversion 693,991 7,511,930 10.18

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock C - Conversion 3,007,297 6,817,939 78.92

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock C - Conversion 1,905,702 3,810,642 100.04

2013-11-20 2013-11-20 4 RLYP Relypsa Inc
Common Stock C - Conversion 1,904,940 1,904,940

2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Warrant P - Purchase 151,632 151,632

2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Warrant P - Purchase 2,408 2,408

2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Warrant P - Purchase 254,122 254,122

2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock P - Purchase 303,265 1,818,677 20.01 2.45 742,999 4,455,759

2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock P - Purchase 4,816 28,997 19.92 2.45 11,799 71,043

2013-11-12 2013-11-07 4 RBM RESPONSE BIOMEDICAL CORP
Common Stock P - Purchase 508,244 3,047,927 20.01 2.45 1,245,198 7,467,421

2013-11-12 2013-11-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units M - Exercise -325 973 -25.04

2013-11-12 2013-11-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share M - Exercise 325 1,735,584 0.02

2013-10-31 2013-10-29 4 MRTX Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share P - Purchase 125,000 1,274,332 10.88 17.50 2,187,500 22,300,810

2013-10-23 2013-10-21 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -40,088 1,735,259 -2.26 62.50 -2,505,500 108,453,688

2013-10-17 2013-10-15 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share S - Sale -376,585 1,775,347 -17.50 62.50 -23,536,562 110,959,188

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series F Convertible Preferred C - Conversion -14,574 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series F Convertible Preferred C - Conversion -38,924 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred C - Conversion -8,466 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred C - Conversion -22,612 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred Stock C - Conversion -31,113 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred C - Conversion -83,097 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series D Convertible Preferred Stock C - Conversion -8,777 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series D Convertible Preferred C - Conversion -23,442 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series C Convertible Preferred Stock C - Conversion -65,680 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series C Convertible Preferred C - Conversion -175,419 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series B Convertible Preferred Stock C - Conversion -422,101 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series B Convertible Preferred Stock C - Conversion -1,127,346 0 -100.00

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 14,574 576,889 2.59

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 38,924 1,540,759 2.59

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 13,431 562,315 2.45

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 35,873 1,501,835 2.45

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 50,145 548,884 10.05

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 133,930 1,465,962 10.05

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 8,777 498,739 1.79

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 23,442 1,332,032 1.79

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 65,680 489,962 15.48

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 175,419 1,308,590 15.48

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 422,101 424,282 19,353.55

2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock C - Conversion 1,127,346 1,133,171 19,353.58

2013-09-18 3 XLRN ACCELERON PHARMA INC
Common Stock 5,825

2013-09-18 3 XLRN ACCELERON PHARMA INC
Common Stock 2,181

2013-08-13 2013-08-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units M - Exercise -325 1,298 -20.02

2013-08-13 2013-08-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share M - Exercise 325 2,151,932 0.02

2013-07-16 3 MRTX Mirati Therapeutics, Inc.
Common Stock 1,149,332

2013-05-24 2013-05-23 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 120 14,067 0.86 6.99 839 98,318

2013-05-24 2013-05-23 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 12,380 1,476,702 0.85 6.99 86,528 10,321,113

2013-05-24 2013-05-22 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 200 13,947 1.45 6.86 1,372 95,690

2013-05-24 2013-05-22 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 21,100 1,464,322 1.46 6.86 144,767 10,046,713

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series D Convertible Preferred Stock C - Conversion -18,795 0 -100.00

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series D Convertible Preferred Stock C - Conversion -1,973,439 0 -100.00

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series D-2 Convertible Preferred Stock C - Conversion -50,256 0 -100.00

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series D-2 Convertible Preferred Stock C - Conversion -5,276,702 0 -100.00

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series E Convertible Preferred Stock C - Conversion -83,959 0 -100.00

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Series E Convertible Preferred Stock C - Conversion -8,815,565 0 -100.00

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 80 13,747 0.59 6.90 552 94,813

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 8,020 1,443,222 0.56 6.90 55,314 9,953,902

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 590 13,667 4.51 8.00 4,720 109,336

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 61,910 1,435,202 4.51 8.00 495,280 11,481,616

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 5,653 13,077 76.14 8.00 45,224 104,616

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 593,618 1,373,292 76.14 8.00 4,748,944 10,986,336

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share C - Conversion 1,730 7,424 30.38

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share C - Conversion 181,689 779,674 30.38

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share C - Conversion 2,094 5,694 58.17

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share C - Conversion 219,863 597,985 58.15

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share C - Conversion 3,498 3,600 3,429.41

2013-05-22 2013-05-21 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share C - Conversion 367,315 378,122 3,398.86

2013-05-22 2013-05-20 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 100 102 5,000.00 6.78 678 691

2013-05-22 2013-05-20 4 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share P - Purchase 10,500 10,807 3,420.20 6.78 71,162 73,242

2013-05-15 3 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 307

2013-05-15 3 AMBI AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share 2

2013-05-13 2013-05-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units M - Exercise -324 1,623 -16.64

2013-05-13 2013-05-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share M - Exercise 324 2,151,607 0.02

2013-04-15 2013-04-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units M - Exercise -649 1,947 -25.00

2013-04-15 2013-04-09 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share M - Exercise 649 2,151,283 0.03

2013-02-14 2013-02-13 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock S - Sale -41,100 817,000 -4.79 7.58 -311,361 6,189,347

2013-02-14 2013-02-13 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock S - Sale -108,900 2,183,000 -4.75 7.58 -824,994 16,537,753

2013-02-14 2013-02-12 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock S - Sale -41,483 858,100 -4.61 7.52 -312,027 6,454,457

2013-02-14 2013-02-12 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock S - Sale -110,700 2,291,900 -4.61 7.52 -832,663 17,239,213

2013-02-01 2013-01-30 4 ANTH Anthera Pharmaceuticals Inc
Common Stock P - Purchase 5,700,000 7,462,000 323.50 0.66 3,762,000 4,924,920

2013-01-29 2013-01-25 4 ANTH Anthera Pharmaceuticals Inc
Common Stock P - Purchase 1,762,000 1,762,000 0.65 1,142,481 1,142,481

2012-12-19 2012-12-18 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock S - Sale -100,000 0 -100.00 7.08 -707,670

2012-12-19 2012-12-17 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock S - Sale -197,815 100,000 -66.42 6.85 -1,354,617 684,790

2012-10-16 2012-10-16 4 ICPT INTERCEPT PHARMACEUTICALS INC
Series C Preferred Stock C - Conversion -10,500,000 0 -100.00

2012-10-16 2012-10-16 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share P - Purchase 333,334 2,150,634 18.34 15.00 5,000,010 32,259,510

2012-10-16 2012-10-16 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share C - Conversion 1,817,300 1,817,300

2012-09-05 2012-09-04 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares S - Sale X -2,244 5,700 -28.25 14.43 -32,388 82,268

2012-09-05 2012-09-04 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares S - Sale X -231,456 594,300 -28.03 14.43 -3,340,604 8,577,532

2012-07-30 2012-07-27 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares S - Sale X -3,456 7,944 -30.32 14.61 -50,483 116,041

2012-07-30 2012-07-27 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares S - Sale X -362,844 825,756 -30.53 14.61 -5,300,207 12,062,148

2012-07-13 2012-07-13 4 GNOM COMPLETE GENOMICS INC
Common Stock S - Sale -4,500 27,859 -13.91 2.51 -11,298 69,943

2012-07-13 2012-07-13 4 GNOM COMPLETE GENOMICS INC
Common Stock S - Sale -474,800 2,922,141 -13.98 2.51 -1,192,033 7,336,327

2012-07-13 2012-07-12 4 GNOM COMPLETE GENOMICS INC
Common Stock S - Sale -2,076 32,359 -6.03 2.85 -5,916 92,210

2012-07-13 2012-07-12 4 GNOM COMPLETE GENOMICS INC
Common Stock S - Sale -218,624 3,396,941 -6.05 2.85 -622,991 9,679,923

2012-07-13 2012-07-11 4 GNOM COMPLETE GENOMICS INC
Common Stock S - Sale -4,792 34,435 -12.22 2.90 -13,891 99,820

2012-07-13 2012-07-11 4 GNOM COMPLETE GENOMICS INC
Common Stock S - Sale -503,144 3,615,565 -12.22 2.90 -1,458,514 10,480,800

2012-07-03 2012-06-29 4 ANTH Anthera Pharmaceuticals Inc
Common Stock S - Sale -1,283,300 0 -100.00 0.73 -942,071

2012-06-19 2012-06-19 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares S - Sale -5,900 11,400 -34.10 12.91 -76,185 147,205

2012-06-19 2012-06-19 4 AMRN AMARIN CORP PLC\UK
Ordinary Shares S - Sale -611,200 1,188,600 -33.96 12.91 -7,892,242 15,348,035

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock C - Conversion -827,627 0 -100.00

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock C - Conversion -2,498,842 0 -100.00

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock C - Conversion -6,673,891 0 -100.00

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock P - Purchase 90,999 297,815 44.00 5.00 454,995 1,489,075

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock P - Purchase 274,873 899,583 44.00 5.00 1,374,365 4,497,915

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock P - Purchase 734,128 2,402,600 44.00 5.00 3,670,640 12,013,000

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock C - Conversion 206,816 206,816

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock C - Conversion 624,710 624,710

2012-05-08 2012-05-04 4 SUPN SUPERNUS PHARMACEUTICALS INC
Common Stock C - Conversion 1,668,472 1,668,472

2012-03-22 2012-03-22 4 ANTH Anthera Pharmaceuticals Inc
Common Stock S - Sale -1,306,700 1,283,300 -50.45 2.40 -3,140,131 3,083,898

2012-03-22 2012-03-21 4 ANTH Anthera Pharmaceuticals Inc
Common Stock S - Sale -125,000 2,590,000 -4.60 2.87 -358,312 7,424,235

2012-03-22 2012-03-20 4 ANTH Anthera Pharmaceuticals Inc
Common Stock S - Sale -116,800 2,715,000 -4.12 2.90 -338,638 7,871,600

2012-03-13 2012-03-12 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -700 2,446,000 -0.03 11.03 -7,722 26,983,783

2012-03-13 2012-03-12 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -62,400 2,446,700 -2.49 11.03 -688,384 26,991,505

2012-03-13 2012-03-09 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -300 2,509,100 -0.01 11.25 -3,374 28,216,335

2012-03-13 2012-03-09 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -36,700 2,509,400 -1.44 11.25 -412,714 28,219,709

2012-02-29 2012-02-29 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -3,000 2,546,100 -0.12 10.86 -32,584 27,654,211

2012-02-29 2012-02-28 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -100 2,549,100 0.00 11.12 -1,112 28,347,012

2012-02-29 2012-02-28 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -10,000 2,549,200 -0.39 11.12 -111,204 28,348,124

2012-02-29 2012-02-27 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -300 2,559,200 -0.01 11.05 -3,314 28,271,994

2012-02-29 2012-02-27 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -28,700 2,559,500 -1.11 11.05 -317,055 28,275,308

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series C Preferred Stock C - Conversion -242,674 0 -100.00

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series B Preferred Stock C - Conversion -1,574,345 0 -100.00

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series C Preferred Stock C - Conversion -514,354 0 -100.00

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series B Preferred Stock C - Conversion -3,888,423 0 -100.00

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series C Preferred Stock C - Conversion -10,706 0 -100.00

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Series B Preferred Stock C - Conversion -78,928 0 -100.00

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Common Stock C - Conversion 908,509 908,509

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Common Stock C - Conversion 2,201,388 2,201,388

2012-02-15 2012-02-13 4 CCXI ChemoCentryx, Inc.
Common Stock C - Conversion 44,817 44,817

2012-02-03 2012-02-03 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -500 2,588,200 -0.02 10.79 -5,395 27,927,713

2012-02-03 2012-02-03 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -49,500 2,588,700 -1.88 10.79 -534,125 27,933,108

2012-02-03 2012-02-02 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -200 2,638,200 -0.01 10.85 -2,171 28,637,133

2012-02-03 2012-02-02 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -23,100 2,638,400 -0.87 10.85 -250,746 28,639,304

2012-02-03 2012-02-01 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -700 2,661,500 -0.03 11.01 -7,704 29,291,937

2012-02-03 2012-02-01 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock S - Sale -69,300 2,662,200 -2.54 11.01 -762,702 29,299,641

P

Pasaran terbuka atau pembelian persendirian sekuriti bukan derivatif atau derivatif

S

Pasaran terbuka atau jualan persendirian sekuriti bukan derivatif atau derivatif

A

Pemberian, penganugerahan atau pemerolehan lain sekuriti daripada syarikat (seperti opsyen)

C

Penukaran derivatif

D

Penjualan atau pemindahan sekuriti kembali kepada syarikat

F

Pembayaran harga pelaksanaan atau liabiliti cukai menggunakan sebahagian daripada sekuriti yang diterima daripada syarikat

G

Hadiah sekuriti oleh atau kepada orang dalam

K

Swap ekuiti dan urus niaga lindung nilai yang serupa

M

Pelaksanaan atau penukaran sekuriti derivatif yang diterima daripada syarikat (seperti opsyen)

V

Transaksi dilaporkan secara sukarela pada Borang 4

J

Lain-lain (disertai dengan nota kaki yang menerangkan transaksi)

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2018-06-06	ADAP	ORBIMED ADVISORS LLC	1,600	13.4900	1,600	13.4900	21,584	357	3.2300	-16,416	-76.06
2018-06-04	ADAP	ORBIMED ADVISORS LLC	17,100	13.5700	17,100	13.5700	232,047
2018-06-01	ADAP	ORBIMED ADVISORS LLC	50,000	13.4900	50,000	13.4900	674,500
2018-05-30	ADAP	ORBIMED ADVISORS LLC	121,000	13.5200	121,000	13.5200	1,635,920
2018-05-14	ADAP	ORBIMED ADVISORS LLC	10,300	13.5000	10,300	13.5000	139,050
2018-03-29	ADAP	ORBIMED ADVISORS LLC	31,983	11.5300	31,983	11.5300	368,764
2018-03-27	ADAP	ORBIMED ADVISORS LLC	1,016,084	11.5000	1,016,084	11.5000	11,684,966

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2021-07-19	AFIB	ORBIMED ADVISORS LLC	714,285	14.0000	714,285	14.0000	9,999,990	4	16.7000	1,928,570	19.29
2021-07-19	AFIB	ORBIMED ADVISORS LLC	357,143	14.0000	357,143	14.0000	5,000,002
2020-08-10	AFIB	ORBIMED ADVISORS LLC	373,500	18.0000	373,500	18.0000	6,723,000
2020-08-10	AFIB	ORBIMED ADVISORS LLC	41,500	18.0000	41,500	18.0000	747,000

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2019-02-11	ALEC	ORBIMED ADVISORS LLC	157,939	19.0000	157,939	19.0000	3,000,841	361	35.2800	2,571,247	85.68
2019-02-11	ALEC	ORBIMED ADVISORS LLC	50,561	19.0000	50,561	19.0000	960,659
2019-02-11	ALEC	ORBIMED ADVISORS LLC	203,200	19.0000	203,200	19.0000	3,860,800

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2020-04-16	ALEC	ORBIMED ADVISORS LLC	47,097	23.5300	47,097	23.5300	1,108,192	187	9.4	-665,480	-60.05
2020-04-16	ALEC	ORBIMED ADVISORS LLC	15,086	23.5300	15,086	23.5300	354,974
2020-04-14	ALEC	ORBIMED ADVISORS LLC	17,595	23.5200	17,595	23.5200	413,834
2020-04-14	ALEC	ORBIMED ADVISORS LLC	5,636	23.5200	5,636	23.5200	132,559
2020-04-09	ALEC	ORBIMED ADVISORS LLC	218,208	23.7900	218,208	23.7900	5,191,168
2020-04-09	ALEC	ORBIMED ADVISORS LLC	69,893	23.7900	69,893	23.7900	1,662,754
2020-04-08	ALEC	ORBIMED ADVISORS LLC	62,573	23.6500	62,573	23.6500	1,479,851
2020-04-08	ALEC	ORBIMED ADVISORS LLC	20,041	23.6500	20,041	23.6500	473,970
2020-04-07	ALEC	ORBIMED ADVISORS LLC	6,946	23.1000	6,946	23.1000	160,453
2020-04-07	ALEC	ORBIMED ADVISORS LLC	2,224	23.1000	2,224	23.1000	51,374
2020-03-31	ALEC	ORBIMED ADVISORS LLC	189,355	24.5000	189,355	24.5000	4,639,198
2020-03-31	ALEC	ORBIMED ADVISORS LLC	60,645	24.5000	60,645	24.5000	1,485,802
2020-03-25	ALEC	ORBIMED ADVISORS LLC	42,727	24.6600	42,727	24.6600	1,053,648
2020-03-25	ALEC	ORBIMED ADVISORS LLC	13,684	24.6600	13,684	24.6600	337,447
2020-03-24	ALEC	ORBIMED ADVISORS LLC	51,235	24.4500	51,235	24.4500	1,252,696
2020-03-24	ALEC	ORBIMED ADVISORS LLC	16,409	24.4500	16,409	24.4500	401,200
2020-03-23	ALEC	ORBIMED ADVISORS LLC	11,057	26.0500	11,057	26.0500	288,035
2020-03-23	ALEC	ORBIMED ADVISORS LLC	3,541	26.0500	3,541	26.0500	92,243
2020-03-02	ALEC	ORBIMED ADVISORS LLC	1,390,309	26.0000	1,390,309	26.0000	36,148,034
2020-03-02	ALEC	ORBIMED ADVISORS LLC	445,086	26.0000	445,086	26.0000	11,572,236
2020-03-02	ALEC	ORBIMED ADVISORS LLC	38,808	26.0000	38,808	26.0000	1,009,008
2020-01-09	ALEC	ORBIMED ADVISORS LLC	286,787	19.5000	286,787	19.5000	5,592,346
2020-01-09	ALEC	ORBIMED ADVISORS LLC	91,818	19.5000	91,818	19.5000	1,790,451
2020-01-09	ALEC	ORBIMED ADVISORS LLC	1,392	19.5000	1,392	19.5000	27,144
2019-12-26	ALEC	ORBIMED ADVISORS LLC	7,275	18.6000	7,275	18.6000	135,315
2019-12-26	ALEC	ORBIMED ADVISORS LLC	2,325	18.6000	2,325	18.6000	43,245
2019-12-26	ALEC	ORBIMED ADVISORS LLC	1,200	18.6000	1,200	18.6000	22,320
2019-12-24	ALEC	ORBIMED ADVISORS LLC	48,324	19.5900	48,324	19.5900	946,667
2019-12-24	ALEC	ORBIMED ADVISORS LLC	15,476	19.5900	15,476	19.5900	303,175
2019-12-24	ALEC	ORBIMED ADVISORS LLC	8,000	19.5900	8,000	19.5900	156,720
2019-12-23	ALEC	ORBIMED ADVISORS LLC	63,535	19.8200	63,535	19.8200	1,259,264
2019-12-23	ALEC	ORBIMED ADVISORS LLC	20,350	19.8200	20,350	19.8200	403,337
2019-12-23	ALEC	ORBIMED ADVISORS LLC	10,400	19.8200	10,400	19.8200	206,128
2019-12-20	ALEC	ORBIMED ADVISORS LLC	230,721	19.6600	230,721	19.6600	4,535,975
2019-12-20	ALEC	ORBIMED ADVISORS LLC	73,879	19.6600	73,879	19.6600	1,452,461
2019-12-20	ALEC	ORBIMED ADVISORS LLC	37,900	19.6600	37,900	19.6600	745,114
2019-12-17	ALEC	ORBIMED ADVISORS LLC	642,807	18.5200	642,807	18.5200	11,904,786
2019-12-17	ALEC	ORBIMED ADVISORS LLC	205,793	18.5200	205,793	18.5200	3,811,286
2019-12-17	ALEC	ORBIMED ADVISORS LLC	105,500	18.5200	105,500	18.5200	1,953,860
2019-08-07	ALEC	ORBIMED ADVISORS LLC	492,364	17.9000	492,364	17.9000	8,813,316
2019-08-07	ALEC	ORBIMED ADVISORS LLC	157,636	17.9000	157,636	17.9000	2,821,684

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2012-06-19	AMRN	ORBIMED ADVISORS LLC	611,200	12.9127	30,560	258.2540	7,892,242	310	6.39	-7,696,964	-97.53
2012-06-19	AMRN	ORBIMED ADVISORS LLC	5,900	12.9127	295	258.2540	76,185

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2013-01-30	ANTH	ORBIMED ADVISORS LLC	5,700,000	0.6600	712,500	5.2800	3,762,000	170	4.53	-534,375	-14.20
2013-01-25	ANTH	ORBIMED ADVISORS LLC	1,762,000	0.6484	220,250	5.1872	1,142,481

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2012-06-29	ANTH	ORBIMED ADVISORS LLC	1,283,300	0.7341	160,412	5.8728	942,071	364	0.4631	-867,783	-92.11
2012-03-22	ANTH	ORBIMED ADVISORS LLC	1,306,700	2.4031	163,338	19.2248	3,140,131
2012-03-21	ANTH	ORBIMED ADVISORS LLC	125,000	2.8665	15,625	22.9320	358,312
2012-03-20	ANTH	ORBIMED ADVISORS LLC	116,800	2.8993	14,600	23.1944	338,638

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2020-10-02	ARQT	ORBIMED ADVISORS LLC	200,000	25.0000	200,000	25.0000	5,000,000	129	36.98	2,396,000	47.92
2020-10-02	ARQT	ORBIMED ADVISORS LLC	296,000	25.0000	296,000	25.0000	7,400,000
2020-02-03	ARQT	ORBIMED ADVISORS LLC	382,388	17.0000	382,388	17.0000	6,500,596
2020-02-03	ARQT	ORBIMED ADVISORS LLC	176,500	17.0000	176,500	17.0000	3,000,500

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2022-06-24	ARQT	ORBIMED ADVISORS LLC	306,027	21.3100	306,027	21.3100	6,521,435	341	7.5100	-4,223,172	-64.76
2022-06-24	ARQT	ORBIMED ADVISORS LLC	35,944	21.3100	35,944	21.3100	765,967
2022-04-08	ARQT	ORBIMED ADVISORS LLC	97,200	20.7100	97,200	20.7100	2,013,012
2022-04-08	ARQT	ORBIMED ADVISORS LLC	102,800	20.7100	102,800	20.7100	2,128,988
2022-04-07	ARQT	ORBIMED ADVISORS LLC	167,800	20.6600	167,800	20.6600	3,466,748
2022-04-07	ARQT	ORBIMED ADVISORS LLC	177,196	20.6600	177,196	20.6600	3,660,869
2022-04-06	ARQT	ORBIMED ADVISORS LLC	162,000	20.6900	162,000	20.6900	3,351,780
2022-04-06	ARQT	ORBIMED ADVISORS LLC	171,204	20.6900	171,204	20.6900	3,542,211

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2024-01-30	AVBP	ORBIMED ADVISORS LLC	222,222	18.0000	222,222	18.0000	3,999,996	282	35.6300	3,917,774	97.94
2024-01-30	AVBP	ORBIMED ADVISORS LLC	222,222	18.0000	222,222	18.0000	3,999,996

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min
2018-03-12	BOLD	ORBIMED ADVISORS LLC	1,066	36.0400	1,066	36.0400	38,419	731
2018-03-12	BOLD	ORBIMED ADVISORS LLC	16,937	34.9200	16,937	34.9200	591,440
2018-03-09	BOLD	ORBIMED ADVISORS LLC	21,300	34.6700	21,300	34.6700	738,471
2018-03-09	BOLD	ORBIMED ADVISORS LLC	47,395	35.8600	47,395	35.8600	1,699,585
2018-03-09	BOLD	ORBIMED ADVISORS LLC	11,305	36.4400	11,305	36.4400	411,954
2018-03-08	BOLD	ORBIMED ADVISORS LLC	58,428	34.0600	58,428	34.0600	1,990,058
2018-03-06	BOLD	ORBIMED ADVISORS LLC	11,372	33.0300	11,372	33.0300	375,617
2018-03-05	BOLD	ORBIMED ADVISORS LLC	200	36.0600	200	36.0600	7,212
2018-03-02	BOLD	ORBIMED ADVISORS LLC	386,080	35.0600	386,080	35.0600	13,535,965
2018-03-02	BOLD	ORBIMED ADVISORS LLC	35,558	36.3300	35,558	36.3300	1,291,822
2017-09-29	BOLD	ORBIMED ADVISORS LLC	672,000	28.2500	672,000	28.2500	18,984,000
2017-09-07	BOLD	ORBIMED ADVISORS LLC	5,000	22.3500	5,000	22.3500	111,750

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2022-11-08	CMPX	ORBIMED ADVISORS LLC	402,000	3.2100	402,000	3.2100	1,290,420	63	5.4800	912,540	70.72
2022-05-13	CMPX	ORBIMED ADVISORS LLC	30,722	2.4900	30,722	2.4900	76,498
2022-05-12	CMPX	ORBIMED ADVISORS LLC	97,094	2.3500	97,094	2.3500	228,171
2022-05-11	CMPX	ORBIMED ADVISORS LLC	64,700	1.7900	64,700	1.7900	115,813
2022-05-10	CMPX	ORBIMED ADVISORS LLC	24,447	1.6000	24,447	1.6000	39,115
2022-05-09	CMPX	ORBIMED ADVISORS LLC	90,712	1.5600	90,712	1.5600	141,511
2022-05-06	CMPX	ORBIMED ADVISORS LLC	10,200	1.6300	10,200	1.6300	16,626
2021-11-04	CMPX	ORBIMED ADVISORS LLC	1,785,715	3.5000	1,785,715	3.5000	6,250,002
2021-11-04	CMPX	ORBIMED ADVISORS LLC	3,571,428	3.5000	3,571,428	3.5000	12,499,998
2020-06-19	NONE	ORBIMED ADVISORS LLC	1,455,132	5.0000	1,455,132	5.0000	7,275,660

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2021-02-17	CRVS	ORBIMED ADVISORS LLC	1,285,714	3.5000	1,285,714	3.5000	4,499,999	216	8.53	6,467,141	143.71
2019-08-06	CRVS	ORBIMED ADVISORS LLC	142,656	3.5100	142,656	3.5100	500,723
2019-07-01	CRVS	ORBIMED ADVISORS LLC	59,243	3.9100	59,243	3.9100	231,640
2019-06-28	CRVS	ORBIMED ADVISORS LLC	565,178	3.7200	565,178	3.7200	2,102,462
2019-06-27	CRVS	ORBIMED ADVISORS LLC	32,923	3.3400	32,923	3.3400	109,963
2018-03-12	CRVS	ORBIMED ADVISORS LLC	588,235	8.5000	588,235	8.5000	4,999,998
2016-06-24	CRVS	ORBIMED ADVISORS LLC	900	12.9900	900	12.9900	11,691
2016-06-23	CRVS	ORBIMED ADVISORS LLC	100	12.9200	100	12.9200	1,292
2016-06-21	CRVS	ORBIMED ADVISORS LLC	26,083	12.8700	26,083	12.8700	335,688
2016-06-17	CRVS	ORBIMED ADVISORS LLC	12,300	12.4800	12,300	12.4800	153,504
2016-06-16	CRVS	ORBIMED ADVISORS LLC	5,000	12.0400	5,000	12.0400	60,200
2016-06-15	CRVS	ORBIMED ADVISORS LLC	5,000	11.9400	5,000	11.9400	59,700
2016-06-14	CRVS	ORBIMED ADVISORS LLC	10,000	12.7100	10,000	12.7100	127,100
2016-06-10	CRVS	ORBIMED ADVISORS LLC	20,000	12.9800	20,000	12.9800	259,600
2016-06-09	CRVS	ORBIMED ADVISORS LLC	30,000	12.9500	30,000	12.9500	388,500
2016-05-20	CRVS	ORBIMED ADVISORS LLC	4,716	13.0900	4,716	13.0900	61,732
2016-05-19	CRVS	ORBIMED ADVISORS LLC	2,539	12.1100	2,539	12.1100	30,747
2016-05-19	CRVS	ORBIMED ADVISORS LLC	61	12.7500	61	12.7500	778
2016-05-18	CRVS	ORBIMED ADVISORS LLC	4,200	11.5500	4,200	11.5500	48,510
2016-03-29	CRVS	ORBIMED ADVISORS LLC	550,000	15.0000	550,000	15.0000	8,250,000

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2025-06-27	CRVS	ORBIMED ADVISORS LLC	1,176,332	4.1586	1,176,332	4.1586	4,891,894	4	3.8600	-351,252	-7.18
2021-09-20	CRVS	ORBIMED ADVISORS LLC	1,109,644	6.0900	1,109,644	6.0900	6,757,732

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2019-11-11	ETNB	ORBIMED ADVISORS LLC	418,750	16.0000	418,750	16.0000	6,700,000	112	41.77	10,791,188	161.06
2019-11-11	ETNB	ORBIMED ADVISORS LLC	418,750	16.0000	418,750	16.0000	6,700,000

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2022-01-26	ETNB	ORBIMED ADVISORS LLC	10,742	8.3800	10,742	8.3800	90,018	103	2.0900	-67,566	-75.06
2022-01-26	ETNB	ORBIMED ADVISORS LLC	10,740	8.3800	10,740	8.3800	90,001
2022-01-25	ETNB	ORBIMED ADVISORS LLC	24,546	8.4000	24,546	8.4000	206,186
2022-01-25	ETNB	ORBIMED ADVISORS LLC	24,545	8.4000	24,545	8.4000	206,178
2020-09-21	ETNB	ORBIMED ADVISORS LLC	137,500	28.0000	137,500	28.0000	3,850,000
2020-09-21	ETNB	ORBIMED ADVISORS LLC	137,500	28.0000	137,500	28.0000	3,850,000

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2025-04-03	EWTX	ORBIMED ADVISORS LLC	372,578	20.1300	372,578	20.1300	7,499,995	29	16.9100	-1,199,701	-16.00
2025-04-03	EWTX	ORBIMED ADVISORS LLC	124,193	20.1300	124,193	20.1300	2,500,005
2024-01-23	EWTX	ORBIMED ADVISORS LLC	454,545	11.0000	454,545	11.0000	4,999,995
2022-09-16	EWTX	ORBIMED ADVISORS LLC	484,496	10.3200	484,496	10.3200	4,999,999
2022-05-18	EWTX	ORBIMED ADVISORS LLC	138,000	7.2100	138,000	7.2100	994,980
2021-03-30	EWTX	ORBIMED ADVISORS LLC	46,875	16.0000	46,875	16.0000	750,000
2021-03-30	EWTX	ORBIMED ADVISORS LLC	312,500	16.0000	312,500	16.0000	5,000,000

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2018-03-06	GKOS	ORBIMED ADVISORS LLC	93,008	30.0100	93,008	30.0100	2,791,170	38	27.6200	-222,289	-7.96
2018-03-06	GKOS	ORBIMED ADVISORS LLC	886	30.0100	886	30.0100	26,589
2018-03-06	GKOS	ORBIMED ADVISORS LLC	20,114	30.7700	20,114	30.7700	618,908
2018-03-06	GKOS	ORBIMED ADVISORS LLC	192	30.7700	192	30.7700	5,908
2018-03-06	GKOS	ORBIMED ADVISORS LLC	46,676	32.0600	46,676	32.0600	1,496,433
2018-03-06	GKOS	ORBIMED ADVISORS LLC	445	32.0600	445	32.0600	14,267
2018-03-05	GKOS	ORBIMED ADVISORS LLC	128,092	32.0500	128,092	32.0500	4,105,349
2018-03-05	GKOS	ORBIMED ADVISORS LLC	1,220	32.0500	1,220	32.0500	39,101
2018-03-05	GKOS	ORBIMED ADVISORS LLC	80,516	33.0600	80,516	33.0600	2,661,859
2018-03-05	GKOS	ORBIMED ADVISORS LLC	768	33.0600	768	33.0600	25,390
2018-03-02	GKOS	ORBIMED ADVISORS LLC	265,766	31.9200	265,766	31.9200	8,483,251
2018-03-02	GKOS	ORBIMED ADVISORS LLC	2,533	31.9200	2,533	31.9200	80,853
2018-03-02	GKOS	ORBIMED ADVISORS LLC	194,433	32.8000	194,433	32.8000	6,377,402
2018-03-02	GKOS	ORBIMED ADVISORS LLC	1,851	32.8000	1,851	32.8000	60,713
2017-09-05	GKOS	ORBIMED ADVISORS LLC	173,349	37.9400	173,349	37.9400	6,576,861
2017-09-05	GKOS	ORBIMED ADVISORS LLC	1,651	37.9400	1,651	37.9400	62,639
2017-09-05	GKOS	ORBIMED ADVISORS LLC	189,792	39.6300	189,792	39.6300	7,521,457
2017-09-05	GKOS	ORBIMED ADVISORS LLC	1,808	39.6300	1,808	39.6300	71,651
2017-09-05	GKOS	ORBIMED ADVISORS LLC	58,047	40.7700	58,047	40.7700	2,366,576
2017-09-05	GKOS	ORBIMED ADVISORS LLC	553	40.7700	553	40.7700	22,546
2017-09-01	GKOS	ORBIMED ADVISORS LLC	109,040	37.7200	109,040	37.7200	4,112,989
2017-09-01	GKOS	ORBIMED ADVISORS LLC	1,038	37.7200	1,038	37.7200	39,153
2017-08-31	GKOS	ORBIMED ADVISORS LLC	44,498	37.8200	44,498	37.8200	1,682,914
2017-08-31	GKOS	ORBIMED ADVISORS LLC	424	37.8200	424	37.8200	16,036
2017-08-17	GKOS	ORBIMED ADVISORS LLC	224,780	37.8500	224,780	37.8500	8,507,923
2017-08-17	GKOS	ORBIMED ADVISORS LLC	2,140	37.8500	2,140	37.8500	80,999
2017-08-16	GKOS	ORBIMED ADVISORS LLC	64,961	38.0100	64,961	38.0100	2,469,168
2017-08-16	GKOS	ORBIMED ADVISORS LLC	619	38.0100	619	38.0100	23,528
2017-08-15	GKOS	ORBIMED ADVISORS LLC	32,193	38.2900	32,193	38.2900	1,232,670
2017-08-15	GKOS	ORBIMED ADVISORS LLC	307	38.2900	307	38.2900	11,755
2017-03-14	GKOS	ORBIMED ADVISORS LLC	73,401	44.5400	73,401	44.5400	3,269,281
2017-03-14	GKOS	ORBIMED ADVISORS LLC	699	44.5400	699	44.5400	31,133
2017-03-13	GKOS	ORBIMED ADVISORS LLC	208,712	45.3000	208,712	45.3000	9,454,654
2017-03-13	GKOS	ORBIMED ADVISORS LLC	1,998	45.3000	1,998	45.3000	90,509
2017-03-13	GKOS	ORBIMED ADVISORS LLC	693	46.1300	693	46.1300	31,968
2017-03-13	GKOS	ORBIMED ADVISORS LLC	7	46.1300	7	46.1300	323
2017-03-10	GKOS	ORBIMED ADVISORS LLC	96,113	45.9800	96,113	45.9800	4,419,276
2017-03-10	GKOS	ORBIMED ADVISORS LLC	915	45.9800	915	45.9800	42,072
2017-03-03	GKOS	ORBIMED ADVISORS LLC	55,246	47.0500	55,246	47.0500	2,599,324
2017-03-03	GKOS	ORBIMED ADVISORS LLC	526	47.0500	526	47.0500	24,748
2016-08-12	GKOS	ORBIMED ADVISORS LLC	13,967	33.7200	13,967	33.7200	470,967
2016-08-12	GKOS	ORBIMED ADVISORS LLC	133	33.7200	133	33.7200	4,485
2016-08-11	GKOS	ORBIMED ADVISORS LLC	159,382	33.6300	159,382	33.6300	5,360,017
2016-08-11	GKOS	ORBIMED ADVISORS LLC	1,518	33.6300	1,518	33.6300	51,050
2016-08-10	GKOS	ORBIMED ADVISORS LLC	116,825	33.7700	116,825	33.7700	3,945,180
2016-08-10	GKOS	ORBIMED ADVISORS LLC	1,113	33.7700	1,113	33.7700	37,586
2016-08-03	GKOS	ORBIMED ADVISORS LLC	420,990	30.5900	420,990	30.5900	12,878,084
2016-08-03	GKOS	ORBIMED ADVISORS LLC	4,010	30.5900	4,010	30.5900	122,666

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2020-11-02	GLTO	ORBIMED ADVISORS LLC	523,833	15.0000	20,953	375.0000	7,857,495	21	16.84	-7,504,646	-95.51
2020-11-02	GLTO	ORBIMED ADVISORS LLC	209,500	15.0000	8,380	375.0000	3,142,500

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2023-08-15	GLTO	ORBIMED ADVISORS LLC	38,327	0.7500	1,533	18.7500	28,745	322	0.4615	-28,038	-97.54
2023-08-15	GLTO	ORBIMED ADVISORS LLC	248,819	0.7500	9,953	18.7500	186,614
2023-08-15	GLTO	ORBIMED ADVISORS LLC	535,534	0.7500	21,421	18.7500	401,650
2023-07-31	GLTO	ORBIMED ADVISORS LLC	26,622	3.0000	1,065	75.0000	79,866
2023-07-31	GLTO	ORBIMED ADVISORS LLC	29,700	3.0000	1,188	75.0000	89,100
2023-07-31	GLTO	ORBIMED ADVISORS LLC	153,078	3.0000	6,123	75.0000	459,234
2023-07-25	GLTO	ORBIMED ADVISORS LLC	7,800	2.9200	312	73.0000	22,776
2023-07-25	GLTO	ORBIMED ADVISORS LLC	4,700	2.9200	188	73.0000	13,724
2023-07-25	GLTO	ORBIMED ADVISORS LLC	26,700	2.9200	1,068	73.0000	77,964
2023-07-13	GLTO	ORBIMED ADVISORS LLC	9,800	2.4000	392	60.0000	23,520
2023-07-13	GLTO	ORBIMED ADVISORS LLC	52,800	2.4000	2,112	60.0000	126,720
2023-07-13	GLTO	ORBIMED ADVISORS LLC	132,100	2.4000	5,284	60.0000	317,040
2023-04-17	GLTO	ORBIMED ADVISORS LLC	660	1.9700	26	49.2500	1,300
2023-04-17	GLTO	ORBIMED ADVISORS LLC	3,551	1.9700	142	49.2500	6,995
2023-04-17	GLTO	ORBIMED ADVISORS LLC	8,878	1.9700	355	49.2500	17,490
2023-04-14	GLTO	ORBIMED ADVISORS LLC	2,091	1.8600	84	46.5000	3,889
2023-04-14	GLTO	ORBIMED ADVISORS LLC	11,245	1.8600	450	46.5000	20,916
2023-04-14	GLTO	ORBIMED ADVISORS LLC	28,110	1.8600	1,124	46.5000	52,285
2023-04-13	GLTO	ORBIMED ADVISORS LLC	703	1.8200	28	45.5000	1,279
2023-04-13	GLTO	ORBIMED ADVISORS LLC	3,784	1.8200	151	45.5000	6,887
2023-04-13	GLTO	ORBIMED ADVISORS LLC	9,459	1.8200	378	45.5000	17,215
2023-04-12	GLTO	ORBIMED ADVISORS LLC	119	1.8100	5	45.2500	215
2023-04-12	GLTO	ORBIMED ADVISORS LLC	641	1.8100	26	45.2500	1,160
2023-04-12	GLTO	ORBIMED ADVISORS LLC	1,603	1.8100	64	45.2500	2,901
2023-04-11	GLTO	ORBIMED ADVISORS LLC	703	1.8200	28	45.5000	1,279
2023-04-11	GLTO	ORBIMED ADVISORS LLC	3,784	1.8200	151	45.5000	6,887
2023-04-11	GLTO	ORBIMED ADVISORS LLC	9,459	1.8200	378	45.5000	17,215
2023-04-10	GLTO	ORBIMED ADVISORS LLC	2,584	1.7900	103	44.7500	4,625
2023-04-10	GLTO	ORBIMED ADVISORS LLC	13,899	1.7900	556	44.7500	24,879
2023-04-10	GLTO	ORBIMED ADVISORS LLC	34,745	1.7900	1,390	44.7500	62,194
2023-04-06	GLTO	ORBIMED ADVISORS LLC	487	2.0000	19	50.0000	974
2023-04-06	GLTO	ORBIMED ADVISORS LLC	2,620	2.0000	105	50.0000	5,240
2023-04-06	GLTO	ORBIMED ADVISORS LLC	6,558	2.0000	262	50.0000	13,116
2023-04-05	GLTO	ORBIMED ADVISORS LLC	4,687	2.1800	187	54.5000	10,218
2023-04-05	GLTO	ORBIMED ADVISORS LLC	25,220	2.1800	1,009	54.5000	54,980
2023-04-05	GLTO	ORBIMED ADVISORS LLC	63,058	2.1800	2,522	54.5000	137,466

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2021-07-16	IMRA	ORBIMED ADVISORS LLC	1,666,666	6.0000	416,666	24.0000	9,999,996	18	5.9400	-7,525,000	-75.25
2020-03-12	IMRA	ORBIMED ADVISORS LLC	937,500	16.0000	234,375	64.0000	15,000,000

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2024-05-16	ELVN	ORBIMED ADVISORS LLC	33,300	22.1400	33,300	22.1400	737,262	329	14.9100	-240,759	-32.66
2024-05-16	ELVN	ORBIMED ADVISORS LLC	1,000,000	22.1400	1,000,000	22.1400	22,140,000

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2020-08-18	INSP	ORBIMED ADVISORS LLC	43,543	108.5400	43,543	108.5400	4,726,157	1	110.97	105,810	2.24
2020-08-17	INSP	ORBIMED ADVISORS LLC	94,900	107.4900	94,900	107.4900	10,200,801
2020-08-14	INSP	ORBIMED ADVISORS LLC	20,257	109.0300	20,257	109.0300	2,208,621
2020-08-13	INSP	ORBIMED ADVISORS LLC	29,251	109.9300	29,251	109.9300	3,215,562
2020-08-12	INSP	ORBIMED ADVISORS LLC	42,679	107.4500	42,679	107.4500	4,585,859
2020-08-11	INSP	ORBIMED ADVISORS LLC	39,877	105.7800	39,877	105.7800	4,218,189
2020-08-10	INSP	ORBIMED ADVISORS LLC	47,700	105.2300	47,700	105.2300	5,019,471
2020-08-07	INSP	ORBIMED ADVISORS LLC	28,993	106.1800	28,993	106.1800	3,078,477
2020-03-06	INSP	ORBIMED ADVISORS LLC	500,000	83.5200	500,000	83.5200	41,760,000
2020-03-03	INSP	ORBIMED ADVISORS LLC	75,000	83.2100	75,000	83.2100	6,240,750
2020-03-03	INSP	ORBIMED ADVISORS LLC	25,000	84.5500	25,000	84.5500	2,113,750
2020-03-03	INSP	ORBIMED ADVISORS LLC	400,000	84.4200	400,000	84.4200	33,768,000
2019-03-08	INSP	ORBIMED ADVISORS LLC	290,231	57.7500	290,231	57.7500	16,760,840
2019-03-07	INSP	ORBIMED ADVISORS LLC	68,218	55.0100	68,218	55.0100	3,752,672
2018-12-11	INSP	ORBIMED ADVISORS LLC	614,772	37.6000	614,772	37.6000	23,115,427

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2021-06-15	JANX	ORBIMED ADVISORS LLC	588,203	17.0000	588,203	17.0000	9,999,451	51	34.69	10,405,311	104.06
2021-06-15	JANX	ORBIMED ADVISORS LLC	117,650	17.0000	117,650	17.0000	2,000,050

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2021-12-29	JANX	ORBIMED ADVISORS LLC	36,700	20.3000	36,700	20.3000	745,010	154	9.5200	-395,626	-53.10
2021-12-29	JANX	ORBIMED ADVISORS LLC	3,700	20.3000	3,700	20.3000	75,110
2021-12-21	JANX	ORBIMED ADVISORS LLC	108,300	19.0000	108,300	19.0000	2,057,700
2021-12-21	JANX	ORBIMED ADVISORS LLC	11,100	19.0000	11,100	19.0000	210,900
2021-12-16	JANX	ORBIMED ADVISORS LLC	356,800	19.0700	356,800	19.0700	6,804,176
2021-12-16	JANX	ORBIMED ADVISORS LLC	36,500	19.0700	36,500	19.0700	696,055

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2018-02-08	KALA	ORBIMED ADVISORS LLC	25,000	12.9300	500	646.5000	323,250	36	905	129,250	39.98
2018-02-02	KALA	ORBIMED ADVISORS LLC	37,840	14.7300	757	736.5000	557,383
2018-02-01	KALA	ORBIMED ADVISORS LLC	22,840	14.9900	457	749.5000	342,372
2018-01-31	KALA	ORBIMED ADVISORS LLC	339,400	15.0000	6,788	750.0000	5,091,000
2018-01-29	KALA	ORBIMED ADVISORS LLC	50,000	14.9900	1,000	749.5000	749,500
2018-01-26	KALA	ORBIMED ADVISORS LLC	22,760	14.9300	455	746.5000	339,807
2018-01-24	KALA	ORBIMED ADVISORS LLC	64,637	14.9100	1,293	745.5000	963,738
2018-01-23	KALA	ORBIMED ADVISORS LLC	4,363	14.9900	87	749.5000	65,401
2018-01-22	KALA	ORBIMED ADVISORS LLC	75,000	14.9800	1,500	749.0000	1,123,500
2018-01-19	KALA	ORBIMED ADVISORS LLC	74,931	14.9500	1,499	747.5000	1,120,218
2018-01-12	KALA	ORBIMED ADVISORS LLC	28,446	15.4000	569	770.0000	438,068
2018-01-12	KALA	ORBIMED ADVISORS LLC	38,354	14.5000	767	725.0000	556,133
2018-01-11	KALA	ORBIMED ADVISORS LLC	41,700	13.6500	834	682.5000	569,205
2018-01-10	KALA	ORBIMED ADVISORS LLC	170,338	12.8300	3,407	641.5000	2,185,437
2017-07-25	KALA	ORBIMED ADVISORS LLC	319,333	15.0000	6,387	750.0000	4,789,995

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2024-08-13	KROS	ORBIMED ADVISORS LLC	220,600	44.0100	220,600	44.0100	9,708,606	231	9.5500	-7,601,876	-78.30
2024-08-13	KROS	ORBIMED ADVISORS LLC	29,400	44.0100	29,400	44.0100	1,293,894

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Min	Harga pada Min	Kerugian Maks Dielakkan ($)	Kerugian Maks Dielakkan (%)
2025-05-14	NPCE	ORBIMED ADVISORS LLC	134,136	15.8300	134,136	15.8300	2,123,373	97	8.2500	-1,016,750	-47.88
2025-05-14	NPCE	ORBIMED ADVISORS LLC	34,000	15.9400	34,000	15.9400	541,960
2024-05-03	NPCE	ORBIMED ADVISORS LLC	4,674	14.0300	4,674	14.0300	65,576
2024-05-02	NPCE	ORBIMED ADVISORS LLC	8,842	14.0100	8,842	14.0100	123,876
2024-05-01	NPCE	ORBIMED ADVISORS LLC	15,690	14.0200	15,690	14.0200	219,974
2024-04-24	NPCE	ORBIMED ADVISORS LLC	1,781	14.0600	1,781	14.0600	25,041
2024-04-23	NPCE	ORBIMED ADVISORS LLC	21,791	14.2900	21,791	14.2900	311,393
2024-04-22	NPCE	ORBIMED ADVISORS LLC	24,609	14.0500	24,609	14.0500	345,756
2024-04-19	NPCE	ORBIMED ADVISORS LLC	18,253	14.0200	18,253	14.0200	255,907
2024-04-18	NPCE	ORBIMED ADVISORS LLC	2,623	14.0600	2,623	14.0600	36,879
2024-04-17	NPCE	ORBIMED ADVISORS LLC	300	14.1500	300	14.1500	4,245
2024-04-16	NPCE	ORBIMED ADVISORS LLC	14,069	14.0100	14,069	14.0100	197,107
2024-04-12	NPCE	ORBIMED ADVISORS LLC	23,101	14.4200	23,101	14.4200	333,116
2024-04-11	NPCE	ORBIMED ADVISORS LLC	461,899	14.4900	461,899	14.4900	6,692,917
2023-10-03	NPCE	ORBIMED ADVISORS LLC	700	9.0200	700	9.0200	6,314
2023-10-02	NPCE	ORBIMED ADVISORS LLC	7,614	9.0800	7,614	9.0800	69,135

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2016-05-11	NTLA	ORBIMED ADVISORS LLC	191,466	18.0000	191,466	18.0000	3,446,388	20	29.57	2,215,262	64.28
2016-05-11	NTLA	ORBIMED ADVISORS LLC	58,534	18.0000	58,534	18.0000	1,053,612

Tarikh Dagangan	Simbol Saham	Orang dalam	Saham Dilaporkan	Harga Dilaporkan	Saham Dilaraskan	Harga Dilaraskan	Asas Kos	Hari ke Maks	Harga pada Maks	Maks Keuntungan ($)	Pulangan Maks (%)
2023-06-28	PASG	ORBIMED ADVISORS LLC	575,195	0.8400	28,760	16.8000	483,164	245	1.73	-433,410	-89.70
2023-06-27	PASG	ORBIMED ADVISORS LLC	617,382	0.8400	30,869	16.8000	518,601
2022-01-20	PASG	ORBIMED ADVISORS LLC	369,100	5.4200	18,455	108.4000	2,000,522
2022-01-20	PASG	ORBIMED ADVISORS LLC	50,800	5.0000	2,540	100.0000	254,000
2022-01-19	PASG	ORBIMED ADVISORS LLC	43,300	5.1100	2,165	102.2000	221,263
2022-01-18	PASG	ORBIMED ADVISORS LLC	114,700	5.4600	5,735	109.2000	626,262
2022-01-14	PASG	ORBIMED ADVISORS LLC	10,300	5.6000	515	112.0000	57,680
2022-01-13	PASG	ORBIMED ADVISORS LLC	41,800	5.5200	2,090	110.4000	230,736
2022-01-12	PASG	ORBIMED ADVISORS LLC	100,000	5.6500	5,000	113.0000	565,000
2022-01-11	PASG	ORBIMED ADVISORS LLC	8,200	5.5300	410	110.6000	45,346
2020-02-28	PASG	ORBIMED ADVISORS LLC	373,300	18.0000	18,665	360.0000	6,719,400